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A B S T R A C T
Background
Every year, at least one million children become ill with tuberculosis and around 200,000 children die. Xpert MTB/RIF and Xpert Ultra are
World Health Organization (WHO)-recommended rapid molecular tests that simultaneously detect tuberculosis and rifampicin resistance
in adults and children with signs and symptoms of tuberculosis, at lower health system levels. To inform updated WHO guidelines on
molecular assays, we performed a systematic review on the diagnostic accuracy of these tests in children presumed to have active
tuberculosis.
Objectives
Primary objectives
• To determine the diagnostic accuracy of Xpert MTB/RIF and Xpert Ultra for (a) pulmonary tuberculosis in children presumed to have
tuberculosis; (b) tuberculous meningitis in children presumed to have tuberculosis; (c) lymph node tuberculosis in children presumed to
have tuberculosis; and (d) rifampicin resistance in children presumed to have tuberculosis
- For tuberculosis detection, index tests were used as the initial test, replacing standard practice (i.e. smear microscopy or culture)
- For detection of rifampicin resistance, index tests replaced culture-based drug susceptibility testing as the initial test
Secondary objectives
• To compare the accuracy of Xpert MTB/RIF and Xpert Ultra for each of the four target conditions
• To investigate potential sources of heterogeneity in accuracy estimates
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- For tuberculosis detection, we considered age, disease severity, smear-test status, HIV status, clinical setting, specimen type, high
tuberculosis burden, and high tuberculosis/HIV burden
- For detection of rifampicin resistance, we considered multi-drug-resistant tuberculosis burden
• To compare multiple Xpert MTB/RIF or Xpert Ultra results (repeated testing) with the initial Xpert MTB/RIF or Xpert Ultra result
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register, MEDLINE, Embase, Science Citation Index, the Cumulative Index
to Nursing and Allied Health Literature (CINAHL), Scopus, the WHO International Clinical Trials Registry Platform, ClinicalTrials.gov, and
the International Standard Randomized Controlled Trials Number (ISRCTN) Registry up to 29 April 2019, without language restrictions.
Selection criteria
Randomized trials, cross-sectional trials, and cohort studies evaluating Xpert MTB/RIF or Xpert Ultra in HIV-positive and HIV-negative
children younger than 15 years. Reference standards comprised culture or a composite reference standard for tuberculosis and drug
susceptibility testing or MTBDRplus (molecular assay for detection of Mycobacterium tuberculosis and drug resistance) for rifampicin
resistance. We included studies evaluating sputum, gastric aspirate, stool, nasopharyngeal or bronchial lavage specimens (pulmonary
tuberculosis), cerebrospinal fluid (tuberculous meningitis), fine needle aspirates, or surgical biopsy tissue (lymph node tuberculosis).
Data collection and analysis
Two review authors independently extracted data and assessed study quality using the Quality Assessment of Studies of Diagnostic
Accuracy - Revised (QUADAS-2). For each target condition, we used the bivariate model to estimate pooled sensitivity and specificity with
95% confidence intervals (CIs). We stratified all analyses by type of reference standard. We assessed certainty of evidence using the GRADE
approach.
Main results
For pulmonary tuberculosis, 299 data sets (68,544 participants) were available for analysis; for tuberculous meningitis, 10 data sets (423
participants) were available; for lymph node tuberculosis, 10 data sets (318 participants) were available; and for rifampicin resistance, 14
data sets (326 participants) were available. Thirty-nine studies (80%) took place in countries with high tuberculosis burden. Risk of bias
was low except for the reference standard domain, for which risk of bias was unclear because many studies collected only one specimen
for culture.
Detection of pulmonary tuberculosis
For sputum specimens, Xpert MTB/RIF pooled sensitivity (95% CI) and specificity (95% CI) verified by culture were 64.6% (55.3% to 72.9%)
(23 studies, 493 participants; moderate-certainty evidence) and 99.0% (98.1% to 99.5%) (23 studies, 6119 participants; moderate-certainty
evidence). For other specimen types (nasopharyngeal aspirate, 4 studies; gastric aspirate, 14 studies; stool, 11 studies), Xpert MTB/RIF
pooled sensitivity ranged between 45.7% and 73.0%, and pooled specificity ranged between 98.1% and 99.6%.
For sputum specimens, Xpert Ultra pooled sensitivity (95% CI) and specificity (95% CI) verified by culture were 72.8% (64.7% to 79.6%) (3
studies, 136 participants; low-certainty evidence) and 97.5% (95.8% to 98.5%) (3 studies, 551 participants; high-certainty evidence). For
nasopharyngeal specimens, Xpert Ultra sensitivity (95% CI) and specificity (95% CI) were 45.7% (28.9% to 63.3%) and 97.5% (93.7% to
99.3%) (1 study, 195 participants).
For all specimen types, Xpert MTB/RIF and Xpert Ultra sensitivity were lower against a composite reference standard than against culture.
Detection of tuberculous meningitis
For cerebrospinal fluid, Xpert MTB/RIF pooled sensitivity and specificity, verified by culture, were 54.0% (95% CI 27.8% to 78.2%) (6 studies,
28 participants; very low-certainty evidence) and 93.8% (95% CI 84.5% to 97.6%) (6 studies, 213 participants; low-certainty evidence).
Detection of lymph node tuberculosis
For lymph node aspirates or biopsies, Xpert MTB/RIF pooled sensitivity and specificity, verified by culture, were 90.4% (95% CI 55.7%
to 98.6%) (6 studies, 68 participants; very low-certainty evidence) and 89.8% (95% CI 71.5% to 96.8%) (6 studies, 142 participants; low-
certainty evidence).
Detection of rifampicin resistance
Xpert MTB/RIF pooled sensitivity and specificity were 90.0% (67.6% to 97.5%) (6 studies, 20 participants; low-certainty evidence) and 98.3%
(87.7% to 99.8%) (6 studies, 203 participants; moderate-certainty evidence).
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Authors' conclusions
We found Xpert MTB/RIF sensitivity to vary by specimen type, with gastric aspirate specimens having the highest sensitivity followed by
sputum and stool, and nasopharyngeal specimens the lowest; specificity in all specimens was > 98%. Compared with Xpert MTB/RIF, Xpert
Ultra sensitivity in sputum was higher and specificity slightly lower. Xpert MTB/RIF was accurate for detection of rifampicin resistance. Xpert
MTB/RIF was sensitive for diagnosing lymph node tuberculosis. For children with presumed tuberculous meningitis, treatment decisions
should be based on the entirety of clinical information and treatment should not be withheld based solely on an Xpert MTB/RIF result. The
small numbers of studies and participants, particularly for Xpert Ultra, limits our confidence in the precision of these estimates.
P L A I N   L A N G U A G E   S U M M A R Y
Xpert tests for active tuberculosis in children
Why is improving the diagnosis of pulmonary tuberculosis important?
In 2018, at least one million children became ill with tuberculosis and around 200,000 died. When detected early and eQectively treated,
tuberculosis is largely curable. Xpert MTB/RIF and Xpert Ultra are World Health Organization-recommended tests that simultaneously
detect tuberculosis and rifampicin resistance in adults and children with tuberculosis symptoms. Rifampicin is an important anti-
tuberculosis drug. Not recognizing tuberculosis early may result in delayed diagnosis and treatment, severe illness, and death. A false
tuberculosis diagnosis may result in anxiety and unnecessary treatment.
What is the aim of this review?
To determine the accuracy of tests in symptomatic children for diagnosing pulmonary tuberculosis, tuberculous meningitis, lymph node
tuberculosis, and rifampicin resistance.
What was studied in this review?
Xpert MTB/RIF and Xpert Ultra, with results measured against culture and a composite reference standard (benchmarks), recognizing that
neither reference is perfect in children.
What are the main results in this review?
A total of 49 studies were included. For pulmonary tuberculosis, we analysed 299 data sets including information describing nearly 70,000
children.
For a population of 1000 children:
Xpert MTB/RIF
- where 100 have pulmonary tuberculosis in sputum (by culture), 74 would be Xpert MTB/RIF-positive, of whom 9 (12%) would not have
tuberculosis (false-positives); 926 would be Xpert MTB/RIF-negative; and 35 (4%) would have tuberculosis (false-negatives)
- where 100 have tuberculous meningitis (by culture), 86 would be Xpert MTB/RIF-positive, of whom 59 (69%) would not have tuberculosis
(false-positives); 914 would be Xpert MTB/RIF-negative; and 23 (3%) would have tuberculosis (false-negatives)
- where 100 people have lymph node tuberculosis (by culture), 142 would be Xpert MTB/RIF-positive, of whom 97 (68%) would not have
lymph node tuberculosis (false-positives); 858 would be Xpert MTB/RIF-negative; and 5 (1%) would have lymph node TB (false-negatives)
- where 100 have rifampicin resistance, 108 would have Xpert MTB/RIF-rifampicin resistance detected, of whom 18 (17%) would not
have rifampicin resistance (false-positives); 892 would have Xpert MTB/RIF-rifampicin resistance NOT detected; and 10 (1%) would have
rifampicin resistance (false-negatives)
Xpert Ultra
- where 100 have pulmonary tuberculosis in sputum (by culture), 100 would be Xpert Ultra-positive, of whom 27 (27%) would not have
tuberculosis (false-positives); 900 would be Xpert Ultra-negative; and 27 (3%) would have tuberculosis (false-negatives)
How confident are we in the results of this review?
We are confident. We included many studies from diQerent countries and settings and used two reference standards. Some studies included
only children at referral centres or did not report the setting. Therefore, we could not assess how the tests would work in a primary care
setting.
What children do the results of this review apply to?
Children with presumed pulmonary tuberculosis, tuberculous meningitis, lymph node tuberculosis, or rifampicin resistance.
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What are the implications of this review?
The results of the review suggest Xpert tests have the potential to be used to detect tuberculosis and rifampicin resistance.
- The risk of missing a diagnosis of pulmonary tuberculosis confirmed by culture with Xpert MTB/RIF (in sputum) is low (4% of those whose
Xpert MTB/RIF suggests they do not have tuberculosis) suggesting that only a small number of children with tuberculosis confirmed by
culture will not receive treatment. The risk of wrongly diagnosing a child as having tuberculosis is slightly higher (12% of those whose Xpert
MTB/RIF test suggests they do have tuberculosis). This may result in some of these children receiving unnecessary treatment.
- The risk of missing a diagnosis of rifampicin resistance with Xpert MTB/RIF is low (1% of those whose Xpert MTB/RIF suggests they do not
have rifampicin resistance) suggesting that only a small number of children with tuberculosis will not receive the appropriate treatment.
The risk of wrongly diagnosing a child as rifampicin resistance tuberculosis is higher (17% of those whose Xpert MTB/RIF test suggests they
do have rifampicin resistance). This may result in some of these children receiving unnecessary treatment.
How up-to-date is this review?
To 29 April 2019.
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Summary of findings 1.   Xpert MTB/RIF and Xpert Ultra for pulmonary tuberculosis in children
Review question: what is the diagnostic accuracy of Xpert MTB/RIF and Xpert Ultra for pulmonary tuberculosis in sputum in children with signs and symptoms of pul-
monary tuberculosis?
Patients/population: children with presumed pulmonary tuberculosis
Index tests: Xpert MTB/RIF and Xpert Ultra
Role: an initial test
Threshold for index tests: an automated result is provided
Reference standard: culture
Types of studies: cross-sectional and cohort studies
Setting: primary care facilities and local hospitals
Number of results per 1000 patients tested(95% CI)Index test Effect (95% Cl) Number of
participants
(studies)
Test result
Prevalence 1% Prevalence 10% Prevalence 20%
Certainty of
the evidence
(GRADE)
True-positives 6 (6 to 7) 65 (55 to 73) 129 (111 to 146)Pooled sensitivity 0.65
(95% CI 0.55 to 0.73)
493
(23)
False-negatives 4 (3 to 4) 35 (27 to 45) 71 (54 to 89)
⨁⨁⨁ ◯
MODERATE
a,b
True-negatives 980 (971 to 985) 891 (883 to 896) 792 (785 to 796)
Xpert MTB/RIF
Pooled specificity 0.99
(95% CI 0.98 to 0.99)
6119
(23)
False-positives 10 (5 to 19) 9 (4 to 17) 8 (4 to 15)
⨁⨁⨁ ◯
MODERATE c
True-positives 7 (6 to 8) 73 (65 to 80) 146 (129 to 159)Pooled sensitivity 0.73
(95% CI 0.65 to 0.80)
136
(3)
False-negatives 3 (2 to 4) 27 (20 to 35) 54 (41 to 71)
⨁⨁◯◯
LOW d,e
True-negatives 960 (950 to 970) 873 (864 to 882) 776 (768 to 784)
Xpert Ultra
Pooled specificity 0.97
(95% CI 0.96 to 0.98)
551
(3)
False-positives 30 (20 to 40) 27 (18 to 36) 24 (16 to 32)
⨁⨁⨁⨁
HIGH
CI: confidence interval.
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Prevalence levels were suggested by the WHO Global Tuberculosis Programme.
aFor individual studies, sensitivity estimates ranged from 27% to 100%. We thought that diQerences in enrolment criteria (diQerent populations targeted), disease severity, and
diQerent ages and settings could explain the heterogeneity. We did not downgrade for inconsistency.
bEight studies (34%) had high or unclear concern about applicability because, in these studies, patients were enrolled from inpatient tertiary care centres, which could lead to the
enrolment of children with more advanced disease. Of these studies, Nhu 2013 and Singh M 2016 had among the highest sensitivities. We downgraded one level for indirectness.
cAs assessed by QUADAS-2, 11 studies (47%) had unclear risk of bias based on the collection of a single culture to exclude tuberculosis. We downgraded one level for risk of bias.
dTwo studies (66%) had high concern about applicability because, in these studies, patients were enrolled from inpatient tertiary care centres, which could lead to the enrolment
of children with more advanced disease. We downgraded one level.
eThe number of children with pulmonary tuberculosis contributing to this analysis for observed sensitivity was low. We downgraded one level for imprecision.
GRADE certainty of the evidence.
High: we are very confident that the true eQect lies close to that of the estimate of the eQect.
Moderate: we are moderately confident in the eQect estimate: the true eQect is likely to be close to the estimate of the eQect, but there is a possibility that it is substantially
diQerent.
Low: our confidence in the eQect estimate is limited: the true eQect may be substantially diQerent from the estimate of the eQect.
Very low: we have very little confidence in the eQect estimate: the true eQect is likely to be substantially diQerent from the estimate of eQect.
The results presented in this table should not be interpreted in isolation from the results of individual included studies contributing to each summary test accuracy measure.
 
 
Summary of findings 2.   Xpert MTB/RIF for tuberculous meningitis in children
Review question: what is the diagnostic accuracy of Xpert MTB/RIF for tuberculous meningitis in CSF in children with signs and symptoms of tuberculous meningitis?
Patients/population: children with presumed tuberculous meningitis
Index tests: Xpert MTB/RIF
Role: an initial test
Threshold for index tests: an automated result is provided
Reference standard: culture
Types of studies: cross-sectional and cohort studies
Setting: inpatient
Pooled sensitivity: 0.54 (95% CI 0.28 to 0.78) | Pooled specificity: 0.94 (95% CI 0.84 to 0.98)
Number of results per 1000 patients tested (95% CI)Test result
Prevalence 1% Prevalence 5% Prevalence 10%
Number of
participants
(studies)
Certainty of the evi-
dence (GRADE)
True-positives 5 (3 to 8) 27 (14 to 39) 54 (28 to 78) 28
(6)
⨁◯◯◯
VERY LOW a,b,c,d
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False-negatives 5 (2 to 7) 23 (11 to 36) 46 (22 to 72)
True-negatives 929 (837 to 966) 891 (803 to 927) 844 (761 to 878)
False-positives 61 (24 to 153) 59 (23 to 147) 56 (22 to 139)
213
(6)
⨁⨁◯◯
LOW e,f
CI: confidence interval; CSF: cerebrospinal fluid.
Prevalence levels were suggested by the WHO Global Tuberculosis Programme.
aAs assessed by QUADAS-2, three studies (50%) had low risk of bias and risk of bias was unclear for the remainder. We downgraded one level for risk of bias.
bFor individual studies, sensitivity estimates ranged from 0% to 100%. We thought that diQerences in enrolment criteria (diQerent populations targeted), disease severity, and
setting could only in part explain heterogeneity. We downgraded one level for inconsistency.
cThe setting was unclear or reflected a tertiary care inpatient setting in three studies (50%). However, this is reflective of where the target condition would typically be diagnosed;
therefore we did not downgrade for indirectness.
dThe number of children with tuberculous meningitis contributing to this analysis for observed sensitivity was low. We thought the 95% CI around false-negatives and true-
positives would likely lead to diQerent decisions, depending on which confidence limits are assumed. We downgraded one level for imprecision.
eThe quality of the reference standard was unclear in three studies (50%). We downgraded one level for risk of bias.
fWe thought the 95% CI around false-positives and true-negatives would likely lead to diQerent decisions, depending on which confidence limits are assumed. We downgraded
one level for imprecision.
GRADE certainty of the evidence.
High: we are very confident that the true eQect lies close to that of the estimate of the eQect.
Moderate: we are moderately confident in the eQect estimate: the true eQect is likely to be close to the estimate of the eQect, but there is a possibility that it is substantially
diQerent.
Low: our confidence in the eQect estimate is limited: the true eQect may be substantially diQerent from the estimate of the eQect.
Very low: we have very little confidence in the eQect estimate: the true eQect is likely to be substantially diQerent from the estimate of eQect.
The results presented in this table should not be interpreted in isolation from the results of individual included studies contributing to each summary test accuracy measure.
 
 
Summary of findings 3.   Xpert MTB/RIF for lymph node tuberculosis in children
Review question: what is the diagnostic accuracy of Xpert MTB/RIF for lymph node tuberculosis in a lymph node specimen in children with signs and symptoms of lymph
node tuberculosis?
Patients/population: children with presumed lymph node tuberculosis
Index tests: Xpert MTB/RIF
Role: an initial test
Threshold for index tests: an automated result is provided
Reference standard: culture
Types of studies: cross-sectional and cohort studies
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Setting: inpatient
Pooled sensitivity: 0.90 (95% CI 0.56 to 0.99) | Pooled specificity: 0.90 (95% CI 0.71 to 0.97)
Number of results per 1000 patients tested (95% CI)Test result
Prevalence 1%
Typically seen in
Prevalence 5%
Typically seen in
Prevalence 10%
Typically seen in
Number
of partici-
pants
(studies)
Certainty of the evi-
dence (GRADE)
True-positives 9 (6 to 10) 45 (28 to 49) 90 (56 to 99)
False-negatives 1 (0 to 4) 5 (1 to 22) 10 (1 to 44)
68
(6)
⨁◯◯◯
VERY LOW a,b,c
True-negatives 889 (708 to 958) 853 (679 to 920) 808 (644 to 871)
False-positives 101 (32 to 282) 97 (30 to 271) 92 (29 to 256)
142
(6)
⨁⨁◯◯
LOW d,e,f
CI: confidence interval.
Prevalence levels were suggested by the WHO Global Tuberculosis Programme.
aAs assessed by QUADAS-2, three studies (50%) had high risk of bias. We downgraded one level for risk of bias.
bThree studies (50%) had high or unclear concern about applicability because, in these studies, patients were enrolled from inpatient tertiary care settings, which could lead
to enrolment of children with more advanced disease. We did not downgrade for indirectness, as a more specialized centre for the diagnosis of extrapulmonary tuberculosis in
children is expected.
cThe number of children with lymph node tuberculosis contributing to this analysis for observed sensitivity was low. We thought the 95% CI around false-negatives and true-
positives would likely lead to diQerent decisions, depending on which confidence limits are assumed. We downgraded two levels for imprecision.
dAs assessed by QUADAS-2, all studies (100%) had unclear risk of bias relative to the quality of the reference standard. We downgraded one level for risk of bias.
eFor individual studies, specificity estimates ranged from 50% to 100%. For most studies, specificity was ≥ 96%. We did not downgrade for inconsistency.
fWe thought the 95% CI around false-positives and true-negatives would likely lead to diQerent decisions, depending on which confidence limits are assumed. We downgraded
one level for imprecision
GRADE certainty of the evidence.
High: we are very confident that the true eQect lies close to that of the estimate of the eQect.
Moderate: we are moderately confident in the eQect estimate: the true eQect is likely to be close to the estimate of the eQect, but there is a possibility that it is substantially
diQerent.
Low: our confidence in the eQect estimate is limited: the true eQect may be substantially diQerent from the estimate of the eQect.
Very low: we have very little confidence in the eQect estimate: the true eQect is likely to be substantially diQerent from the estimate of eQect.
The results presented in this table should not be interpreted in isolation from the results of individual included studies contributing to each summary test accuracy measure.
 
 
Summary of findings 4.   Xpert MTB/RIF for rifampicin resistance in children
Review question: what is the diagnostic accuracy of Xpert MTB/RIF for rifampicin resistance in children with signs and symptoms of tuberculosis?
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Patients/population: children with presumed tuberculosis
Index tests: Xpert MTB/RIF
Role: an initial test
Threshold for index tests: an automated result is provided
Reference standard: phenotypic culture-based drug susceptibility testing and MTBDRplus
Types of studies: cross-sectional and cohort studies
Setting: inpatient
Pooled sensitivity: 0.90 (95% CI 0.68 to 0.98) | Pooled specificity: 0.98 (95% CI 0.88 to 0.99)
Number of results per 1000 patients tested (95% CI)Test result
Prevalence 2% Prevalence 10% Prevalence 15%
Number of par-
ticipants
(studies)
Certainty of the evi-
dence (GRADE)
True-positives 18 (14 to 20) 90 (68 to 98) 135 (102 to 147)
False-negatives 2 (0 to 6) 10 (2 to 32) 15 (3 to 48)
20
(6)
⨁⨁◯◯
LOW a
True-negatives 960 (862 to 970) 882 (792 to 891) 833 (748 to 842)
False-positives 20 (10 to 118) 18 (9 to 108) 17 (8 to 102)
203
(6)
⨁⨁⨁◯
MODERATE b,c
CI: confidence interval.
Prevalence levels were suggested by the WHO Global Tuberculosis Programme.
aThe number of children with rifampicin resistance contributing to this analysis for observed sensitivity was low. We thought the 95% CI around false-negatives and true-positives
would likely lead to diQerent decisions, depending on which confidence limits are assumed. We downgraded two levels for imprecision.
bFor individual studies, specificity estimates ranged from 67% in Saini 2018 to 100%. For most studies, specificity was ≥ 97%. We did not downgrade for inconsistency.
cWe thought the 95% CI around false-positives and true-negatives would likely lead to diQerent decisions, depending on which confidence limits are assumed. We downgraded
one level for imprecision.
GRADE certainty of the evidence.
High: we are very confident that the true eQect lies close to that of the estimate of the eQect.
Moderate: we are moderately confident in the eQect estimate: the true eQect is likely to be close to the estimate of the eQect, but there is a possibility that it is substantially
diQerent.
Low: our confidence in the eQect estimate is limited: the true eQect may be substantially diQerent from the estimate of the eQect.
Very low: we have very little confidence in the eQect estimate: the true eQect is likely to be substantially diQerent from the estimate of eQect.
The results presented in this table should not be interpreted in isolation from the results of individual included studies contributing to each summary test accuracy measure.
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B A C K G R O U N D
Tuberculosis is one of the top 10 causes of death and the leading
cause from a single infectious agent (above HIV/AIDS), causing
an estimated 1.2 million deaths in 2018 (WHO Global TB Report
2019). Globally during that year, an estimated 10 million people
developed tuberculosis disease, including around one million
children younger than 14 years and 205,000 children who died of
the disease (WHO Global TB Report 2019). Recent models that have
been accepted and supported by the World Health Organization
(WHO) suggest that there is substantial underreporting as well
as under-diagnosis of tuberculosis in children. Furthermore,
tuberculosis-associated deaths take a disproportionate toll among
children: 253,000 deaths were estimated in 2016 in children
younger than 15 years, accounting for 6.9% of the total deaths
notified in that year; of these deaths, 80% occurred in children
younger than five years of age (Dodd 2017; Jenkins 2017). Estimates
suggest that most deaths among children occur in undiagnosed
cases and represent a missed opportunity to start adequate
treatment (Jenkins 2017).
Tuberculosis treatment for children follows the same principles
as for adults, and the same drugs are used in most cases. The
standard four-drug combination regimen of isoniazid, rifampicin,
pyrazinamide, and ethambutol given daily for a period of two
months followed by isoniazid and rifampicin given daily for an
additional four to six months is used for treatment of drug-
susceptible tuberculosis - both pulmonary and extrapulmonary
forms. Central nervous system tuberculosis is an exception in
that treatment with isoniazid and rifampicin is extended to a
total of 12 months. The recent introduction of paediatric fixed-
dose combinations with optimised dosing and taste masking has
improved the eQiciency of treatment (Wademan 2019). Treatment
of drug-resistant tuberculosis in children generally has better
outcomes than in adults. Of note, in August 2018, the WHO
released a rapid communication containing new recommendations
for treatment of child tuberculosis, including the use of all-oral
regimens (Furin 2019; WHO 2018).
The diagnosis of child tuberculosis relies on a mix of clinical,
epidemiological, radiological, and laboratory information. Child
tuberculosis is typically paucibacillary (tuberculosis disease
caused by a smaller number of bacteria), and young children
cannot voluntarily produce sputum specimens (Marais 2005;
Theart 2005). Hence, even under ideal clinical and laboratory
conditions, only 30% to 40% of child tuberculosis cases are
microbiologically confirmed (Dunn 2016). The probability of
microbiological confirmation is increased in children with more
severe or advanced disease (Marais 2006c; Marais 2006d). However,
the diagnostic gap is perpetuated because conventional smear
microscopy, which is of little value in diagnosing child tuberculosis,
remains the most used and most widely available tuberculosis
diagnostic method in low- and middle-income countries. Further,
the clinical skills and equipment needed for sputum induction and
gastric aspiration are oUen not available in peripheral health clinics
(Reid 2012). Tuberculosis culture methods have shown greater, yet
highly variable, sensitivity in child tuberculosis (Chiang 2017; Frigati
2015); unfortunately, tuberculosis culture to support diagnosis is
not widely available in high-burden settings.
Xpert MTB/RIF represents a promising diagnostic modality for
child tuberculosis. Since 2010, the WHO has recommended the
use of Xpert MTB/RIF as the preferred initial microbiological
test for people thought to have multi-drug-resistant tuberculosis
or HIV-associated tuberculosis (strong recommendation); this
recommendation was extended to include children with presumed
tuberculosis on the strength of evidence reported in adults
(WHO 2011). In 2013 this guidance was updated with a
recommendation specific to children, that is, that Xpert MTB/
RIF should be used as the preferred initial diagnostic test for
children thought to have multi-drug-resistant tuberculosis or
HIV-associated tuberculosis (strong recommendation; very low-
quality evidence) and as the initial diagnostic test for all children
with presumptive tuberculosis (conditional recommendation
acknowledging resource implications; very low-quality evidence)
(WHO 2013). At present, the WHO supports the use of Xpert MTB/RIF
for diagnosis of child tuberculosis in the following four scenarios.
• As the initial diagnostic test of choice, rather than
conventional smear microscopy or culture (conditional
recommendation acknowledging resource implications; very
low-quality evidence - also called certainty of evidence).• For diagnosis in children suspected of having drug-
resistant tuberculosis or HIV-associated tuberculosis (strong
recommendation; very low-quality evidence).• As a replacement test for culture in specific non-respiratory
specimens (lymph nodes and other tissues) for children
presumed to have extrapulmonary tuberculosis (conditional
recommendation; very low-quality evidence).• As the preferred initial diagnostic in cerebrospinal fluid (CSF)
for children suspected of having tuberculous meningitis (strong
recommendation given the urgency of rapid diagnosis; very low-
quality evidence) (WHO 2014a).
The WHO does not currently recommend Xpert MTB/RIF for use with
other specimen types such as stool. Further, existing guidelines
acknowledge that all current recommendations regarding use of
Xpert MTB/RIF in children rely on “very low-certainty evidence” and
are currently evolving with expansion of the use of Xpert MTB/RIF
Ultra (Xpert Ultra) (WHO 2017).
A non-inferiority analysis of Xpert Ultra compared to Xpert MTB/
RIF found that Xpert Ultra has higher sensitivity than Xpert MTB/
RIF, particularly in smear-negative, culture-positive specimens and
in specimens from HIV-positive patients. Xpert Ultra was also
found to have accuracy that was at least as good as Xpert MTB/
RIF for detection of rifampicin resistance. However, it was noted
that Xpert Ultra may have reduced specificity in settings with
high tuberculosis burden. Current WHO recommendations for
the use of Xpert MTB/RIF now also apply to the use of Xpert
Ultra as the initial diagnostic test for all adults and children
with signs and symptoms of tuberculosis as well as to testing of
selected extrapulmonary specimens (cerebrospinal fluid, lymph
nodes, and tissue specimens). However, a negative test result does
not exclude tuberculosis in children (WHO 2017). This systematic
review estimated and compared the diagnostic accuracy of Xpert
MTB/RIF and Xpert Ultra for children presumed to have pulmonary
tuberculosis or specific forms of extrapulmonary tuberculosis.
Target condition being diagnosed
Tuberculosis is an infectious disease caused by bacteria
within the Mycobacterium tuberculosis complex, most
commonly Mycobacterium tuberculosis (M tuberculosis). Typically
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disseminated through the air, M tuberculosis predominantly aQects
the lungs, causing pulmonary tuberculosis, and less typically can
cause disease in other organs of the body in extrapulmonary
tuberculosis forms. Lymph node tuberculosis is the most common
form of extrapulmonary tuberculosis in children, and tuberculous
meningitis results in the highest morbidity and mortality. For
this review, we limited evaluation of extrapulmonary tuberculosis
to lymph node tuberculosis and tuberculous meningitis because
other forms of extrapulmonary tuberculosis in children are less
common, and because evidence evaluating Xpert (Xpert MTB/
RIF and Xpert Ultra) as a diagnostic tool for other forms of
extrapulmonary child tuberculosis is sparse.
The natural history of tuberculosis in children is distinct from
that in adults due to more frequent progression to primary
tuberculosis disease (Marais 2004). Children younger than five
years are at particularly high risk of progression to tuberculous
disease following infection, but the risk for older children and
adolescents is also higher than in adults. Overall, it is estimated
that 90% of tuberculous disease in young children occurs within
one year of infection (Marais 2014). In addition to age, factors
such as nutritional status, immune-compromising conditions (e.g.
HIV infection), BCG (bacillus Calmette–Guérin) vaccination status,
and genetic susceptibility contribute to children’s risk of disease
progression. Immediately following infection with M tuberculosis
in a child, hematogenous spread (by way of the bloodstream)
can occur. The period of highest risk for presentation with
tuberculous meningitis and miliary tuberculosis is one to three
months following primary infection. Children between six months
and two years of age are at particularly high risk of these severe
forms of tuberculous disease. Approximately 50% of children in
this age range progress to tuberculous disease following infection,
and 20% to 40% of those children will present with disseminated
disease (Marais 2004; Marais 2014). Children younger than five
years most commonly present with hilar lymph node forms of
intrathoracic tuberculous disease. Older children and adolescents
more commonly manifest adult-type disease, including pleural
tuberculosis and upper lobe consolidations (Marais 2004).
Laboratory confirmation of child tuberculosis disease is
challenging for two reasons. First, child tuberculosis most
commonly represents as a primary disease process, without
the formation of cavities (Marais 2006a). The number of acid-
fast bacilli (the presence of acid-fast bacilli on a sputum
smear or other specimen oUen indicates tuberculous disease)
present in forms of primary tuberculosis such as hilar lymph
node or bronchial tuberculosis is substantially lower than the
number present in a pulmonary cavity. Consequently, child
tuberculosis is oUen referred to as ‘paucibacillary’, and it is
more diQicult to obtain the organisms needed to confirm
disease via conventional smear or culture (Dunn 2016). Second,
most children younger than six years of age lack the ability
to expectorate sputum and are unable to voluntarily produce
good-quality specimens. Therefore, respiratory specimens are
oUen obtained through sputum induction. As children swallow
respiratory secretions, early-morning gastric aspiration is another
well-established approach to specimen collection. In one study,
the yield of three consecutive morning gastric aspirates was
similar to the yield of one induced sputum specimen (Zar 2005).
Nasopharyngeal aspiration for respiratory specimens is a less
invasive mode of specimen collection (Zar 2012). Stool has also
been studied as a child tuberculosis diagnostic specimen; although
sensitivity has been lower than with traditional specimens, this
specimen has great appeal because collection is non-invasive and
requires no training (Nicol 2013). Because laboratory diagnostics
for tuberculosis perform poorly in children, algorithms involving
signs, symptoms, tuberculosis exposure, HIV status, laboratory
tests, and radiographic findings are commonly used to make a
clinical diagnosis of child tuberculosis. However, these algorithms
have been shown to perform diQerently across settings, and their
sensitivity and specificity may be site-specific (David 2017).
Index test(s)
The index tests in this review are Xpert MTB/RIF and Xpert Ultra
(Cepheid Inc, Sunnyvale, CA, USA). Xpert MTB/RIF and Xpert Ultra
are nucleic acid amplification tests (NAATs) that function as an
automated, closed system that performs real-time polymerase
chain reaction (PCR). Specimens are processed using Xpert Sample
Reagent and are incubated for 15 minutes, aUer which the
processed samples are pipetted into the cartridge. These tests
can be run by operators (such as laboratory technicians and
nurses) with minimal technical expertise. Within two hours, the
tests detect both live and dead M tuberculosis complex DNA and
simultaneously recognize mutations in the M tuberculosis gene
encoding the beta subunit of the RNA polymerase (rpoB) gene,
which is the most common site of M tuberculosis mutations leading
to rifampicin resistance. Xpert MTB/RIF and Xpert Ultra require
an uninterrupted and stable electrical power supply, temperature
control, and yearly calibration of the cartridge modules (WHO
2014b). The WHO has published extensive guidance and practical
information on implementing the test (WHO 2014b).
There have been five generations of the cartridge: G1, G2, G3,
G4, and Xpert Ultra. G1 to G4 cartridges initially improved the
detection of tuberculosis and rifampicin resistance, but Xpert
MTB/RIF sensitivity was still suboptimal in people with smear-
negative (which is oUen seen in children) and HIV-associated
tuberculosis. Xpert Ultra was developed in part to overcome this
limitation and improve test sensitivity. There are limited data
on the diQerent sensitivity that Xpert Ultra oQers as compared
to the G4 cartridge; however, existing data suggest it may
oQer improved sensitivity for tuberculosis detection in hard-
to-diagnose populations such as children, people living with
HIV, and individuals with extrapulmonary tuberculosis (Dorman
2018; WHO 2017). To improve detection of M tuberculosis, Xpert
Ultra incorporates two diQerent multi-copy amplification targets
(IS6110 and IS1081). These revisions resulted in an approximately
1–log improvement in the lower limit of detection compared
with Xpert MTB/RIF, including improved diQerentiation of certain
silent mutations, improved detection of rifampicin resistance
in mixed infections, and avoidance of false-positive results for
detection of rifampicin resistance in paucibacillary specimens
(Chakravorty 2017). As mentioned above, Xpert Ultra also has
decreased specificity compared to G4 and may be more likely to
identify M tuberculosis DNA from prior episodes of tuberculosis
disease, particularly in patients classified in the new ‘trace'
category (Dorman 2018). Trace call corresponds to the lowest
bacillary burden for M tuberculosis detection, as described below
(WHO 2017). This Cochrane Review includes studies that used
any of the Xpert generations in the diagnosis of tuberculosis
(pulmonary tuberculosis, tuberculous meningitis, and lymph node
tuberculosis) in children younger than 15 years.
Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children (Review)
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Clinical pathway
Figure 1 presents an example of the clinical pathway and placement
of the index tests. A careful clinical history of tuberculosis exposure
and symptoms is the first step in the diagnostic pathway for child
tuberculosis. Children with household or other close and persistent
exposure to a person with tuberculosis are at increased risk of
tuberculosis infection and resultant progression to tuberculous
disease. All children with recent exposure to tuberculosis must
be evaluated for clinical symptoms and for examination findings
consistent with tuberculous disease. Additional testing depends
on the context but may include chest radiography and a test
of tuberculosis infection. Symptoms of tuberculosis disease are
generally persistent for longer than two weeks and are unremitting
(Marais 2005). The most common symptoms are cough, fever,
decreased appetite, weight loss or failure to thrive, and fatigue
or reduced playfulness. Symptoms of extrapulmonary tuberculosis
are typically localized, and diagnostic findings are generally
obtained from the site of disease (Figure 1). However, no
symptom-based diagnostic algorithms have been validated or have
been shown to be reliable in multiple contexts. Symptom-based
diagnostic algorithms tend to perform poorly in children younger
than three years and in HIV-positive children - two populations at
high risk for disease progression (Marais 2006b).
 
Figure 1.   AFB: acid-fast bacilli; CT: computed tomography; LAM: mycobacterial lipoarabinomannan antigen; MRI:
magnetic resonance imaging; NAAT: nucleic acid amplification test; TB: tuberculosis; TST: tuberculin skin test. The
Clinical Pathway. Clinical suspicion of tuberculosis includes persistent cough, fever, weight loss or failure to thrive,
lymphadenitis, irritability, lethargy, headache, vomiting or neurological symptoms, history of possible or confirmed
exposure to M tuberculosis, increased risk for tuberculosis disease due to immunocompromising conditions.
1Availability of investigations and tests may be di?erent in high- and low-resource settings and may influence the
approach to the diagnosis of child tuberculosis.
2Non-microbiological confirmation of M tuberculosis does not exclude tuberculosis disease in children; therefore
initiation of treatment should be considered empirically if other clinical indications are present.
Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children (Review)
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3Mycobacterial culture results are rarely timely to aid the decision to initiate treatment but can confirm or refute
clinical decision-making if positive.
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Figure 1.   (Continued)
 
Unfortunately, no clinical examination features are specific
to pulmonary tuberculosis in children. However, examination
findings in extrapulmonary tuberculosis can be quite specific
when identified. Clinicians should consider medical comorbidities
that increase the risk for tuberculous disease and should
modify diagnostic algorithms accordingly. HIV infection not only
significantly increases risk of tuberculosis in the paediatric
population, it also raises the risk of increased disease severity. HIV-
positive children, especially before eQective antiretroviral therapy
is established, oUen present with advanced tuberculosis such as
disseminated disease and have high levels of immunosuppression,
further complicating diagnosis and management.
Additional diagnostic imaging studies can assist in the diagnosis
of pulmonary tuberculosis and nearly all forms of extrapulmonary
tuberculosis. Tests of tuberculous infection, such as interferon
gamma release assays or tuberculin skin tests, can also aid in
establishing the probability of tuberculosis in a child but are not
necessary to make the diagnosis. Diagnostic recommendations
strongly suggest collecting appropriate specimens from suspected
sites of involvement in both pulmonary and extrapulmonary
tuberculosis for microbiological examination. The preferred
specimen in pulmonary tuberculosis is sputum; however in young
children who cannot expectorate, the specimen is commonly
obtained via a gastric aspirate or induced sputum, and stool
is increasingly used. To diagnose extrapulmonary tuberculosis,
collection of samples targets the aQected site of disease.
The purpose of Xpert MTB/RIF and Xpert Ultra testing is diagnosis
of pulmonary and extrapulmonary tuberculosis and detection of
rifampicin resistance. Results of Xpert can be used as a decision-
making tool in the following ways.
• M tuberculosis detected/rifampicin resistance not detected:
child would start treatment for drug-sensitive tuberculosis.• M tuberculosis detected/rifampicin resistance detected: child
would need further resistance testing and would start treatment
for drug-resistant tuberculosis according to country guidelines.• M tuberculosis not detected: a negative Xpert result does
not rule out tuberculous disease; therefore, clinicians should
still consider initiation of tuberculosis treatment in children
with history and clinical or radiological features suggestive of
tuberculosis disease despite a negative Xpert result. A negative
Xpert result may also represent a true-negative.
Possible consequences of a false-positive and a false-negative
result may include the following.
• False-positives (FPs): children and their families would likely
experience anxiety and morbidity caused by additional testing,
unnecessary treatment, and possible adverse eQects; as well
as missed time at school, possible stigma associated with
tuberculosis or a diagnosis of drug-resistant tuberculosis, and
the chance that a false-positive may halt further diagnostic
evaluation for other causes of illness. Families also experience
unnecessary expense.• False-negatives (FNs): would imply increased risk of morbidity
and mortality and delayed start of treatment.
Alternative test(s)
Alternative approaches to Xpert for diagnosis of tuberculosis are
still used extensively globally. Main tests include examination
of smears for acid-fast bacilli (tuberculosis bacteria) under a
microscope (light microscopy, using the classical Ziehl-Neelsen
staining technique), fluorescence microscopy, and light-emitting
diode (LED)-based fluorescence microscopy. The sensitivity of
smear microscopy ranges from 0% to 10% in children (Kunkel
2016). Examination of histology specimens under a microscope
following a tissue biopsy targets finding acid-fast bacilli and
granulomatous inflammation, frequently with caseous necrosis
(necrotizing granulomas); however these options are seldom
pursued to diagnose child tuberculosis in low-resource settings
due to the invasive nature of the procedures and the technical
expertise required. Lipoarabinomannan (LAM) antigen is a
lipopolysaccharide present in the mycobacterial cell wall that
can be detected in the urine of people with tuberculous disease
(Bjerrum 2019). This urine test oQers potential advantages over
sputum-based testing due to ease of sample collection. The
accuracy of urinary LAM detection is improved among people living
with HIV with advanced immunosuppression (Bjerrum 2019; Nicol
2014; Shah 2016b). In two randomized trials, the use of lateral
flow urine lipoarabinomannan assay (LF-LAM) in HIV-positive
adult inpatients was shown to reduce mortality (Gupta-Wright
2018; Peter 2016). Based on evidence from randomized trials and
from a Cochrane Review (Bjerrum 2019), the WHO recommends
that LF-LAM (Alere Determine™ TB LAM Ag, Alere Inc, Waltham,
MA, USA) was the only product available at the time of this
recommendation and should be used to assist in the diagnosis
of active tuberculosis in HIV-positive adults, adolescents, and
children. The full recommendations, which diQer for inpatients and
outpatients, are described at WHO Lateral flow LAM 2019. However,
the evidence for LF-LAM in children is limited and is primarily
extrapolated from adults. A new urine-based, point-of-care LAM
test, Fujifilm SILVAMP TB LAM (FujiLAM, co-developed by FIND,
Geneva, Switzerland, and Fujifilm, Tokyo, Japan), for diagnosis of
tuberculosis, is currently under investigation and has the potential
to increase sensitivity in children (Broger 2019).
The quest for novel and more eQicient technologies for diagnosis
of tuberculosis is a cornerstone of current eQorts to reduce the
burden of disease worldwide. Over the past decade, unprecedented
Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children (Review)
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activity has focused on the development of new tools for
diagnosis of extrapulmonary tuberculosis, largely supported by the
engagement of global agencies. As a result, a strong pipeline of
new tools for diagnosis of tuberculosis will complement the use of
existing ones and will oQer improved options (Boyle 2017).
Rationale
Timely and reliable diagnosis of tuberculosis in children remains
challenging due to both diQiculties in collecting sputum samples
and the paucibacillary nature of the disease. As a result,
undiagnosed cases of disease increase morbidity, mortality, and
disease transmission in this key group.
We are aware of two systematic reviews that determined the
diagnostic accuracy of Xpert MTB/RIF for tuberculosis in children.
Wang 2015 (literature searched up to 28 October 2014) included 11
studies (3801 children) and found that Xpert MTB/RIF had pooled
sensitivity and specificity (95% confidence interval) of 65% (61% to
69%) and 99% (98% to 99%) against a culture reference standard.
Detjen 2015 (literature searched up to 6 January 2015) included 15
studies (3640 children). Similar to Wang 2015, Detjen 2015 found
that sputum Xpert MTB/RIF had pooled sensitivity and specificity
(95% credible interval) of 62% (51% to 73%) and 98% (97% to 99%)
against culture.
In 2013, informed in part by the Detjen 2015 review, the WHO
recommended the use of Xpert MTB/RIF for children as a front-
line test for diagnosis. In preparation for a WHO meeting to
update recommendations on the use of molecular tests for
active tuberculosis, we performed a Cochrane Review to update
the literature, assess the accuracy of both Xpert MTB/RIF and
Xpert Ultra, and address limitations noted in the prior reviews,
in particular, the small number of included studies and the
predominance of hospitalised children.
O B J E C T I V E S
Primary objectives• To determine the diagnostic accuracy of Xpert MTB/RIF and
Xpert Ultra for (a) pulmonary tuberculosis in children presumed
to have tuberculosis; (b) tuberculous meningitis in children
presumed to have tuberculosis; (c) lymph node tuberculosis
in children presumed to have tuberculosis; and (d) rifampicin
resistance in children presumed to have tuberculosis* For tuberculosis detection, index tests were used as the initial
test, replacing standard practice (i.e. smear microscopy or
culture)* For detection of rifampicin resistance, index tests replaced
culture-based drug susceptibility testing as the initial test
Secondary objectives• To compare the accuracy of Xpert MTB/RIF and Xpert Ultra for
each of the four target conditions• To investigate potential sources of heterogeneity in accuracy
estimates* For tuberculosis detection, we considered age, disease
severity, smear-test status, HIV status, clinical setting,
specimen type, high tuberculosis burden, and high
tuberculosis/HIV burden* For detection of rifampicin resistance, we considered multi-
drug-resistant tuberculosis burden• To compare multiple Xpert MTB/RIF or Xpert Ultra results
(repeated testing) with the initial Xpert MTB/RIF or Xpert Ultra
result
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included cross-sectional studies, cohort studies, and
randomized controlled trials from all settings. We included
randomized controlled trials that evaluated use of the test
for patient health outcomes but also reported sensitivity and
specificity. Although the study was a randomized trial for the
purpose of determining the impact of the test versus a comparator
(e.g. usual practice, another test) on health outcomes, the study
design was a cross-sectional design for the purpose of determining
diagnostic accuracy for the index tests in this review. We included
only studies from which we could extract or derive data on
the index test being a true-positive, a false-positive, a true-
negative, or a false-negative as measured against the reference
standards specified below. We excluded case-control studies and
case reports. We used abstracts to identify published studies and
included those that met the inclusion criteria.
Participants
We included studies that evaluated the index tests for pulmonary
or extrapulmonary tuberculosis in HIV-positive and HIV-negative
children aged 0 to 14 years presumed to have tuberculosis.
Studies were eligible for inclusion if they described the use of
Xpert MTB/RIF or Xpert Ultra on routine respiratory specimens
such as expectorated or induced sputum and gastric and
nasopharyngeal specimens. Gastric specimens could be obtained
via gastric aspiration, lavage, or washing as described by study
authors. We included studies that evaluated bronchoalveolar
lavage specimens. In addition, we included studies evaluating stool
specimens because tuberculosis bacilli are present in swallowed
sputum and are recoverable from stool samples using Xpert MTB/
RIF or Xpert Ultra. We also included studies that assessed several
diQerent specimen types.
Index tests
The index tests were Xpert MTB/RIF and Xpert Ultra.
Index test results are automatically generated, and the user is
provided with a printable test result as follows.
• MTB (M tuberculosis) DETECTED; Rif (rifampicin) resistance
DETECTED.• MTB DETECTED; Rif resistance NOT DETECTED.• MTB DETECTED; Rif resistance INDETERMINATE.• MTB NOT DETECTED.• INVALID (the presence or absence of MTB cannot be
determined).• ERROR (the presence or absence of MTB cannot be determined).
Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children (Review)
Copyright © 2020 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
15
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
• NO RESULT (the presence or absence of MTB cannot be
determined).
Xpert Ultra incorporates a semi-quantitative classification for
results: trace, very low, low, moderate, and high. ‘Trace'
corresponds to the lowest bacterial burden for detection of M
tuberculosis (Chakravorty 2017). Although no rifampicin resistance
result will be available for patients with trace results, a trace-
positive result is suQicient to initiate anti-tuberculosis therapy in
children or HIV-positive patients, according to the WHO report
(WHO 2017). Hence, we considered a trace result to mean M
tuberculosis DETECTED.
Target conditions
The target conditions were active pulmonary tuberculosis; two
forms of extrapulmonary tuberculosis - lymph node tuberculosis
and tuberculous meningitis; and rifampicin resistance.
Reference standards
For detection of pulmonary tuberculosis, tuberculous meningitis,
and lymph node tuberculosis, we included two reference
standards.
• Culture: tuberculosis was defined as a positive culture on solid
or liquid medium.• Composite reference standard: tuberculosis was defined as a
positive culture or a clinical decision, based on clinical features,
to initiate treatment for tuberculosis (i.e. clinically diagnosed
tuberculosis). Clinical features might include cough longer than
two weeks, fever, or weight loss; pneumonia that did not
improve with antibiotics; or a history of close contact with an
adult who had tuberculosis.* In the absence of information on tuberculosis treatment,
for the composite reference standard, we accepted a
study-specific definition (i.e. a standardized definition of
tuberculosis defined by the primary study authors), if
available.* For the composite reference standard, when information
about tuberculosis treatment was not available, we accepted
the uniform research definition (Graham 2012; Graham 2015).
In these situations, using the older definition (Graham 2012),
we defined tuberculosis as:□ confirmed, probable, and possible cases; and□ non-tuberculosis.• For the newer definition (Graham 2015), we used the categories
tuberculosis confirmed and not confirmed.* In cases where a study-specific definition for the composite
references standard was applied, this was accepted as well.
A child was considered as ‘not tuberculosis' if the culture result was
negative. In the absence of a culture result, a child was considered
‘not tuberculosis’ if an alternative diagnosis was established, his
or her symptoms resolved without tuberculosis treatment, or he
or she did not progress to tuberculosis disease aUer at least one
month.
Children with unconfirmed tuberculosis were included among
the true-negative population when evaluated against a culture
reference standard. In contrast, children who were not treated for
tuberculosis, or who did not meet the study research definition for
tuberculosis, were included in the true-negative population when
evaluated against a composite reference standard.
Regarding stool specimens (used for the diagnosis of pulmonary
tuberculosis), we defined the reference standard as in MacLean
2019: (1) culture, or (2) Xpert MTB/RIF or Xpert Ultra performed
on a routine respiratory specimen, such as sputum or gastric
aspirate specimen. Stool Xpert MTB/RIF and stool Xpert Ultra
were not included in the definition of the reference standard. In
addition, none of the included studies used stool culture to verify
pulmonary tuberculosis. For these reasons, we thought bias due
to incorporation of the index test was unlikely. Hence, tuberculosis
was defined as a positive culture or a positive Xpert MTB/RIF or a
positive Xpert Ultra on a routine respiratory specimen.
Regarding stool specimens, we also included a composite reference
standard as defined above.
Culture is generally considered the best reference standard for
tuberculosis diagnosis. However, particularly in children with
paucibacillary disease, tuberculosis is verified by culture in only
15% to 50% of cases, depending on disease severity, challenges
of obtaining specimens, and resources (Graham 2015). Evaluation
of multiple specimens, of the same or diQerent types, may
increase the yield of culture for confirming tuberculosis (Cruz 2012;
Zar 2012). Therefore, we considered a higher-quality reference
standard to be one in which more than one specimen was used
to confirm tuberculosis. We considered a lower-quality reference
standard to be one in which only one specimen was used for
tuberculosis diagnosis. We reflected these considerations in the
Quality Assessment of Studies of Diagnostic Accuracy - Revised
(QUADAS-2), Reference Standard domain.
For rifampicin resistance, the reference standards were phenotypic
drug susceptibility testing and MTBDRplus. MTBDRplus is a
molecular line probe assay designed to detect the presence of
multiple mutations causing resistance to isoniazid and rifampicin.
Search methods for identification of studies
We attempted to identify all relevant studies regardless of language
or publication status (published, unpublished, in press, and in
progress).
Electronic searches
We searched the following databases up to 29 April 2019 using the
search terms and strategy described in Appendix 1.
• Cochrane Infectious Diseases Group Specialized Register.• MEDLINE (OVID, from 1966).• Embase (OVID, from 1974).• Cumulative Index to Nursing and Allied Health Literature
(CINAHL (EBSCOHost), from 1982).• Science Citation Index - Expanded (from 1900), Conference
Proceedings Citation Index - Science (CPCI-S, from 1990), from
the Web of Science (Clarivate Analytics).• Scopus (Elsevier, from 1970).
We also searched ClinicalTrials.gov, the WHO International Clinical
Trials Registry Platform (ICTRP; www.who.int/trialsearch), and
the International Standard Randomized Controlled Trials Number
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(ISRCTN) Registry (www.isrctn.com/) for trials in progress, up to 28
January 2020.
Searching other resources
We contacted researchers and experts in the field to identify
additional eligible studies. We checked the references of relevant
reviews and studies to identify additional studies.
Data collection and analysis
Selection of studies
Two review authors independently screened all titles and abstracts
to identify potentially eligible studies. We then obtained the
full-text articles of potentially eligible studies, and two review
authors independently assessed whether they should be included
based on pre-defined inclusion and exclusion criteria. We resolved
disagreements by discussion or by consultation with a third review
author if necessary. We contacted study authors for clarification
of methods and other information as needed. We recorded and
summarized reasons for excluding studies in a Characteristics of
excluded studies table. We illustrated the study selection process in
a PRISMA diagram (Moher 2009).
Data extraction and management
We designed a data extraction form and piloted it on two included
studies (Appendix 2); we then finalized the form based on the pilot
test. As above, two review authors independently extracted data
using this data extraction form and discussed inconsistencies to
achieve consensus. We consulted a third review author to resolve
discrepancies as needed. We entered abstracted data into an
Excel database on password-protected computers (Excel 2013). We
secured the data set in a cloud storage workspace (Dropbox), and
we stored extracted data for future review updates. Selected details
of data extraction are listed below.
Study details• Number of participants aUer screening for exclusion and
inclusion criteria• Total number of children included in the analysis• Total number of specimens included with collection methods• Unit of sample collection: one specimen, multiple specimens,
unknown, or unclear• Percentage (numerator/denominator) of children with prior
tuberculosis• Target condition(s)? - pulmonary tuberculosis, lymph node
tuberculosis, tuberculous meningitis, rifampicin resistance
Patient characteristics and setting• Description of study population• Age: median, mean, range, and disaggregation into categories (0
to 4, 5 to 14)• Gender• HIV status• Smear status• Percentage and number of HIV-positive or HIV-negative
participants, if both were included in the study• Type of respiratory specimen included: expectorated, induced,
nasopharyngeal aspirate, gastric lavage, stool
• Type of non-respiratory specimen included: fine needle
aspirate, lymph node biopsy, cerebrospinal fluid, multiple types,
other, unknown• Number of cultures performed per child to exclude tuberculosis• Data on culture performance: number of contaminated cultures
with respect to total cultures performed• Clinical setting: outpatient or inpatient or both• Description of radiographic findings• Information on tuberculosis burden in the country
We classified ‘country' as being high burden or not high burden for
tuberculosis, tuberculosis/HIV, or multi-drug-resistant tuberculosis
according to the WHO post-2015 era classification (WHO Global TB
Report 2019). A country could be classified as high burden for one,
two, or all three of the high-burden categories.
Index tests• Xpert cartridge: MTB/RIF or Ultra• Pretreatment processing procedure for specimens used for
Xpert MTB/RIF or Xpert Ultra• Specimen condition: fresh, frozen, or both• Numbers of true-positives, false-positives, false-negatives, and
true-negatives (see example table in Appendix 3)• Uninterpretable results for tuberculosis detection (invalid, error,
or no result)• Indeterminate results for detection of rifampicin resistance
Reference standards• Details of culture - solid or liquid• Composite reference standard - description• Rifampicin resistance - phenotypic drug susceptibility testing or
MTBDRplus
For each target condition and specimen type, we considered one
index test result per child. Hence, the primary unit of analysis was
the patient. If studies evaluated more than one specimen type,
we extracted data for each specimen. Hence, a study may have
contributed more than one 2 × 2 table (data set) - one for each type
of specimen evaluated.
Assessment of methodological quality
We assessed the methodological quality of included studies using
the QUADAS-2 instrument, which we adapted for this review
(Whiting 2011). The QUADAS-2 tool consists of four domains: (1)
patient selection, (2) index test(s), (3) reference standard(s), and
(4) flow and timing. All domains are assessed for risk of bias,
and the first three domains for concerns regarding applicability.
We first developed guidance on how to appraise each signalling
question within the domains and how to make the overall
judgement for each domain. One review author piloted the tool
with two of the included studies. We finalized the guidance based
on experience gained from the pilot. The QUADAS-2 tool with
signalling questions tailored to this review is provided in Appendix
4. Two review authors independently completed QUADAS-2. We
resolved disagreements through discussion or by arbitration with a
third review author when necessary. We have presented results of
the quality assessment in the text, in tables, and in graphs.
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Statistical analysis and data synthesis
We performed descriptive analyses of the included studies and
presented their key characteristics in the Characteristics of
included studies table. We presented individual study estimates of
sensitivity and specificity graphically in forest plots and in receiver
operating characteristics (ROC) space using Review Manager 5
(Review Manager 2014).
For detection of rifampicin resistance, we included children who:
• were culture-positive;• had a valid phenotypic drug susceptibility test (DST) result;• were Xpert tuberculosis-positive; and• had a valid Xpert rifampicin result.
Sensitivity = Xpert rifampicin resistant/phenotypic or MTBDRplus
DST rifampicin resistant.
Specificity = Xpert rifampicin susceptible/phenotypic MTBDRplus
DST rifampicin susceptible.
When data were suQicient, we performed meta-analyses to
estimate average sensitivities and specificities using a bivariate
model (Chu 2006; Reitsma 2015). We used the bivariate model
because the index tests, Xpert MTB/RIF, and Xpert Ultra all apply
a common positivity criterion (Macaskill 2010). When we were
unable to fit a bivariate model due to sparse data, few studies,
or little observed variability in specificity, we simplified the model
to a univariate random-eQects logistic regression model to pool
sensitivity and specificity separately (Takwoingi 2015). For the
analysis of Xpert MTB/RIF in the subgroup of smear-positive
children, we performed a univariate analysis of only sensitivity. We
did this because studies or subgroups of smear-positive children
had few or zero false-positives and true-negatives; thus pooling
specificity was not meaningful. We performed meta-analyses using
the meqrlogit command in Stata version 15 (Stata 15). We stratified
all analyses by type of reference standard. For rifampicin resistance
detection, we identified few studies evaluating Xpert MTB/RIF and
zero studies evaluating Xpert Ultra. Therefore, we analysed all
specimen types together.
We performed comparative meta-analyses by restricting the
analyses to only those studies that made direct comparisons
between Xpert MTB/RIF and Xpert Ultra within the same
participants. We performed comparative meta-analyses using
meta-regression by including test type as a covariate in a bivariate
model. We assessed model fit using likelihood ratio tests to
compare models with and without the covariate terms. We
calculated absolute diQerences in sensitivity and specificity using
the bivariate model parameters. We obtained 95% confidence
intervals and P values for the absolute diQerences using the delta
method and Wald tests, respectively. We performed additional
comparative analyses in which we compared the accuracy of Xpert
MTB/RIF and Xpert Ultra for pulmonary tuberculosis on repeated
testing versus a first test.
Approach to uninterpretable index test results
Xpert MTB/RIF and Xpert Ultra report an uninterpretable test
result for unexpected results with any of the internal control
measures of the assay. The uninterpretable rate for detection
of tuberculosis is the number of tests classified as "invalid",
"error", or "no result" divided by the total number of Xpert tests
performed. The indeterminate rate for detection of rifampicin
resistance is the number of tests classified as "MTB DETECTED;
Rif resistance INDETERMINATE" divided by the total number of
Xpert-positive results. We had planned to estimate the pooled
proportion of uninterpretable Xpert MTB/RIF and Xpert Ultra results
for tuberculosis detection and indeterminate Xpert MTB/RIF and
Xpert Ultra results for detection of rifampicin resistance. We were
unable to perform the analyses owing to limited data, but we
have summarized these results in a table along with the key
characteristics of included studies.
Investigations of heterogeneity
We visually inspected forest and summary ROC plots for
heterogeneity. When data allowed, we evaluated sources of
heterogeneity using subgroup analyses and meta-regression. We
were interested in tests performed in key subgroups of children:
age zero to four years, age 5 to 14 years, smear-positive,
smear-negative, HIV-positive, and HIV-negative. For tuberculosis
detection, we performed bivariate meta-regression with the
following potential sources of heterogeneity as a single covariate in
the model.
• High tuberculosis burden: yes or no.• High tuberculosis/HIV burden: yes or no.• Cultures used to verify tuberculosis: multiple or single.
Detection of rifampicin resistance
We had planned to perform bivariate meta-regression while
considering high multi-drug-resistant tuberculosis burden as a
potential source of heterogeneity, but we were unable to perform
this analysis owing to limited data.
Sensitivity analyses
Data were suQicient for sensitivity analyses to explore the eQects
of risk of bias items and study characteristics on pooled estimates
of the accuracy of Xpert MTB/RIF. Such analyses were possible only
for studies that used sputum as the specimen. We limited the meta-
analyses to the following.
• Studies that used consecutive or random selection of
participants.• Studies in which the reference standard results were interpreted
without knowledge of the index test results.• Studies that included only untreated patients.• Studies that explicitly reported enrolling children 0 to 14 years
old.
In addition, for studies in which gastric aspirate specimens and
sputum specimens were collected, data were included with the
sputum analyses within the main analyses; so we performed a
sensitivity analysis excluding these studies.
Assessment of reporting bias
We did not formally assess reporting bias using funnel plots or
regression tests because these have not been reported as helpful
for diagnostic test accuracy studies (Macaskill 2010).
Assessment of certainty of the evidence
We assessed certainty of the evidence by using the GRADE
approach for diagnostic studies (Balshem 2011; Schünemann 2008;
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Schünemann 2016). As recommended, we rated certainty of the
evidence as high (not downgraded), moderate (downgraded by one
level), low (downgraded by two levels), or very low (downgraded
by more than two levels) based on five domains: risk of bias,
indirectness, inconsistency, imprecision, and publication bias. For
each outcome, certainty of the evidence started as high when
high-quality studies (cross-sectional or cohort studies) enrolled
participants with diagnostic uncertainty. If we found a reason for
downgrading, we used our judgement to classify the reason as
serious (downgraded by one level) or very serious (downgraded by
two levels).
Three review authors (AWK, LGF, and KRS) discussed judgements
and applied GRADE in the following way (Schünemann 2020a;
Schünemann 2020b).
Risk of bias
We used QUADAS-2 to assess risk of bias.
Indirectness
We assessed indirectness in relation to the population (including
disease spectrum), setting, interventions, and outcomes (accuracy
measures). We also used prevalence as a guide to whether there
was indirectness in the population.
Inconsistency
GRADE recommends downgrading for unexplained inconsistency in
sensitivity and specificity estimates. We carried out pre-specified
analyses to investigate potential sources of heterogeneity and
downgraded when we could not explain inconsistency in accuracy
estimates.
Imprecision
We considered a precise estimate to be one that would allow a
clinically meaningful decision. We considered the width of the
confidence interval (CI) and asked, “Would we make a diQerent
decision if the lower or upper boundary of the CI represented
the truth?” In addition, we worked out projected ranges for true-
positive (TP), false-negative (FN), true-negative (TN), and false-
positive (FP) for a given prevalence of tuberculosis and made
judgements on imprecision from these calculations.
Publication bias
We rated publication bias as undetected (not serious) for several
reasons including comprehensiveness of the literature search and
extensive outreach to tuberculosis researchers to identify studies.
R E S U L T S
Results of the search
We identified 2174 records through database searches conducted
up to 29 April 2019 and one additional record identified through
other sources. AUer excluding duplicate records, we scrutinized
the titles and abstracts of 835 records and excluded 701 records
for relevance. We retrieved 134 articles and, aUer full-text review,
included 49 studies in the review (Anderson 2014; Andriyoko 2019;
Atwebembeire 2016; Bacha 2017; Bates 2013; Bhatia 2016; Bholla
2016; Brent 2017; Bunyasi 2015; Causse 2011; Chipinduro 2017;
Chisti 2014; Coetzee 2014; Das 2019; Gous 2015; Hanrahan 2018;
Hasan 2017; Kasa Tom 2018; Kim 2015; LaCourse 2014; LaCourse
2018; Ligthelm 2011; Malbruny 2011; Marcy 2016; Moussa 2016;
Myo 2018; Nhu 2013; Nicol 2011; Nicol 2013; Nicol 2018; Orikiriza
2018; Pang 2014; Rachow 2012; Reither 2015; Sabi 2018; Saini 2018;
Sekadde 2013; Singh M 2016; Solomons 2015; Togun 2015; Tortoli
2012; Vadwai 2011; Walters 2014; Walters 2017a; Walters 2018a; Yin
2014; Zar 2012; Zar 2013; Zar 2019) See Characteristics of included
studies. All studies were written in English. Figure 2 shows the flow
of studies in the review. We recorded the excluded studies and
reasons for their exclusion in the Characteristics of excluded studies
table.
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Figure 2.   Study flow diagram.
 
The 49 studies included one randomized trial, 20 cohort studies,
and 28 cross-sectional studies. Thirty-nine studies (80%) took
place in countries with high tuberculosis burden and 39 (80%) in
countries with high TB/HIV burden. Most studies (30/49; 61%) used
liquid culture for the reference standard (Table 1).
For pulmonary tuberculosis, 299 data sets (68,544 participants)
were available for analysis; for tuberculous meningitis, 10 data
sets (423 participants) were available; for lymph node tuberculosis,
10 data sets (318 participants) were available; and for rifampicin
resistance, 14 data sets (326 participants) were available.
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Methodological quality of included studies
Pulmonary tuberculosis, tuberculous meningitis, and lymph
node tuberculosis
Figure 3 and Figure 4 show risk of bias and applicability concerns
for 49 studies that evaluated Xpert MTB/RIF and Xpert Ultra for
detection of pulmonary tuberculosis, tuberculous meningitis, or
lymph node tuberculosis.
 
Figure 3.   Risk of bias and applicability concerns graph: review authors' judgements about each domain presented
as percentages across included studies.
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Figure 4.   Risk of bias and applicability concerns summary: review authors' judgements about each domain for each
included study.
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Figure 4.   (Continued)
 
In the Patient Selection domain, we considered 39 studies (80%)
to have low risk of bias because studies enrolled a consecutive or
random sample of eligible participants and avoided inappropriate
exclusions. We considered five studies (10%) to have high risk
of bias because they did not avoid inappropriate exclusions:
one study enrolled participants whose sputum specimens were
primarily or exclusively smear-positive or smear-negative (Pang
2014); three studies enrolled only participants with negative testing
for tuberculosis before performance of bronchoalveolar lavage
(Saini 2018; Walters 2014; Yin 2014); and one study enrolled
patients using a convenience sample (Hasan 2017). In addition,
we considered five studies to have unclear risk of bias because
the manner of participant selection was not stated (Ligthelm 2011;
Malbruny 2011; Moussa 2016; Solomons 2015; Tortoli 2012). With
respect to applicability, we considered 24 studies (49%) to have
low concern because participants in these studies were evaluated
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in primary care facilities, in local hospitals, or in both settings
(Anderson 2014; Atwebembeire 2016; Bacha 2017; Bhatia 2016;
Chipinduro 2017; Chisti 2014; Coetzee 2014; Das 2019; Gous 2015;
Hanrahan 2018; Hasan 2017; Marcy 2016; Myo 2018; Nicol 2013;
Nicol 2018; Orikiriza 2018; Rachow 2012; Reither 2015; Sabi 2018;
Sekadde 2013; Solomons 2015; Togun 2015; Walters 2018a; Zar
2013). We considered 17 studies (34%) to have high concern
because participants were evaluated exclusively as inpatients in
tertiary care centres (Andriyoko 2019; Bates 2013; Kasa Tom 2018;
Kim 2015; LaCourse 2014; LaCourse 2018; Nhu 2013; Nicol 2011;
Pang 2014; Saini 2018; Singh M 2016; Vadwai 2011; Walters 2014;
Walters 2017a; Yin 2014; Zar 2012; Zar 2019). We considered eight
studies to have unclear concern because we could not be sure
about concerns (Bholla 2016; Brent 2017; Bunyasi 2015; Causse
2011;Ligthelm 2011; Malbruny 2011; Moussa 2016; Tortoli 2012).
In the Index Test domain, we considered all studies to have
low risk of bias. With respect to applicability, we considered 37
studies (76%) to have low concern and one study to have high
concern because the ratio of sample reagent to specimen volume
diQered from that recommended by the manufacturer (Gous 2015).
We also considered all 11 studies (22%) that evaluated stool
specimens to have unclear concern because of the absence of
an established protocol for stool processing before Xpert MTB/
RIF testing (Andriyoko 2019; Chipinduro 2017; Hanrahan 2018;
Hasan 2017; LaCourse 2018; Marcy 2016; Moussa 2016; Nicol 2013;
Orikiriza 2018; Walters 2017a; Walters 2018a).
In the Reference Standard domain, we considered 23 studies
to have low risk of bias and 26 studies (53%) to have unclear
risk of bias because the ability of the reference standard to
appropriately classify child tuberculosis was uncertain (Anderson
2014; Andriyoko 2019; Atwebembeire 2016; Bacha 2017; Bates 2013;
Bhatia 2016; Bholla 2016; Causse 2011; Chipinduro 2017; Chisti
2014; Coetzee 2014; Das 2019; Gous 2015; Hasan 2017; Kasa Tom
2018; Kim 2015; Ligthelm 2011; Malbruny 2011; Myo 2018; Orikiriza
2018; Pang 2014; Singh M 2016; Solomons 2015; Tortoli 2012;
Vadwai 2011; Yin 2014). With respect to applicability, we considered
45 studies to have low concern because speciation was performed,
confirming M tuberculosis instead of other mycobacterial species,
and four studies (8%) to have unclear concern because we could not
tell whether speciation was performed (Bacha 2017; Bhatia 2016;
Hanrahan 2018; Kasa Tom 2018).
In the Flow and Timing domain, we considered 44 studies (90%)
to have low risk of bias because all participants were included in
the analysis. We considered four studies to have high risk of bias
because results of the index or reference tests were not available
for many participants (Anderson 2014; Bacha 2017; Kasa Tom 2018;
Pang 2014). We considered one study to have unclear risk of bias
because we could not tell whether the index and reference tests
were collected at appropriate intervals (Tortoli 2012).
Rifampicin resistance
Figure 5 shows risk of bias and applicability concerns for 14 studies
evaluating Xpert MTB/RIF for detection of rifampicin resistance.
 
Figure 5.   Risk of bias and applicability concerns graph for rifampicin resistance: review authors' judgements about
each domain presented as percentages across included studies.
 
In the Patient Selection domain, we considered eight studies (57%)
to have low risk of bias because studies enrolled a consecutive or
random sample of eligible participants and avoided inappropriate
exclusions (Bates 2013; Bholla 2016; Chipinduro 2017; Das 2019;
Rachow 2012; Reither 2015; Zar 2012; Zar 2013). We considered
four studies (29%) to have high risk of bias because studies did not
avoid inappropriate exclusions and instead enrolled participants
pre-selected on the basis of their sputum specimens being smear-
negative or studies exclusively enrolled participants who had
negative testing before bronchoalveolar lavage (Pang 2014; Saini
2018; Walters 2014; Yin 2014). We considered two studies (14%)
to have unclear risk of bias because the manner of participant
selection was not reported (Malbruny 2011; Tortoli 2012). With
respect to applicability, we considered five studies (36%) to have
low concern because participants in these studies were evaluated
in primary care facilities, in local hospitals, or in both settings
(Chipinduro 2017; Das 2019; Rachow 2012; Reither 2015; Zar 2013).
We considered six studies to have high concern (43%) because
participants were evaluated exclusively as inpatients in tertiary
care centres (Bates 2013; Pang 2014; Saini 2018; Walters 2014; Yin
2014; Zar 2012). We considered the remaining three studies (21%) to
have unclear concern because we could not be sure about concerns
(Bholla 2016; Malbruny 2011; Tortoli 2012).
In the Index Test domain, we considered all studies to have low
risk of bias. With respect to applicability, we considered 13 studies
(93%) to have low concern and one study (7%) that evaluated
stool specimens to have unclear concern because of the absence of
an established protocol for stool processing before Xpert MTB/RIF
testing (Chipinduro 2017).
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In the Reference Standard domain, we considered eight studies
(57%) to have low risk of bias because results of the reference
standard were interpreted without knowledge of results of the
index test (Bholla 2016; Chipinduro 2017; Rachow 2012; Reither
2015; Saini 2018; Tortoli 2012; Yin 2014; Zar 2012). We considered
the remaining six studies (43%) to have unclear risk of bias because
information about blinding was not reported (Bates 2013; Das 2019;
Malbruny 2011; Pang 2014; Walters 2014; Zar 2013). With respect
to applicability, we considered all studies to have low concern
because in these studies, all specimens had already been speciated
and identified as M tuberculosis.
In the Flow and Timing domain, we considered 12 studies (86%) to
have low risk of bias because all participants were included in the
analysis. We considered one study (7%) to have high risk of bias
because all participants were not included in the analysis (Pang
2014). We considered one study (7%) to have unclear risk of bias
because we could not tell if the index and reference tests were
collected at appropriate intervals (Tortoli 2012).
Findings
I. Detection of pulmonary tuberculosis
Due to little observed variability in specificity and in the volume of
analyses, we chose to present only forest plots, as such plots were
more informative than corresponding summary receiver operator
characteristics (SROC) plots.
I.A. Xpert MTB/RIF and Xpert Ultra for pulmonary tuberculosis
I.A.1. Xpert MTB/RIF in sputum - induced or expectorated
Studies were conducted in Bangladesh, Gambia, India, Kenya,
Malawi, South Africa, Tanzania, Uganda, Vietnam, Zambia, and
Zimbabwe.
I.A.I.a. Culture reference standard
Twenty-five studies (6812 participants) evaluated Xpert MTB/RIF in
sputum specimens against culture (Anderson 2014; Atwebembeire
2016; Bacha 2017; Bates 2013; Brent 2017; Bunyasi 2015;
Chipinduro 2017; Chisti 2014; Das 2019; Gous 2015; Hanrahan 2018;
LaCourse 2014; Malbruny 2011; Nhu 2013; Nicol 2011; Nicol 2013;
Orikiriza 2018; Rachow 2012; Reither 2015; Sekadde 2013; Singh M
2016; Togun 2015; Walters 2017a; Zar 2012; Zar 2013). Xpert MTB/
RIF sensitivity ranged from 23% to 100%, and specificity from 87%
to 100% (Figure 6). Two studies had no cases of tuberculosis, and
so sensitivity was not estimable (Hanrahan 2018; Malbruny 2011).
In sputum, Xpert MTB/RIF pooled sensitivity and specificity were as
follows against culture (95% CI): 64.6% (55.3% to 72.9%) and 99.0%
(98.1% to 99.5%).
 
Figure 6.   Forest plots of Xpert MTB/RIF sensitivity and specificity for pulmonary tuberculosis in sputum (culture
reference standard). The squares represent the sensitivity and specificity of one study, the black line its confidence
interval. FN: false-negative; FP: false-positive; TN: true-negative; TP: true-positive.
 
I.A.I.b. Composite reference standard
Seventeen studies (4382 participants) evaluated Xpert MTB/RIF
in sputum specimens against a composite reference standard
(Anderson 2014; Bacha 2017; Brent 2017; Chipinduro 2017; Chisti
2014; Hanrahan 2018; LaCourse 2014; Malbruny 2011; Nhu 2013;
Nicol 2011; Nicol 2013; Rachow 2012; Reither 2015; Singh M 2016;
Togun 2015; Zar 2012; Zar 2013) (Figure 7). Malbruny 2011 had no
cases without tuberculosis, and so specificity was not estimable.
In sputum, Xpert MTB/RIF pooled sensitivity and specificity were
Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children (Review)
Copyright © 2020 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
25
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
as follows against a composite reference standard (95% CI): 19.7%
(12.1% to 30.4%) and 100% (99.8% to 100%) (Table 2).
 
Figure 7.   Forest plots of Xpert MTB/RIF sensitivity and specificity for pulmonary tuberculosis in sputum (composite
reference standard). The squares represent the sensitivity and specificity of one study, the black line its confidence
interval. FN: false-negative; FP: false-positive; TN: true-negative; TP: true-positive.
 
I.B. Xpert Ultra in sputum
Studies were conducted in South Africa and Tanzania.
I.B.1.a. Culture reference standard
Three studies (697 participants) evaluated Xpert Ultra in sputum
specimens against culture (Nicol 2018; Sabi 2018; Zar 2019). Xpert
Ultra sensitivity ranged from 64% to 75%, and specificity from 97%
to 100% (Figure 8). Xpert Ultra pooled sensitivity and specificity
were as follows in sputum specimens (95% CI): 72.8% (64.7% to
79.6%) and 97.5% (95.8% to 98.5%) (Table 2).
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Figure 8.   Forest plots of Xpert Ultra sensitivity and specificity for pulmonary tuberculosis by specimen type,
reference standard, HIV status, and results of testing using multiple specimens compared to one specimen (culture
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reference standard). The squares represent the sensitivity and specificity of one study, the black line its confidence
interval. FN: false-negative; FP: false-positive; TN: true-negative; TP: true-positive.
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I.B.2.b. Composite reference standard
Three studies (753 participants) evaluated Xpert Ultra in sputum
specimens against a composite reference standard (Nicol 2018;
Sabi 2018; Zar 2019) (Figure 8). Xpert Ultra pooled sensitivity and
specificity were as follows against a composite reference standard
(95% CI): 23.5% (20.0% to 27.4%) and 99.2% (96.9% to 99.8%) (Table
2).
I.A.2. Xpert MTB/RIF in gastric aspirate specimens
Studies were conducted in Bangladesh, Burkina Faso, Cambodia,
Cameroon, China, India, Italy, Kenya, Myanmar, Pakistan, South
Africa, Spain, Vietnam, and Zambia.
I.A.2.a. Culture reference standard
FiUeen studies (3487 participants) evaluated Xpert MTB/RIF in
gastric aspirate specimens against culture (Bates 2013; Bunyasi
2015; Causse 2011; Chisti 2014; Das 2019; Hanrahan 2018; Hasan
2017; LaCourse 2018; Malbruny 2011; Marcy 2016; Myo 2018; Nhu
2013; Pang 2014; Tortoli 2012; Walters 2017a (Figure 9). Malbruny
2011 had no cases with tuberculosis, and so sensitivity was not
estimable. Xpert MTB/RIF sensitivity ranged from 0% to 100%, and
specificity from 90% to 100%. In gastric aspirate specimens, Xpert
MTB/RIF pooled sensitivity and specificity against culture were as
follows (95% CI): 73.0% (52.9% to 86.7%) and 98.1% (95.5% to
99.2%) (Table 2).
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Figure 9.   Forest plots of tests Xpert MTB/RIF sensitivity and specificity for pulmonary tuberculosis in gastric
aspirate specimens, stool specimens, and nasopharyngeal aspirates (culture reference standard).The squares
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represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false-negative; FP:
false-positive; TN: true-negative; TP: true-positive.
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I.A.2.b. Composite reference standard
Seven studies (948 participants) evaluated Xpert MTB/RIF in gastric
aspirate specimens against a composite reference standard (Chisti
2014; Hasan 2017; Kasa Tom 2018; LaCourse 2018; ; Nhu 2013;
Pang 2014). Nhu 2013 had no cases without tuberculosis, and so
specificity was not estimable. In gastric aspirate specimens, Xpert
MTB/RIF pooled sensitivity and specificity against a composite
reference standard were as follows (95% CI): 31.7% (20.2% to
46.0%) and 99.7% (97.1% to 100%) (Table 2).
I.B.2. Xpert Ultra in gastric aspirate specimens
We did not identify any studies that evaluated Xpert Ultra in
gastric aspirate specimens, against culture or against a composite
reference standard.
I.A.3. Xpert MTB/RIF in stool specimens
Studies were conducted in Burkina Faso, Cambodia, Cameroon,
Egypt, Indonesia, Kenya, Pakistan, South Africa, Uganda, Vietnam,
and Zimbabwe.
1.A.3.a. Culture reference standard
Eleven studies (1592 participants) evaluated Xpert MTB/RIF in
stool specimens against culture (Andriyoko 2019; Chipinduro 2017;
Hanrahan 2018; Hasan 2017; LaCourse 2018; Marcy 2016; Moussa
2016; Nicol 2013; Orikiriza 2018; Walters 2017a; Walters 2018a)
(Figure 9). In stool specimens, Xpert MTB/RIF pooled sensitivity and
specificity against culture were as follows (95% CI): 61.5% (44.1% to
76.4%) and 98.5% (97.0% to 99.2%) (Table 2).
I.A.3.b. Composite reference standard
Ten studies (1739 participants) evaluated Xpert MTB/RIF in stool
specimens against a composite reference standard (Chipinduro
2017; Hanrahan 2018; Hasan 2017; LaCourse 2018; Marcy 2016;
Moussa 2016; Nicol 2013; Orikiriza 2018; Walters 2017a; Walters
2018a). In stool specimens, Xpert MTB/RIF pooled sensitivity and
specificity against a composite reference standard were as follows
(95% CI): 16.3% (8.4% to 29.2%) and 99.7% (97.8% to 100%) (Table
2).
I.B.3. Xpert Ultra in stool specimens
We did not identify any studies that evaluated Xpert Ultra in stool
specimens against culture or a composite reference standard.
I.A.4. Xpert MTB/RIF in nasopharyngeal specimens
Studies were conducted in Burkina Faso, Cambodia, Cameroon,
Vietnam, and South Africa.
1.A.4.a. Culture reference standard
Four studies (1125 participants) evaluated Xpert MTB/RIF in
nasopharyngeal specimens against culture (Hanrahan 2018; Marcy
2016; Zar 2012; Zar 2013) (Figure 9). In nasopharyngeal specimens,
Xpert MTB/RIF pooled sensitivity and specificity against culture
were as follows (95% CI): 45.7% (27.6% to 65.1%) and 99.6% (98.9%
to 99.8%) (Table 2).
I.A.4.b. Composite reference standard
For Xpert MTB/RIF, we did not extract data on nasopharyngeal
specimens against a composite reference standard.
I.B.4. Xpert Ultra in nasopharyngeal specimens
1.B.4.a. Culture reference standard
One study evaluated Xpert Ultra in nasopharyngeal specimens
against culture. Xpert Ultra sensitivity and specificity (95% CI) were
45.7% (28.9% to 63.3%) and 97.5% (93.7% to 99.3%), respectively
(Zar 2019) (Figure 8).
I.B.4.b. Composite reference standard
For Xpert Ultra, we did not extract data on nasopharyngeal
specimens against a composite reference standard.
I.C. Xpert Ultra versus Xpert MTB/RIF
Three studies compared Xpert Ultra and Xpert MTB/RIF in frozen
sputum specimens against a reference standard of culture on a
sputum specimen (Nicol 2018; Sabi 2018; Zar 2019). Each study
mainly compared the tests head-to-head for the same participants.
Xpert Ultra sensitivity (95% CI) was higher (70.5%, 62.7% to 77.45)
than that of Xpert MTB/RIF (63.2%, 54.8% to 70.9%), and specificity
lower (Xpert Ultra: 97.3%, 95.5% to 98.4% versus Xpert MTB/RIF:
99.2%, 97.8% to 99.7%). The absolute diQerence in sensitivity was
not statistically significant, but test specificity was reduced with
Xpert Ultra (P = 0.02) (Table 3).
I.D. Investigations of heterogeneity
I.D.1. Xpert MTB/RIF accuracy by smear status
I.D.1.a. Smear-positive
Eleven studies (103 participants) evaluated Xpert MTB/RIF from
sputum specimens in smear-positive children against culture
(Bacha 2017; Bates 2013; Brent 2017; Chipinduro 2017; LaCourse
2014; Nhu 2013; Nicol 2011; Rachow 2012; Sekadde 2013; Singh M
2016; Zar 2012) (Figure 10). In smear-positive children, Xpert MTB/
RIF pooled sensitivity in sputum specimens (95% CI) was 97.8%
(91.6% to 99.4%) (Table 2).
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Figure 10.   Forest plots of Xpert MTB/RIF sensitivity and specificity for pulmonary tuberculosis in sputum by smear
status (culture reference standard). The squares represent the sensitivity and specificity of one study, the black line
its confidence interval. FN: false-negative; FP: false-positive; TN: true-negative; TP: true-positive.
 
I.D.1.b. Smear-negative
Thirteen studies (3121 participants) evaluated Xpert MTB/RIF from
sputum specimens in smear-negative children against culture
(Bacha 2017; Bates 2013; Brent 2017; Chipinduro 2017; Chisti 2014;
LaCourse 2014; Malbruny 2011; Nhu 2013; Nicol 2011; Rachow 2012;
Sekadde 2013; Singh M 2016; Zar 2012) (Figure 10). Malbruny 2011
had no cases of tuberculosis, and so sensitivity was not estimable.
For smear-negative children, Xpert MTB/RIF pooled sensitivity and
specificity (95% CI) in sputum specimens were 58.9% (45.6% to
71.0%) and 99.1% (97.1% to 99.7%) (Table 2).
I.D.2. Xpert MTB/RIF accuracy by HIV status
I.D.2.a. HIV-positive sputum specimens
In HIV-positive children, 11 studies (649 participants) evaluated
Xpert MTB/RIF in sputum specimens (Anderson 2014; Bacha 2017;
Bates 2013; Chipinduro 2017; LaCourse 2014; Nhu 2013; Nicol 2011;
Nicol 2013; Rachow 2012; Sekadde 2013; Zar 2012) (Figure 11).
LaCourse 2014 had no cases of tuberculosis, and so sensitivity
was not estimable. Xpert MTB/RIF pooled sensitivity and specificity
(95% CI) were 72.2% (59.9% to 81.8%) and 99.4% (97.2% to 99.9%)
(Table 2).
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Figure 11.   Forest plot of Xpert MTB/RIF sensitivity and specificity in sputum specimens, gastric aspirate specimens,
and stool specimens in HIV-positive children (culture reference standard). The squares represent the sensitivity
and specificity of one study, the black line its confidence interval. FN: false-negative; FP: false-positive; TN: true-
negative; TP: true-positive.
 
I.D.2.b. HIV-negative sputum specimens
In HIV-negative children, 12 studies (Anderson 2014; Bacha 2017;
Bates 2013; Bunyasi 2015; LaCourse 2014; Nicol 2011; Nicol 2013;
Rachow 2012; Reither 2015; Sekadde 2013; Togun 2015; Zar 2012)
(2784 participants) evaluated Xpert MTB/RIF in sputum specimens.
Xpert MTB/RIF pooled sensitivity and specificity (95% CI) were
54.3% (43.5% to 64.7%) and 99.3% (98.1% to 99.7%) (Table 2).
Restricting the analysis to studies that provided data for both HIV-
positive and HIV-negative children within the same study did not
make a diQerence in the accuracy estimates.
I.D.2.c. HIV-positive gastric aspirate specimens
In HIV-positive children, three studies (634 participants) evaluated
Xpert MTB/RIF in gastric aspirate specimens against culture (Bates
2013; LaCourse 2018; Marcy 2016) (Figure 11). Xpert MTB/RIF pooled
sensitivity and specificity (95% CI) were 73.3% (54.9% to 86.1%) and
98.5% (97.1% to 99.2%) (Table 2).
I.D.2.d. HIV-positive stool specimens
In HIV-positive children, four studies (526 participants) evaluated
Xpert MTB/RIF in stool specimens against culture (Chipinduro 2017;
LaCourse 2018; Marcy 2016; Nicol 2013) (Figure 11). Xpert MTB/RIF
pooled sensitivity and specificity (95% CI) were 69.8% (56.3% to
80.6%) and 98.6% (96.1% to 99.5%) (Table 2).
I.D.3. Xpert MTB/RIF accuracy in children by age group
I.D.3.a. Sputum specimens - induced
In children 5 to 14 years of age, five studies (627 participants)
evaluated Xpert MTB/RIF in induced sputum specimens against
culture (Chipinduro 2017; Nicol 2011; Rachow 2012; Sekadde 2013;
Zar 2012). Xpert MTB/RIF pooled sensitivity and specificity (95%
CI) were 80.5% (66.9% to 89.4%) and 98.2% (94.4% to 99.4%). In
children birth to four years of age, seven studies (2062 participants)
evaluated induced sputum specimens against culture (Bunyasi
2015; Chisti 2014; LaCourse 2014; Nicol 2011; Rachow 2012;
Sekadde 2013; Zar 2012). Xpert MTB/RIF pooled sensitivity and
specificity (95% CI) were 48.6% (32.5% to 65.0%) and 99.4% (96.7%
to 99.9%). The absolute diQerence in sensitivity was statistically
significant, at 31.9% (95% CI 11.7 to 52.2) (P = 0.002; Table 4).
I.D.3.b. Gastric aspirate specimens
In children birth to four years of age, four studies (1795 participants)
evaluated Xpert MTB/RIF in gastric aspirate specimens against
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culture. Xpert MTB/RIF pooled sensitivity and specificity (95% CI)
were 43.0% (16.2% to 74.6%) and 99.5% (97.0% to 99.9%) (Table 4).
I.D.4. Xpert MTB/RIF accuracy, e?ects of tuberculosis burden and TB/
HIV burden
I.D.4.a. Countries with high tuberculosis burden
In countries with high tuberculosis burden, 18 studies (5162
participants) evaluated Xpert MTB/RIF in sputum against culture.
Xpert MTB/RIF pooled sensitivity and specificity (95% CI) were
63.8% (53.5% to 73.0%) and 99.1% (97.9% to 99.6%). In countries
not considered to be high burden, five studies (1466 participants)
evaluated Xpert MTB/RIF in sputum against culture. Xpert MTB/RIF
pooled sensitivity and specificity (95% CI) were 70.2% (46.9% to
86.3%) and 98.8% (97.6% to 99.4%). We did not find a significant
diQerence in accuracy estimates (Table 4).
I.D.4.b. Countries with high TB/HIV burden
In countries with high TB/HIV burden, 19 studies (5824 participants)
evaluated Xpert MTB/RIF in sputum against culture. Xpert MTB/RIF
pooled sensitivity and specificity (95% CI) were 65.7% (55.0% to
75.1%) and 99.2% (98.3% to 99.7%). In countries not considered to
be high TB/HIV burden, four studies (879 participants) evaluated
Xpert MTB/RIF in sputum against culture. Xpert MTB/RIF pooled
sensitivity and specificity (95% CI) were 59.5% (39.6% to 76.7%) and
97.4% (93.8% to 98.9%). We did not find a significant diQerence in
accuracy estimates (Table 5).
I.D.5. Xpert MTB/RIF accuracy in sputum - multiple specimens versus a
single specimen used for the reference standard
We stratified studies that inoculated multiple sputum specimens
on culture to verify pulmonary tuberculosis (higher-quality
reference standard) and those that inoculated a single sputum
specimen on culture (lower-quality reference standard) because
we suspected that the former was likely to correctly classify more
patients with tuberculosis (Figure 6). In comparison to studies that
used a single culture (Xpert MTB/RIF pooled sensitivity (95% CI)
69.1% (56.6% to 79.3%) and specificity (95% CI) 98.6% (96.5% to
99.5%)), studies that used multiple cultures had lower sensitivity
(95% CI), at 61.0% (48.9% to 71.9%) and similar specificity, at 99.3%
(98.4% to 99.7%). We did not find a significant diQerence in accuracy
estimates (Table 4).
II. Detection of tuberculous meningitis
II.A. Xpert MTB/RIF for tuberculous meningitis
Studies were conducted in France, India, Italy, Spain, South Africa,
and Vietnam.
II. A.1. Culture reference standard
Eight studies (268 participants) evaluated Xpert MTB/RIF in
cerebrospinal fluid against culture (Bhatia 2016; Causse 2011; Das
2019; Malbruny 2011; Nhu 2013; Solomons 2015; Tortoli 2012;
Vadwai 2011) (Figure 12). Two of the studies had no cases of
tuberculosis, and so sensitivity was not estimable (Causse 2011;
Nhu 2013). Xpert MTB/RIF pooled sensitivity and specificity (95% CI)
were 54.0% (27.8% to 78.2%) and 93.8% (84.5% to 97.6%) (Table 5).
 
Figure 12.   Forest plots of Xpert MTB/RIF sensitivity and specificity for tuberculous meningitis and lymph node
tuberculosis (culture reference standard). The squares represent the sensitivity and specificity of one study, the
black line its confidence interval. FN: false-negative; FP: false-positive; TN: true-negative; TP: true-positive.
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II.A.2. Composite reference standard
Two studies evaluated Xpert MTB/RIF in cerebrospinal fluid against
a composite reference standard. Sensitivities were 25% (95% CI 15
to 39) and 38% (95% CI 22 to 56) (Bhatia 2016; Solomons 2015);
specificity was 100% in both studies. We did not perform a meta-
analysis owing to insuQicient data.
II.B. Xpert Ultra for detection of tuberculous meningitis
We did not identify any studies that evaluated Xpert Ultra for
tuberculous meningitis.
III. Detection of lymph node tuberculosis
III.A. Xpert MTB/RIF for detection of lymph node tuberculosis
Studies were conducted in India, Italy, South Africa, and Tanzania.
III.A.1. Culture reference standard
Seven studies (211 participants) evaluated Xpert MTB/RIF in lymph
node specimens against culture (Bholla 2016; Coetzee 2014; Das
2019; Ligthelm 2011; Malbruny 2011; Tortoli 2012; Vadwai 2011)
(Figure 12). Malbruny 2011 had no cases of tuberculosis, and so
sensitivity was not estimable. Xpert MTB/RIF pooled sensitivity and
specificity (95% CI) were 90.4% (55.7% to 98.6%) and 89.8% (71.5%
to 96.8%) (Table 5).
III.A.2. Composite reference standard
Three studies (107 participants) evaluated Xpert MTB/RIF in lymph
node specimens against a composite reference standard (Bholla
2016; Kim 2015; Ligthelm 2011). Ligthelm 2011 had no cases
without tuberculosis, and so specificity was not estimable. In Bholla
2016, Xpert MTB/RIF sensitivity and specificity (95% CI) were 18%
(9% to 30%) and 100% (4% to 100%), and in Kim 2015, sensitivity
and specificity (95% CI) were 78% (52% to 94%) and 100% (87%
to 100%). We did not perform a meta-analysis owing to insuQicient
data.
III.B. Xpert Ultra for detection of lymph node tuberculosis
We did not identify any studies that evaluated Xpert Ultra for lymph
node tuberculosis.
IV. Detection of rifampicin resistance
IV.A. Xpert MTB/RIF for detection of rifampicin resistance
Fourteen studies provided data on detection of rifampicin
resistance (Bates 2013; Bholla 2016; Chipinduro 2017; Das 2019;
Malbruny 2011; Pang 2014; Rachow 2012; Reither 2015; Saini 2018;
Tortoli 2012; Walters 2014; Yin 2014; Zar 2012; Zar 2013) (Figure
13). Studies were conducted in China, India, South Africa, and
Zambia. We were able to include only six studies in the meta-
analysis because the remaining eight studies did not have any
cases of rifampicin resistance, and we could not estimate sensitivity
(Bates 2013; Das 2019; Pang 2014; Saini 2018; Yin 2014; Zar 2012).
All six studies (223 participants) evaluated only Xpert MTB/RIF
and were conducted in countries with high multi-drug-resistant
tuberculosis burden. These studies included sputum, gastric and
bronchoalveolar lavage, and cerebrospinal fluid and lymph node
specimens. Xpert MTB/RIF sensitivity for rifampicin resistance
ranged from 67% to 100%, and specificity from 67% to 100%. Xpert
MTB/RIF pooled sensitivity and specificity (95% CI) were 90.0%
(67.6% to 97.5%) and 98.3% (87.7% to 99.8%) (Table 2).
 
Figure 13.   Forest plots of Xpert MTB/RIF sensitivity and specificity for rifampicin resistance. The squares represent
the sensitivity and specificity of one study, the black line its confidence interval. FN: false-negative; FP: false-
positive; TN: true-negative; TP: true-positive.
 
IV.B. Xpert Ultra for detection of rifampicin resistance
We identified one study that evaluated Xpert Ultra in
nasopharyngeal specimens for rifampicin resistance verified by
MGIT-drug susceptibility testing and MTBDRplus as the reference
standards (Zar 2019). Of 30 isolates tested, Xpert Ultra identified
one isolate as rifampicin-resistant, 22 isolates as rifampicin-
susceptible, and seven isolates as inconclusive. Among specimens
with valid results, both sensitivity and specificity of Xpert Ultra for
detection of rifampicin resistance were 100%.
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Other analyses
Detection of pulmonary tuberculosis using more than one Xpert MTB/
RIF or Xpert Ultra tests
Xpert MTB/RIF
We identified five studies that evaluated more than one Xpert MTB/
RIF test (1935 participants) versus a single Xpert MTB/RIF test (1939
participants) in sputum specimens (Bunyasi 2015; Rachow 2012;
Sabi 2018; Zar 2012; Zar 2013); one study (935 participants) that
evaluated Xpert MTB/RIF in gastric aspirate specimens (Bunyasi
2015); one study (247 participants with multiple Xpert MTB/RIF
tests and 236 with one Xpert MTB/RIF test) that evaluated Xpert
MTB/RIF in stool specimens (Walters 2018a); and two studies
(705 participants) that evaluated Xpert MTB/RIF in nasopharyngeal
specimens (Zar 2012; Zar 2013) (Figure 14).
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Figure 14.   Forest plots of Xpert MTB/RIF sensitivity and specificity for pulmonary tuberculosis in various
specimens, multiple Xpert MTB/RIF tests versus one Xpert MTB/RIF test. The squares represent the sensitivity
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and specificity of one study, the black line its confidence interval. FN: false-negative; FP: false-positive; TN: true-
negative; TP: true-positive.
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The absolute diQerence in pooled sensitivity (95% CI) for more
than one Xpert MTB/RIF test versus a single Xpert MTB/RIF test by
specimen type was 12.8% (-6.78% to 32.3%; P = 0.20) in sputum
specimens; 13.2% (-4.64% to 31.1%; P = 0.15) in gastric aspirate
specimens; 13.5% (-9.50% to 36.5%; P = 0.25) in nasopharyngeal
specimens; and 10.3% (-20.8% to 41.4%; P = 0.52) in stool
specimens. The absolute diQerence in pooled specificity (95% CI)
for multiple Xpert MTB/RIF tests versus a single Xpert MTB/RIF
test by specimen type was -0.34% (-1.09% to 0.41%; P = 0.37) for
sputum; -0.45% (-0.99% to 0.09%; P = 0.10) for gastric aspirate
specimens; -0.49% (-1.63% to 0.66%; P = 0.40) for nasopharyngeal
specimens; and 0.02% (-1.21% to 1.25%; P =. 0.97) for stool
specimens (Table 6).
Xpert Ultra
We identified one study (135 participants) that evaluated Xpert
Ultra in sputum specimens (Sabi 2018), and we identified
another study (130 participants) that evaluated Xpert Ultra in
nasopharyngeal specimens (Zar 2019) (Figure 8). The absolute
diQerence in pooled sensitivity (95% CI) for more than one Xpert
Ultra test versus a single Xpert Ultra test by specimen type was
10.7% (-13.2% to 34.6%; P = 0.38) for sputum specimens and 16.7%
(-11.1% to 44.5%; P = 0.25) for nasopharyngeal specimens. The
absolute diQerence in pooled specificity (95% CI) by specimen type
was -1.87% (-4.44% to 0.70%; P = 0.16) for sputum and -1.89%
(-6.34% to 2.57%; P = 0.41) for nasopharyngeal specimens (Table 6).
Uninterpretable index test results
Detection of tuberculosis, uninterpretable results
Few reported results were uninterpretable (i.e. invalid, error,
or no result) for Xpert MTB/RIF and Xpert Ultra for detection
of tuberculosis in the included studies. We summarized this
information in Table 1.
Indeterminate results, rifampicin resistance
In 15 studies that reported indeterminate results for rifampicin
resistance, few Xpert MTB/RIF results were indeterminate for
detection of rifampicin resistance. Zero indeterminate results
were reported in 11 studies (Bates 2013; Bholla 2016; Das 2019;
Gous 2015; Ligthelm 2011; Malbruny 2011; Nhu 2013; Nicol 2011;
Rachow 2012; Tortoli 2012; Sekadde 2013). Walters 2018a reported
10% (1/10) indeterminate results in stool specimens, and Zar
2012reported 3% (4/127) indeterminate results in nasopharyngeal
and stool specimens.
Sensitivity analyses
We undertook sensitivity analyses by limiting inclusion in the meta-
analysis to the following,
• Random or consecutive recruitment of participants.• Blinding of reference standard to index test results.• No pre-treatment of participants.• Enrolment only of children aged 0 to 14 years.• Sputum only (excluding studies that also collected gastric
aspirate specimens).
These sensitivity analyses made little diQerence to any of the
findings (Table 7).
D I S C U S S I O N
Summary of main results
This systematic review summarizes the current literature and
includes 49 unique studies on the accuracy of Xpert MTB/RIF
and Xpert Ultra for pulmonary tuberculosis (TB), tuberculous
meningitis, lymph node tuberculosis, and rifampicin resistance.
Major findings from the review include the following.
Xpert MTB/RIF accuracy for pulmonary TB (culture reference
standard)• In sputum specimen, Xpert MTB/RIF pooled sensitivity was
64.6% (95% CI 55.3% to 72.9%) (23 studies, 493 participants)• In gastric aspirate specimens, Xpert MTB/RIF pooled sensitivity
was 73.0% (95% CI 52.9% to 86.7%) (14 studies, 273 participants)• In stool specimens, Xpert MTB/RIF pooled sensitivity was 61.5%
(95% CI 44.1% to 76.4%) (11 studies, 174 participants)• In nasopharyngeal specimens, Xpert MTB/RIF pooled sensitivity
was 45.7% (95% CI 27.6% to 65.1%) (4 studies, 144 participants)• In the above specimens, Xpert MTB/RIF pooled specificity was ≥
98.1%
Xpert Ultra accuracy for pulmonary tuberculosis (culture
reference standard)• In sputum specimens, Xpert Ultra pooled sensitivity was 72.8%
(95% CI 64.7% to 79.6%) (3 studies, 136 participants)• In nasopharyngeal specimens, Xpert Ultra sensitivity was 45.7%
(95% CI 28.9% to 63.3%) (1 study, 35 participants)• Xpert Ultra specificity was 97.5% in both specimen types
Xpert MTB/RIF accuracy for pulmonary TB (composite
reference standard)• In sputum specimen, Xpert MTB/RIF pooled sensitivity was
19.7% (95% CI 12.1% to 30.4%) (16 studies, 1541 participants)• In gastric aspirate specimens, Xpert MTB/RIF pooled sensitivity
was 31.7% (95% CI 20.2% to 46.0%) (6 studies, 461 participants)• In stool specimens, Xpert MTB/RIF pooled sensitivity was 16.3%
(95% CI 8.4% to 29.2%) (10 studies, 879 participants)• In the above specimens, Xpert MTB/RIF specificity was ≥ 99.7%
Xpert Ultra accuracy for pulmonary tuberculosis (composite
reference standard)• In sputum specimens, Xpert Ultra sensitivity was 23.5% (95% CI
20.0% to 27.4%) (3 studies, 498 participants)
Xpert MTB/RIF accuracy for tuberculous meningitis (culture
reference standard)• In cerebrospinal fluid, Xpert MTB/RIF sensitivity and specificity
were 54.0% (95% CI 27.8% to 78.2%) and 93.8% (95% CI 84.5%
to 97.6%) (6 studies, 262 participants; 28 with tuberculosis)
We did not identify any studies of Xpert Ultra for tuberculous
meningitis.
Xpert MTB/RIF accuracy for lymph node tuberculosis (culture
reference standard)• In lymph node specimens, Xpert MTB/RIF sensitivity and
specificity were 90.4% (95% CI 55.7% to 98.6%) and 89.8%
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(95% CI 71.5% to 96.8%) (6 studies, 210 participants; 54 with
tuberculosis)
We did not identify any studies of Xpert Ultra for lymph node
tuberculosis.
Rifampicin resistance• Xpert MTB/RIF sensitivity and specificity were 90.0% (95% CI
67.6% to 97.5%) and 98.3% (95% CI 87.7% to 99.8%) (6 studies,
223 participants; 20 with rifampicin resistance)
We did not identify studies of Xpert Ultra for detection of rifampicin
resistance.
The main findings of the review are summarized in Summary of
findings 1, Summary of findings 2, Summary of findings 3, and
Summary of findings 4.
Xpert MTB/RIF for pulmonary tuberculosis, sputum specimens
In theory, for a population of 1000 children, 100 of whom have
pulmonary tuberculosis on culture, 74 would be Xpert MTB/RIF-
positive and 9 (12%) would not have tuberculosis (false-positives);
926 would be Xpert MTB/RIF-negative and 35 (4%) would have
tuberculosis (false-negatives) (Summary of findings 1).
Xpert Ultra for pulmonary tuberculosis, sputum specimens
In theory, for a population of 1000 children, 100 of whom have
pulmonary tuberculosis on culture, 100 would be Xpert Ultra-
positive and 27 (27%) would not have tuberculosis (false-positives);
900 would be Xpert Ultra-negative and 27 (3%) would have
tuberculosis (false-negatives) (Summary of findings 1).
Xpert MTB/RIF for tuberculous meningitis, cerebrospinal fluid
In theory, for a population of 1000 children, 100 of whom have
tuberculous meningitis on culture, 86 would be Xpert MTB/RIF-
positive and 59 (69%) would not have tuberculosis (false-positives);
914 would be Xpert MTB/RIF-negative and 23 (3%) would have
tuberculosis (false-negatives) (Summary of findings 2).
Xpert MTB/RIF for lymph node tuberculosis, lymph node
specimens
In theory, for a population of 1000 children, 100 of whom have
lymph node tuberculosis on culture, 142 would be Xpert MTB/RIF-
positive and 97 (68%) would not have lymph node tuberculosis
(false-positives); 858 would be Xpert MTB/RIF-negative and 5 (1%)
would have lymph node tuberculosis (false-negatives) (Summary
of findings 3).
Xpert MTB/RIF for detection of rifampicin resistance
In theory, for a population of 1000 children, 100 of whom
have rifampicin resistance, 108 would have Xpert MTB/RIF-
rifampicin resistance detected and 18 (17%) would not have
rifampicin resistance (false-positives); 892 would have Xpert MTB/
RIF-rifampicin resistance NOT detected and 10 (1%) would have
rifampicin resistance (false-negatives) (Summary of findings 4).
Overall this review adds to the existing body of evidence on
Xpert MTB/RIF and Xpert Ultra diagnostic accuracy in children.
Most notable are the new data on performance of diQerent
specimen types that are now being introduced to improve access to
diagnostic testing for tuberculosis in children. Further, this review
expands on evidence supporting the increase in test sensitivity that
is achieved through testing multiple specimens by Xpert MTB/RIF
and Xpert Ultra. These findings provide new evidence by which
to shape the development of global practice guidelines for the
diagnosis of tuberculosis in children.
Specifically, our review demonstrated diQering sensitivities in the
diQerent types of specimens. We think that these findings may
in part be attributable to diQerences in the clinical setting and
in the quality of the reference standard, mainly culture. With
respect to the clinical setting, it is more common to collect
gastric aspirate specimens in inpatient settings; further, these
settings tend to include a higher number of children with advanced
disease, which oUen has a higher microbiological yield (Marais
2006d). Thus, the higher sensitivity against a culture and composite
reference standard for gastric aspirate specimens may in part be
due to the inpatient setting and higher likelihood of advanced
disease. Regarding the reference standard, some studies performed
only one culture, and other studies more than one culture,
to verify tuberculosis. We considered multiple cultures to be a
higher-quality reference standard. However, we did not observe a
significant diQerence in Xpert MTB/RIF accuracy in sputum when
multiple versus single cultures were used to verify pulmonary
tuberculosis. In some studies from low-income countries, only one
culture was performed; this is consistent with standard practice in
many countries with a high burden of tuberculosis. As has been
previously documented, the sensitivity (95% CI) of Xpert MTB/RIF
was nearly perfect in children with smear-positive tuberculosis
97.8% (91.6% to 99.4%) and was still 58.9% (45.6% to 71.0%) in the
smear-negative subgroup. Data indicate clearly that the diagnostic
accuracy of Xpert MTB/RIF is superior to that of sputum smear in
children.
Against a composite reference standard, we found that Xpert MTB/
RIF had a sensitivity of 19.7% and Xpert Ultra had a sensitivity of
23.5%. These results were higher then those reported in the prior
review (Detjen 2015) and may reflect changes in the consensus
definition or the broader sample of research sites included in this
review. In adults, Xpert Ultra trace results may be more likely
to reflect false-positive results, particularly in patients with prior
tuberculosis (Dorman 2018). Xpert Ultra trace results on sputum
were reported in two studies (Nicol 2018; Sabi 2018). Twenty-one
trace results were obtained on frozen specimens, with 20 occurring
in patients with confirmed or unconfirmed tuberculosis; one
occurred in a patient with unlikely tuberculosis. Nasopharyngeal
specimens specifically yielded nine trace results (Zar 2019), none
of which were identified in patients unlikely to have tuberculosis.
These limited data suggest that trace results in children indicate
true disease and should be treated as such. More data are needed
with regard to trace results, particularly on specimens other than
sputum.
We found the sensitivity (95% CI) of stool Xpert MTB/RIF to be
slightly lower at 61.5% (44.1% to 76.4%) than that of sputum Xpert
MTB/RIF at 64.6% (95% CI 55.3% to 72.9%). Nonetheless, stool is
a promising specimen for diagnosis because, unlike sputum, it is
non-invasive. Its greatest benefit may be seen in children younger
than five years owing to the challenges of collecting specimens
through sputum induction and gastric aspiration in this population.
However, no studies evaluating Xpert MTB/RIF in stool provided
disaggregated data for analyses in the youngest age groups. As in
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MacLean 2019, we noted the lack of standardized procedures for
processing stool, with each study using a diQerent approach.
When multiple specimens of the same type were tested, we
noted an increase in Xpert MTB/RIF sensitivity for pulmonary
tuberculosis in all specimen types. In comparison with testing
an initial specimen, Xpert MTB/RIF specificity was similar when
multiple specimens were tested.
In a head-to-head comparison of frozen sputum specimens, Xpert
Ultra yielded higher sensitivity (70.5%) than Xpert MTB/RIF (63.2%)
and lower specificity (Ultra: 97.3% versus Xpert MTB/RIF: 99.2%).
Although in comparison with Xpert MTB/RIF, Ultra specificity was
slightly decreased, the improvement in Xpert Ultra sensitivity may
provide greater benefit than the harm associated with a slight
reduction in Ultra specificity in the paediatric population.
In subgroup analyses, we found the sensitivity of Xpert MTB/RIF to
be higher in HIV-positive than HIV-negative children. These findings
were similar when we limited the analysis to studies that included
both HIV-positive and HIV-negative children in the same study. We
note that the number of cases in most studies was small: HIV-
positive group, median (interquartile range) = 8 (5 to 13), and HIV-
negative group, median (interquartile range) = 13 (5.5 to 26). We
think random variation may in part explain these results, although
they may also reflect the increased likelihood of presentation with
severe tuberculosis in HIV-positive children.
Regarding age, we found higher sensitivity of Xpert MTB/RIF in
sputum from children 5 to 14 years old compared to children 0
to 4 years old. The sensitivity of Xpert MTB/RIF in gastric aspirate
specimens from children 0 to 4 years old was similar to that
in sputum. This has implications for clinical decision-making in
children 0 to 4 years of age, when a negative Xpert may provide less
reassurance to the treating clinician, particularly due to higher risk
for adverse tuberculosis outcomes in this population.
Although Xpert MTB/RIF sensitivity in lymph node specimens was
90%, specificity was lower than in sputum specimens (98%).
Regarding the accuracy of the reference standard in lymph node
specimens in particular, several factors may have contributed
to false-negative culture results, including ineQicient specimen
collection and overly harsh decontamination (Kohli 2018). As
with pulmonary tuberculosis, the sensitivity of Xpert MTB/RIF for
tuberculous meningitis is not adequate to withhold treatment
based on the test result, and the entirety of the clinical information
must be considered.
For detection of rifampicin resistance, we found Xpert MTB/RIF to
have lower sensitivity (95% CI) at 90.0% (67.6% to 97.5%) than that
in a Cochrane Review of Xpert MTB/RIF for pulmonary tuberculosis
and rifampicin resistance in adults at 96% (94% to 97%) (Horne
2019). We note that in the current review, only 20 rifampicin-
resistant specimens contributed to the determination of sensitivity,
whereas in Horne 2019, there were 1775 rifampicin-resistant
specimens. Compared to the current review, the sensitivity
estimate in Horne 2019 was more precise. Specificities were similar
(98%).
We identified one large pilot project in India that evaluated Xpert
MTB/RIF for pulmonary tuberculosis in sputum verified by smear
microscopy (Raizada 2015a). We did not include this study in
our systematic review because the reference standard (smear)
did not satisfy the criterion for inclusion. Results of this project
demonstrated high sensitivity (1521/1530; 99.4%) of Xpert MTB/RIF
against smear.
Strengths and weaknesses of the review
Completeness of evidence
The data set resulted from comprehensively searching numerous
databases, handsearching references of included studies, and
contacting investigators for additional evidence. We included
all identified non-English studies from which we could obtain
accuracy data. However, we acknowledge that we may have
missed some studies despite the comprehensive search and
outreach to investigators. We included the two most common
forms of extrapulmonary tuberculosis - tuberculous meningitis and
lymph node tuberculosis. Hence, the review does not include an
evaluation of the accuracy of Xpert MTB/RIF and Xpert Ultra in less
common forms of child tuberculosis.
Accuracy of the reference standards used
In a systematic review of diagnostic test accuracy studies,
the reference standard is the best available test to determine
the presence or absence of the target condition. In this
review, we included two reference standards - culture and
a composite reference standard. Although culture is the best
available microbiological reference standard, it is not a perfect
reference standard for active tuberculosis in children owing to
the paucibacillary nature of the disease. Some studies performed
only one culture and others more than one culture to verify
tuberculosis. We considered multiple cultures to be a higher-
quality reference standard. We also evaluated the accuracy of
Xpert MTB/RIF and Xpert Ultra against a composite reference
standard defined as (1) a positive culture or a clinician decision
to treat for pulmonary or extrapulmonary tuberculosis, or (2)
a standardized research definition of child tuberculosis. The
accuracy of composite reference standards is also variable and
limited (in most analyses, Xpert MTB/RIF and Ultra identified
less than 30% of cases) but may reflect the paucibacillary
nature of childhood tuberculosis, which is not taken into account
when culture positivity is taken as the reference standard for
comparison. If data on tuberculosis treatment were not provided,
we accepted the uniform research definitions or the definition used
by the primary study authors (study-specific definition) for the
composite reference standard. Therefore, clinical characteristics
and component tests in the composite reference standard diQered
across studies, and these diQerences may have contributed to
variation in accuracy estimates.
Quality of reporting of the included studies
We considered risk of bias to be low for the patient selection,
index test, and flow and timing domains, and low or unclear for
the reference standard domain, because some studies collected
only a single specimen for culture. In general, studies were fairly
well reported. When data were unclear, or when we needed
additional information, we corresponded with many of the primary
study authors. The quality of the studies was good, but for some
specimen types and for Xpert Ultra, the numbers of studies and
participants enrolled were small, limiting our ability to draw
definitive conclusions in these circumstances.
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Comparison with other systematic reviews
Our systematic review on the diagnostic accuracy of Xpert MTB/
RIF and Xpert Ultra for tuberculosis in children builds on a prior
systematic review on this topic - Detjen 2015 - and includes 34
additional studies on Xpert MTB/RIF published since that time, as
well as emerging data on Xpert Ultra. For detection of pulmonary
tuberculosis, Detjen 2015 found Xpert MTB/RIF sensitivity of 62% in
sputum specimens and 66% in gastric aspirate specimens against
culture. The current review found slightly higher Xpert MTB/RIF
sensitivity estimates - 65% in sputum specimens and 73% in gastric
aspirate specimens. Another systematic review for pulmonary
tuberculosis found Xpert MTB/RIF sensitivity of 65% in respiratory
specimens (culture reference standard) (Wang 2015) - similar to the
pooled sensitivity estimate for sputum specimens in this review.
Specificity in these reviews was similar to ours, at 98% to 99%.
We identified two additional systematic reviews on the diagnostic
accuracy of Xpert MTB/RIF in stool specimens. MacLean 2019 found
that stool Xpert MTB/RIF had a pooled sensitivity of 67% against
a microbiological reference standard consisting of either culture
or Xpert MTB/RIF on a respiratory specimen. Mesman 2019 found
that stool Xpert MTB/RIF had a pooled sensitivity of 57% against
culture on respiratory specimens and 60% against Xpert MTB/RIF
on respiratory specimens. Our systematic review found stool Xpert
MTB/RIF had a pooled sensitivity of 61.5% against a microbiological
reference standard consisting of either culture or Xpert MTB/RIF on
respiratory specimens - findings consistent with those of the prior
reviews. Specificity in both reviews was similar to ours, at 98% to
99%.
Applicability of findings to the review question
To assess the applicability of findings to the review question,
we considered QUADAS-2 domains for patient selection, index
test, and reference standard. With respect to the patient selection
domain, we considered many studies to have high or unclear
risk of bias because either patients were evaluated exclusively
as inpatients in a tertiary care setting or the clinical setting was
not clearly reported. Therefore, our findings cannot definitively
be applied to the primary care setting. Studies that take place
in referral settings may include patients whose condition is more
advanced or more diQicult to diagnose than patients seen at lower
levels of the health system. With respect to the index test, we
considered most studies to have low concern about applicability.
However, we considered applicability of the index test in stool to
be unclear, as currently, there is not a standardized protocol for
stool testing with Xpert MTB/RIF or Xpert Ultra. The applicability of
Xpert Ultra in respiratory specimens comes with some uncertainty,
as all data were reported in frozen specimens. With respect to the
reference test domain, we considered most studies to have low
concern about applicability.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
For detection of pulmonary tuberculosis, the sensitivity of
Xpert Ultra was higher than that of Xpert MTB/RIF in sputum,
suggesting that Xpert Ultra may detect an increased proportion
of paucibacillary tuberculosis in children. Although in comparison
with Xpert MTB/RIF, Ultra specificity was slightly decreased, the
improvement in Xpert Ultra sensitivity may provide greater benefit
than the harm associated with a slight reduction in Ultra specificity
in the paediatric population. Nonetheless, owing to the small
numbers of studies and participants in many of the analyses in this
review, we advise caution in interpreting these results. In addition,
we note that, in this review, all studies assessing the performance
of Xpert Ultra evaluated the test in frozen specimens originally
collected for testing Xpert MTB/RIF. Additional prospective studies
on the performance of Xpert Ultra in fresh clinical specimens
are needed. As always, the prevalence of tuberculosis in the test
population will influence the predictive value of Xpert MTB/RIF and
Xpert Ultra results.
Xpert MTB/RIF sensitivity (defined by culture) for pulmonary
tuberculosis was variable across diQerent specimen types,
including sputum, gastric, stool, and nasopharyngeal specimens.
The highest sensitivity was seen with gastric aspirate specimens,
followed by sputum specimens, and the lowest in nasopharyngeal
specimens. Specificity was high in all of these aforementioned
specimens. Xpert MTB/RIF sensitivity may increase when multiple
specimens of the same type are tested compared with a single
specimen. Although not evaluated in this review, it is likely that
collecting multiple specimens of diQerent types will also increase
Xpert MTB/RIF and Xpert Ultra sensitivity. However, considering
the diQiculties of collecting sputum specimens from children,
as well as the limitations of culture to verify the diagnosis
of tuberculosis, clinicians should consider collecting additional
specimens, whenever possible the least invasive, for testing with
Xpert MTB/RIF or Xpert Ultra. The lower sensitivity of the Xpert MTB/
RIF test in children 0 to 4 years of age should prompt clinicians not
only to collect multiple specimens but also to treat based on other
clinical information in this vulnerable population.
Xpert MTB/RIF was accurate for detection of rifampicin resistance.
Xpert MTB/RIF was sensitive for lymph node tuberculosis.
Regarding tuberculous meningitis, as with pulmonary tuberculosis,
treatment decisions should be based on the entirety of clinical
information, and treatment not withheld based solely on an Xpert
MTB/RIF result.
Evidence in this review is based mainly on culture as the reference
standard and accuracy calculated on the assumption that the
reference standard is 100% sensitive and specific. Although culture
is acceptable, it is an imperfect reference standard for child
tuberculosis. Without a more accurate reference standard that
has a limit of detection low enough to detect paucibacillary
tuberculosis, the accuracy of novel diagnostic tests for tuberculosis
in children will remain diQicult to estimate. Despite the presence
of a negative Xpert MTB/RIF or Xpert Ultra result, clinicians will still
need to consider anti-tuberculosis treatment in children with a high
suspicion of tuberculosis or at high risk of a poor outcome.
Implications for research
There are several areas for which additional research regarding
the diagnostic accuracy of molecular tests in children is necessary.
Studies are urgently needed that evaluate the accuracy of Xpert
Ultra in gastric and stool specimens for pulmonary tuberculosis
and extrapulmonary tuberculosis in children. Ideally, these studies
would be prospective and would evaluate fresh specimens, rather
than retrospective utilizing frozen specimens. Establishing the
diagnostic accuracy of Xpert Ultra in extrapulmonary specimens
is also an urgent need, particularly given the encouraging results
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regarding Xpert Ultra performance in cerebrospinal fluid obtained
from adults.
Xpert MTB/RIF sensitivity estimates increased with multiple as
compared to one specimen in a small number of studies;
however, additional studies evaluating the combinatorial benefit
of multiple specimen types are needed. Limited data suggest that
the combination of non-invasive specimens performs comparably
with traditional gastric aspirate specimens or induced sputum
specimens.
More research is needed to identify an improved reference
standard that accurately defines tuberculosis in children.
Additional operational and qualitative research is needed
to determine the best approach to less invasive specimen
collection. Implementation studies on a method of suction for
nasopharyngeal aspiration that is appropriate for low-skill or
low-resource environments are needed. Addtional operational
research concerning the use of stool as a diagnostic specimen
is needed. These studies should address integration into normal
diagnostic clinical pathways, definition of laboratory protocols
that successfully balance ease of implementation and diagnostic
performance, and the impact of stool testing on patient-important
outcomes. There is a dearth of qualitative research identifying
child and family preferences for and acceptability of comparative
diagnostic approaches and specimen collection procedures.
We underscore the continued urgent need to develop new tools
that accurately diagnose tuberculosis in children. Ideally, these
new tools will be rapid, aQordable, feasible, and acceptable to
children and their parents.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Study characteristics
Patient Sampling Cohort study, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: persistent cough for > 2 weeks; pneu-
monia not responding to first-line antibiotics; unexplained fever for >
2 weeks; unexplained progressive weight loss or failure to thrive for
> 4 weeks; history of close TB contact; and/or a doctor’s clinical sus-
picion of TB for any other reason. Children with ≥ 1 of these features
plus those referred for outpatient investigation for TB and children < 5
years old who were identified as household TB contacts of smear-posi-
tive pulmonary TB were eligible for inclusion in the study
Age: range for study population 0 to 180 months; culture-confirmed
cases: median (interquartile range) 37 (12 to 104) months 
Sex, female: 35%
HIV infection: 40%
Sample size included for analysis: 134
Clinical setting: inpatient and outpatient
Laboratory level where index test was performed: not reported
Country: Kenya
World Bank income classification: middle income
Anderson 2014 
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High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 26%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
MGIT; composite reference standard; clinical reference standard (re-
ceived tuberculosis treatment)
Flow and timing 87% of enrolled children were excluded before selection for the array
study for feasibility
Comparative  
Notes Primary aim of study was to evaluate a gene signature for TB diagnosis
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and set-
ting do not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test
have introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or in-
terpretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the tar-
get condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Unclear    
Anderson 2014  (Continued)
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Could the reference standard, its conduct, or its inter-
pretation have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined
by the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? No    
Could the patient flow have introduced bias?   High risk  
Anderson 2014  (Continued)
 
 
Study characteristics
Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: presumptive TB
symptoms (no additional details)
Age: median (IQR) 17 (5.5 to 78) months 
Sex: NR
HIV infection: NR
Sample size included for analysis: 27
Clinical setting: inpatient
Laboratory level where index test was performed: in-
termediate
Country: Indonesia
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 22%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
Xpert test on standard specimens (7 induced sputum
and 20 gastric specimens)
Flow and timing Index and reference test specimens were collected
within 7 days
Comparative  
Notes No consensus has been reached on appropriate stool
processing methods; this study used gravity separa-
tion
Andriyoko 2019 
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Methodological quality
Item Authors'
judgement
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Unclear
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Andriyoko 2019  (Continued)
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Study characteristics
Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: presumptive TB
symptoms (no additional details)
Age: 18% younger than 60 months; 82% 60 months or
older
Sex, female: 55%
HIV infection: 31%
Sample size included for analysis: 85
Clinical setting: inpatient
Laboratory level where index test was performed: re-
search
Country: Uganda
World Bank income classification: low income
High TB burden country: no
High TB/HIV burden country: yes
High MDR-TB burden country: no
Prevalence of tuberculosis cases in the study: 13%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
MGIT; LJ
Flow and timing Index and reference test specimens were collected
within 7 days of each other
Comparative  
Notes  
Methodological quality
Item Authors'
judgement
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Atwebembeire 2016 
Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children (Review)
Copyright © 2020 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
59
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Unclear    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Atwebembeire 2016  (Continued)
 
 
Study characteristics
Patient Sampling Cohort, consecutive, retrospective
Patient characteristics and setting Presenting signs and symptoms: clinicians used a combination of
TB screening questions (e.g. history of known TB contact, failure
to gain weight/weight loss, persistent cough, persistent fever, re-
duced activities, irritability) and clinical examination findings (e.g.
malnutrition, lymphadenopathy, abnormal lung findings) based
on national guidelines
Age: mean (range) 60 (1 to 168) months 
Sex, female: 52%
HIV infection: 54%
Sample size included for analysis: 286
Clinical setting: inpatient and outpatient
Laboratory level where index test was performed: research
Country: Tanzania
World Bank income classification: low income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: no
Bacha 2017 
Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children (Review)
Copyright © 2020 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
60
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Prevalence of tuberculosis cases in the study: 13%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
Microbiological confirmation (culture type not reported); compos-
ite reference standard; clinical reference standard (received tuber-
culosis treatment)
Flow and timing Xpert and reference test performed within 7 days of each other
Comparative  
Notes All patients did not have a specimen collected for the microbiolog-
ical reference standard
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Unclear    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Unclear    
Bacha 2017  (Continued)
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Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? No    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   High risk  
Bacha 2017  (Continued)
 
 
Study characteristics
Patient Sampling Cross-sectional design, manner of selection not reported,
prospective
Patient characteristics and setting Presenting signs and symptoms: suspected tuberculosis defined
as having tuberculosis on the basis of a symptom-and-risk factor
screen (≥ 1 of 5 factors: cough for longer than 2 weeks, weight loss,
malnutrition, HIV, or tuberculosis contact) according to the Zam-
bia National TB Programme and WHO guidelines
Age: median (IQR) 24 (12 to 74) months
Sex, female: not reported
HIV infection: 32%
Sample size included for analysis: 142 for expectorated sputum;
788 for gastric aspirate lavage
Clinical setting: inpatient
Laboratory level where index test was performed: university hos-
pital laboratory (tertiary referral centre)
Country: Zambia
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: no
Prevalence of TB cases in the study: 5%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Target condition: pulmonary tuberculosis
Reference standard: MGIT
Flow and timing Index and reference tests were collected simultaneously
Bates 2013 
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Comparative  
Notes Only 1 culture was used to exclude TB, indicating an unclear abili-
ty of the reference standard to classify the target condition
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Unclear    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Bates 2013  (Continued)
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Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Bates 2013  (Continued)
 
 
Study characteristics
Patient Sampling Cross-sectional, manner of selection not reported,
prospective
Patient characteristics and setting Presenting signs and symptoms: clinically suspected TBM
(fever > 1 week, headache, vomiting, neck stiffness, con-
vulsions, focal deficits, altered consciousness, history of
TB contact)
Age: median 59 months
Sex, female: 41%
HIV infection: not reported
Sample size included for analysis: 55
Clinical setting: inpatient
Laboratory level where index test was performed: regional
Country: India
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 10%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Tuberculous meningitis
MGIT; composite reference standard; clinical reference
standard
Flow and timing Index test and reference standard were collected simulta-
neously
Comparative  
Notes Only 1 culture was used to exclude TB, indicating an un-
clear ability of the reference standard to classify the target
condition
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Did the study avoid inappropriate exclusions? Yes    
Bhatia 2016 
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Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Unclear    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Bhatia 2016  (Continued)
 
 
Study characteristics
Patient Sampling Cohort, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: ≥ 1 palpable lymph nodes ≥ 1
cm persisting for longer than 4 weeks in spite of oral antibiotic
therapy and a strong clinical suspicion or microbiological con-
firmation of mycobacterial infection
Bholla 2016 
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Age: 0 to 60 months (59%); 61 to 204 months (41%)
Sex, female: 39%
HIV infection: 20%
Sample size included for analysis: 75
Clinical setting: not reported
Laboratory level where index test was performed: not report-
ed
Country: Tanzania
World Bank income classification: low income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: no
Prevalence of tuberculosis cases in the study: 9%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Lymph node tuberculosis
MGIT; composite reference standard; clinical reference stan-
dard
Flow and timing Index and reference tests performed simultaneously
Comparative  
Notes There was a high percentage of culture contamination (48%),
and only 1 culture was used to exclude TB, indicating an un-
clear ability of the reference standard to classify the target
condition
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the re-
sults of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpre-
tation differ from the review question?
    Low concern
Bholla 2016  (Continued)
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DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target con-
dition?
Unclear    
Were the reference standard results interpreted without knowledge
of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation
have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the
reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Bholla 2016  (Continued)
 
 
Study characteristics
Patient Sampling Cohort, manner of selection not reported, prospective
Patient characteristics and setting Presenting signs and symptoms: children aged < 15 years were in-
vestigated for TB if ≥ 1 of the following features of suspected TB
were present and they were not already on TB treatment; unex-
plained persistent cough for > 2 weeks; pneumonia not respond-
ing to first-line antibiotics; unexplained fever for > 2 weeks; unex-
plained progressive weight loss or failure to thrive for > 4 weeks;
history of close contact with a suspected or confirmed case of pul-
monary TB; clinical suspicion of TB for any other reason
Age, months: confirmed group median (IQR) 53 (21 to 112)
Sex, female: confirmed group 39%
HIV infection: confirmed group 28%
Sample size included for analysis: 1442
Clinical setting: not reported
Laboratory level where index test was performed: not reported
Country: Kenya
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 4%
Index tests Xpert MTB/RIF
Brent 2017 
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Target condition and reference standard(s) Pulmonary tuberculosis
MGIT; composite reference standard; clinical reference standard
Flow and timing Index and reference tests were collected simultaneously
Comparative  
Notes  
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Brent 2017  (Continued)
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Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Brent 2017  (Continued)
 
 
Study characteristics
Patient Sampling Randomized controlled trial, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: children were followed
quarterly for ≥ 2 years to identify signs, symptoms, or
household exposure that merited investigation for sus-
pected TB disease, for example, weight loss in the preced-
ing 2 months, cough for longer than 2 weeks without im-
provement, failure to thrive, conversion to a positive test
of TB infection
Age, months: median (IQR) 16.8 (12.0 to 22.1)
Sex, female: 54%
HIV infection: 0%
Sample size included for analysis: 1020
Clinical setting: inpatient
Laboratory level where index test was performed: not re-
ported
Country: South Africa
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 3%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
MGIT
Flow and timing Index test and reference standard were collected simulta-
neously
Comparative  
Notes  
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Bunyasi 2015 
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Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Yes    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Low risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Bunyasi 2015  (Continued)
 
 
Study characteristics
Patient Sampling Cross-sectional, consecutive, prospective
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Patient characteristics and setting Presenting signs and symptoms: presumptive tuber-
culosis
Age, months: mean 43
Sex, female: not reported
HIV infection: 0%
Sample size included for analysis: 44
Clinical setting: not reported
Laboratory level where index test was performed:
central
Country: Spain
World Bank income classification: high income
High TB burden country: no
High TB/HIV burden country: no
High MDR-TB burden country: no
Prevalence of tuberculosis cases in the study: not re-
ported
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary TB; tuberculous meningitis
Liquid culture (Middlebrook)
Flow and timing Index and reference tests were collected simultane-
ously
Comparative  
Notes It is unclear whether those interpreting the reference
test were blinded to results of the index test
Methodological quality
Item Authors'
judgement
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Causse 2011  (Continued)
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Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Unclear    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Causse 2011  (Continued)
 
 
Study characteristics
Patient Sampling Cross-sectional, manner of selection not reported, unknown
Patient characteristics and setting Presenting signs and symptoms: participants were children 5 to 16
years of age presenting with a chronic cough of 2 weeks and any of
the classic signs and symptoms of TB, including weight loss, loss of
appetite, persistent fever without an apparent cause, night sweats,
or history of close contact with a TB index patient, defined as living in
close proximity (sharing a room within a household) with an adult di-
agnosed with TB within the preceding 12 months
Age, months: median 127
Sex, female: 56%
HIV infection: 50%
Sample size included for analysis: 218
Clinical setting: outpatient
Laboratory level where index test was performed: not reported
Country: Zimbabwe
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 9%
Chipinduro 2017 
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Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
Solid culture (LJ); composite reference standard; clinical reference
standard
Flow and timing Index test and reference standard were collected within pre-speci-
fied interval
Comparative  
Notes Study evaluated Xpert MTB/RIF in stool and induced sputum; no con-
sensus has been reached on the proper stool processing method for
Xpert; this study used centrifugation
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting
do not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or in-
terpretation differ from the review question?
    Unclear
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the tar-
get condition?
Unclear    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpre-
tation have introduced bias?
  Unclear risk  
Chipinduro 2017  (Continued)
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Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Chipinduro 2017  (Continued)
 
 
Study characteristics
Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: respiratory symp-
toms (cough and/or respiratory distress) and radio-
logical pneumonia
Age, months: mean 12
Sex, female: not reported
HIV infection: not reported
Sample size included for analysis: 214
Clinical setting: inpatient
Laboratory level where index test was performed: re-
search laboratory
Country: Bangladesh
World Bank income classification: low income
High TB burden country: yes
High TB/HIV burden country: no
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 5%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
Solid culture (LJ); composite reference standard; clin-
ical reference standard
Flow and timing Index and reference tests were collected within pre-
specified time period
Comparative  
Notes  
Methodological quality
Item Authors'
judgement
Risk of bias Applicability
concerns
Chisti 2014 
Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children (Review)
Copyright © 2020 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
74
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Unclear    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Chisti 2014  (Continued)
 
 
Study characteristics
Coetzee 2014 
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Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: all children < 13 years of
age who were referred to the fine needle aspirate clinics
or were admitted to the inpatient wards/clinics of both
hospitals with persistent superficial lymphadenopathy
and clinical suspicion of mycobacterial infection were in-
cluded in the study
Age, months: median 23
Sex, female: 40%
HIV infection: 8%
Sample size included for analysis: 72
Clinical setting: inpatient and outpatient
Laboratory level where index test was performed: inter-
mediate
Country: South Africa
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 35%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Lymph node TB
MGIT
Flow and timing Index and reference tests were collected within pre-speci-
fied time
Comparative  
Notes  
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Coetzee 2014  (Continued)
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Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Unclear    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Coetzee 2014  (Continued)
 
 
Study characteristics
Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: ≥ 1 of the following symptoms
persisting for > 2 weeks without sustained improvement or reso-
lution following appropriate treatment for other potential diag-
noses (e.g. antibiotics for pneumonia; antimalarials for fever; nu-
tritional support for failure to thrive): cough, fever, weight loss, or
failure to thrive. Signs and symptoms of meningitis not respond-
ing to antibiotic treatment, with a subacute onset and/or raised
intracranial pressure. Non-painful enlarged lymph nodes without
fistula formation
Age, months: 45% 0 to 60, 55% 61 to 180
Sex, female: 40%
HIV infection: 2%
Sample size included for analysis: 171
Clinical setting: inpatient and outpatient
Laboratory level where index test was performed: university hos-
pital laboratory
Country: India
Das 2019 
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World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 10%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis; lymph node tuberculosis; tuberculosis
meningitis
Solid culture (LJ)
Flow and timing Index and reference tests were collected within pre-specified time
period
Comparative  
Notes  
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? No    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Unclear    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Unclear    
Das 2019  (Continued)
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Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Das 2019  (Continued)
 
 
Study characteristics
Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: clinician suspicion of
pulmonary tuberculosis
Age, months: median 24
Sex, female: not reported
HIV infection: not reported
Sample size included for analysis: 345
Clinical setting: not reported
Laboratory level where index test was performed: in-
termediate
Country: South Africa
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 4%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
MGIT
Flow and timing Index and reference tests were collected within pre-
specified time period
Comparative  
Notes Children younger than 5 years had small volumes of
sputum collected via physiotherapy-supported expec-
toration; Xpert was performed after "top up" of these
small volumes with normal saline
Gous 2015 
Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children (Review)
Copyright © 2020 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
79
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Methodological quality
Item Authors'
judgement
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    High
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Gous 2015  (Continued)
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Study characteristics
Patient Sampling Cohort, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: inclusion criteria for presumptive tuber-
culosis: (i) children 60 days to ≤ 10 years of age were eligible if they pre-
sented with ≥ 1 signs and symptoms of presumptive TB: persistent, non-
remitting, and unexplained cough for ≥ 2 weeks; (ii) unexplained weight
loss > 5% in the last 3 months or failure to thrive, and not responding to
nutritional rehabilitation (or antiretroviral treatment if HIV-positive); (iii)
persistent and unexplained fever for 1 week or longer; persistent, unex-
plained lethargy or decrease in playfulness/activity. Symptomatic child
household contacts of an adult diagnosed with TB were also offered par-
ticipation in the study regardless of symptom duration
Age, months: median (IQR) 21.4 (12 to 43)
Sex, female: 47%
HIV infection: 18%
Sample size included for analysis: 99
Clinical setting: outpatient
Laboratory level where index test was performed: Central
Country: South Africa
World Bank income classification: Upper middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 3%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
MGIT; composite reference standard
Flow and timing Index and reference tests were collected within pre-specified time period
Comparative  
Notes Stool was included as a specimen for index testing; no protocol has been
established for stool processing; the approach used in this study was cen-
trifugation; method used for confirmation of M tuberculosis by culture was
not reported
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced
bias?
  Low risk  
Hanrahan 2018 
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Are there concerns that the included patients and
setting do not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test
have introduced bias?
  Low risk  
Are there concerns that the index test, its conduct,
or interpretation differ from the review question?
    Unclear
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Yes    
Were the reference standard results interpreted with-
out knowledge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its in-
terpretation have introduced bias?
  Low risk  
Are there concerns that the target condition as de-
fined by the reference standard does not match the
question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Hanrahan 2018  (Continued)
 
 
Study characteristics
Patient Sampling Cross-sectional, convenience, prospective
Patient characteristics and setting Presenting signs and symptoms: children younger than 15
years based on clinical symptoms, chest radiography, and
Kenneth Jones score ≥ 5
Age, months: median (IQR) 82 (24 to 108)
Sex, female: 22%
Hasan 2017 
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HIV infection: 0%
Sample size included for analysis: 50
Clinical setting: inpatient and outpatient
Laboratory level where index test was performed: inter-
mediate
Country: Pakistan
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: no
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 18%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
MGIT; composite reference standard; clinical reference
standard
Flow and timing Index and reference tests were collected within pre-speci-
fied time period
Comparative  
Notes The index test was performed on stool; no stool process-
ing method for Xpert has been established; centrifugation
was used in this study
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? No    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   High risk  
Are there concerns that the included patients and setting do not
match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Unclear
DOMAIN 2: Index Test (Xpert Ultra)
Hasan 2017  (Continued)
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DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Unclear    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Hasan 2017  (Continued)
 
 
Study characteristics
Patient Sampling Cohort, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: children younger
than 15 years with presumptive TB symptoms
Age, months: median (IQR) 36 (17 to 72)
Sex, female: 35%
HIV infection: 18%
Sample size included for analysis: 93
Clinical setting: inpatient
Laboratory level where index test was performed:
central
Country: Papa New Guinea
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 95%
composite
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
Composite reference standard
Kasa Tom 2018 
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Flow and timing Index and reference data were collected within pre-
specified time period
Comparative  
Notes Only some children received the microbiological ref-
erence standard, so only a composite reference stan-
dard was applied
Methodological quality
Item Authors'
judgement
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Unclear    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Kasa Tom 2018  (Continued)
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Did all patients receive the same reference standard? No    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   High risk  
Kasa Tom 2018  (Continued)
 
 
Study characteristics
Patient Sampling Cross-sectional, consecutive, retrospective
Patient characteristics and setting Presenting signs and symptoms: children 0 to 18 years
of age evaluated for extrapulmonary tuberculosis in
whom Xpert MTB/RIF was used, as well as culture, and
who were not on treatment for tuberculosis
Age, months: not reported
Sex, female: not reported
HIV infection: not reported
Sample size included for analysis: 30
Clinical setting: inpatient
Laboratory level where index test was performed: re-
gional
Country: South Korea
World Bank income classification: high income
High TB burden country: no
High TB/HIV burden country: no
High MDR-TB burden country: no
Prevalence of tuberculosis cases in the study: 13%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Lymph node tuberculosis
Composite reference standard
Flow and timing Index and reference tests were performed within pre-
specified time period
Comparative  
Notes  
Methodological quality
Item Authors'
judgement
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Kim 2015 
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Are there concerns that the included patients and setting do not match
the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Unclear    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Kim 2015  (Continued)
 
 
Study characteristics
Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: enrollees met WHO se-
vere acute malnutrition criteria for children aged 6 to 60
months with weight-for-height z-score ≤ 3 standard devi-
ations below the median, mid-upper arm circumference
(MUAC) ≤ 115 mm, or bilateral pedal oedema
Age, months: median (IQR0 18 (12 to 26)
Sex, female: 51%
LaCourse 2014 
Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children (Review)
Copyright © 2020 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
87
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
HIV infection: 18%
Sample size included for analysis: 300
Clinical setting: inpatient
Laboratory level where index test was performed: re-
search
Country: Malawi
World Bank income classification: low income
High TB burden country: no
High TB/HIV burden country: yes
High MDR-TB burden country: no
Prevalence of tuberculosis cases in the study: 0.6%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
MGIT; composite reference standard; clinical reference
standard
Flow and timing Index and reference tests were collected within pre-speci-
fied time period
Comparative  
Notes  
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results
of the reference standard?
No    
If a threshold was used, was it pre-specified? No    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
LaCourse 2014  (Continued)
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Is the reference standards likely to correctly classify the target condi-
tion?
Yes    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Low risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
LaCourse 2014  (Continued)
 
 
Study characteristics
Patient Sampling Randomized controlled trial, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: all children living
with HIV who were hospitalized with an acute illness
Age, months: median (IQR) 24 (13 to 58)
Sex, female: 45%
HIV infection: 100%
Sample size included for analysis: 165
Clinical setting: inpatient
Laboratory level where index test was performed:
central
Country: Kenya
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 6%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
MGIT; composite reference standard; clinical refer-
ence standard
Flow and timing Index and reference tests were collected within pre-
specified time period
LaCourse 2018 
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Comparative  
Notes No protocol for stool processing has been estab-
lished; this study used the centrifugation method in a
central laboratory
Methodological quality
Item Authors'
judgement
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Unclear
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
LaCourse 2018  (Continued)
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Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
LaCourse 2018  (Continued)
 
 
Study characteristics
Patient Sampling Cross-sectional, manner of selection not reported,
prospective
Patient characteristics and setting Presenting signs and symptoms: not reported
Age, months: mean 36
Sex, female: not reported
HIV infection: not reported
Sample size included for analysis: 50
Clinical setting: inpatient and outpatient
Laboratory level where index test was performed:
central
Country: South Africa
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 60%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Lymph node tuberculosis
MGIT; composite reference standard
Flow and timing Index and reference tests were collected within pre-
specified time period
Comparative  
Notes  
Methodological quality
Item Authors'
judgement
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Unclear risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
Ligthelm 2011 
Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children (Review)
Copyright © 2020 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
91
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Ligthelm 2011  (Continued)
 
 
Study characteristics
Patient Sampling Cross-sectional, manner of selection not reported,
prospective
Patient characteristics and setting Presenting signs and symptoms: clinically suspected
tuberculosis
Age, months: mean 88
Sex, female: not reported
HIV infection: not reported
Sample size included for analysis: 12
Clinical setting: laboratory
Laboratory level where index test was performed: re-
search laboratory
Malbruny 2011 
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Country: France
World Bank income classification: high income
High TB burden country: no
High TB/HIV burden country: no
High MDR-TB burden country: no
Prevalence of tuberculosis cases in the study: 8%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary TB, lymph node TB, tuberculous meningi-
tis
Solid culture; composite reference standard
Flow and timing Index and reference tests were collected within pre-
specified time period
Comparative  
Notes  
Methodological quality
Item Authors'
judgement
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Unclear risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Unclear    
Malbruny 2011  (Continued)
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Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Malbruny 2011  (Continued)
 
 
Study characteristics
Patient Sampling Cohort, manner of selection not reported, prospective
Patient characteristics and setting Presenting signs and symptoms: children aged ≤ 13 years with
suspicion of intrathoracic tuberculosis based on ≥ 1 of the fol-
lowing: persistent cough; persistent fever; failure to thrive, de-
fined as recent deviation in the growth curve or weight-for-age
z-score < −2 standard deviations; failure of broad-spectrum an-
tibiotics for pulmonary infection; suggestive chest radiograph
anomaly
Age, months: median (IQR) 86 (49 to 85)
Sex, female: 49%
HIV infection: 100%
Sample size included for analysis: 272
Clinical setting: not reported
Laboratory level where index test was performed: not reported
Country: Burkina Faso; Cambodia; Cameroon; Vietnam
World Bank income classification: low and middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 11%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
MGIT and LJ; composite reference standard
Flow and timing Index and reference tests were collected within pre-specified
time period
Comparative  
Notes No method for stool processing with Xpert has been established;
this study used centrifugation
Marcy 2016 
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Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the
results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have in-
troduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Unclear
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by the
reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Marcy 2016  (Continued)
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Study characteristics
Patient Sampling Cohort, manner of selection not reported, prospective
Patient characteristics and setting Presenting signs and symptoms: children older than
1 year and younger than 15 years with clinical signs of
PTB
Age, months: not reported
Sex, female: 39%
HIV infection: 0%
Sample size included for analysis: 115
Clinical setting: not reported
Laboratory level where index test was performed: in-
termediate
Country: Egypt
World Bank income classification: middle income
High TB burden country: no
High TB/HIV burden country: no
High MDR-TB burden country: no
Prevalence of tuberculosis cases in the study: 31%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
Solid culture (LJ); composite reference standard; clin-
ical reference standard
Flow and timing Index and reference tests were collected within pre-
specified time period
Comparative  
Notes No method for stool processing before Xpert has been
established; this study used centrifugation
Methodological quality
Item Authors'
judgement
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Unclear risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
Moussa 2016 
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If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Unclear
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Moussa 2016  (Continued)
 
 
Study characteristics
Patient Sampling Cross-sectional, manner of selection not reported,
prospective
Patient characteristics and setting Presenting signs and symptoms: children 13 years of age
or younger with suspected PTB were recruited into the
study. PTB was suspected if a child had cough for ≥ 14
days and any of the following features; fever for 7 days,
failure to thrive, unexplained loss of appetite, or lethargy
Age, months: median 48
Sex, female: 47%
HIV infection: 13%
Sample size included for analysis: 231
Clinical setting: inpatient
Laboratory level where index test was performed: central
Country: Myanmar
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
Myo 2018 
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High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 7%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
Solid culture (LJ); composite reference standard; clinical
reference standard
Flow and timing Index and reference test specimens were collected within
pre-specified time period
Comparative  
Notes  
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Unclear    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Unclear    
Myo 2018  (Continued)
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Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Myo 2018  (Continued)
 
 
Study characteristics
Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: clinical suspicion of
tuberculosis
Age, months: median 106
Sex, female: not reported
HIV infection: 10%
Sample size included for analysis: 72
Clinical setting: inpatient
Laboratory level where index test was performed: in-
termediate
Country: Vietnam
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: no
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 30%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis and tuberculous meningitis
MGIT; composite reference standard; clinical refer-
ence standard
Flow and timing Index and reference tests were collected within pre-
specified time period
Comparative  
Notes  
Methodological quality
Nhu 2013 
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Item Authors'
judgement
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Nhu 2013  (Continued)
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Study characteristics
Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: cough for longer than
14 days and 1 of the following: household contact infect-
ed with tuberculosis within previous 3 months, loss of
weight or failure to gain weight in previous 3 months, pos-
itive skin test to purified protein derivative, or chest radi-
ograph suggestive of pulmonary tuberculosis
Age, months: median 72
Sex, female: not reported
HIV infection: 37%
Sample size included for analysis: 48
Clinical setting: inpatient
Laboratory level where index test was performed: inter-
mediate
Country: South Africa
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 15%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
MGIT; composite reference standard; clinical reference
standard
Flow and timing Index and reference tests were collected within pre-speci-
fied time period
Comparative  
Notes  
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
Nicol 2011 
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If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Yes    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Low risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Nicol 2011  (Continued)
 
 
Study characteristics
Patient Sampling Cohort, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: children 0 to 14 years of
age with cough lasting longer than 2 weeks and at least 1 of
the following: (1) household tuberculosis contact in prior 3
months, (2) weight loss or failure to gain weight in previous
3 months, (3) positive tuberculin skin test, or (4) chest radi-
ograph suggestive of PTB
Age, months: median (IQR) 31 (19 to 57)
Sex, female: not reported
HIV infection: 15%
Sample size included for analysis: 115
Clinical setting: outpatient and inpatient
Laboratory level where index test was performed: intermedi-
ate
Country: South Africa
World Bank income classification: middle income
Nicol 2013 
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High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 15%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
MGIT; composite reference standard; clinical reference stan-
dard
Flow and timing Index and reference tests were collected within pre-specified
time period
Comparative  
Notes No consensus has been reached about stool processing tech-
niques on stool before Xpert; this study used centrifugation
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the re-
sults of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpre-
tation differ from the review question?
    Unclear
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target con-
dition?
Yes    
Were the reference standard results interpreted without knowledge
of the results of the index tests?
Yes    
Nicol 2013  (Continued)
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Could the reference standard, its conduct, or its interpretation
have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by the
reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Nicol 2013  (Continued)
 
 
Study characteristics
Patient Sampling Cohort, manner of selection not reported, prospective
Patient characteristics and setting Presenting signs and symptoms: children 0 to 14 years
of age with cough lasting longer than 2 weeks and ≥
1 of the following: (1) household tuberculosis con-
tact in prior 3 months, (2) weight loss or failure to gain
weight in previous 3 months, (3) positive tuberculin
skin test, or (4) chest radiograph suggestive of PTB
Age, months: median (IQR) 33 (15 to 74)
Sex, female: 49%
HIV infection: 19%
Sample size included for analysis: 367
Clinical setting: inpatient and outpatient
Laboratory level where index test was performed: re-
search laboratory
Country: South Africa
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 20%
Index tests Xpert Ultra and Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
MGIT; composite reference standard; clinical refer-
ence standard
Flow and timing Index and reference tests were performed within pre-
specified time period
Comparative  
Notes  
Nicol 2018 
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Methodological quality
Item Authors'
judgement
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Did the study avoid inappropriate exclusions? No    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Nicol 2018  (Continued)
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Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Nicol 2018  (Continued)
 
 
Study characteristics
Patient Sampling Cohort, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: children 1 month to 14
years of age with presumptive TB defined as presence of ≥ 1
clinical sign suggestive of TB or TB contact history with ab-
normal chest X-ray, or any child with chest X-ray suggestive
of TB
Age, months: not reported
Sex, female: 45%
HIV infection: 30%
Sample size included for analysis: 357
Clinical setting: inpatient and outpatient
Laboratory level where index test was performed: intermedi-
ate
Country: Uganda
World Bank income classification: low income
High TB burden country: no
High TB/HIV burden country: yes
High MDR-TB burden country: no
Prevalence of tuberculosis cases in the study: 4%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
Solid and liquid cultures (LJ and MGIT); composite reference
standard; clinical reference standard
Flow and timing Index and reference tests were obtained within pre-specified
time period
Comparative  
Notes No consensus method for stool processing before Xpert is
known; this study used centrifugation
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Orikiriza 2018 
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Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the re-
sults of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpreta-
tion differ from the review question?
    Unclear
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Yes    
Were the reference standard results interpreted without knowledge
of the results of the index tests?
Unclear    
Could the reference standard, its conduct, or its interpretation
have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the
reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Orikiriza 2018  (Continued)
 
 
Study characteristics
Patient Sampling Cross-sectional, consecutive, prospective
Pang 2014 
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Patient characteristics and setting Presenting signs and symptoms: TB suspects had at least
1 of the following symptoms: cough for longer than 2
weeks, fever for longer than 2 weeks, weight loss, TB con-
tact history, and radiological features
Age, months: range 0 to 180
Sex, female: 39%
HIV infection: not reported
Sample size included for analysis: 211
Clinical setting: inpatient
Laboratory level where index test was performed: central
Country: China
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 8%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
MGIT; composite reference standard; clinical reference
standard
Flow and timing Index and reference tests were collected within pre-speci-
fied time period
Comparative  
Notes Study included only smear-negative participants
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? No    
Could the selection of patients have introduced bias?   High risk  
Are there concerns that the included patients and setting do not
match the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Pang 2014  (Continued)
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Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Unclear    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? No    
Could the patient flow have introduced bias?   High risk  
Pang 2014  (Continued)
 
 
Study characteristics
Patient Sampling Cohort, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: children with 6 weeks to
14 years of clinical signs of tuberculosis were enrolled in the
study and were prospectively followed up for a minimum of 12
months. All children had ≥ 1 of the following symptoms: persis-
tent unremitting cough for.21 days; repeated episodes of fever
within the last 21 days; weight loss or failure to thrive within the
previous 3 months; or signs and symptoms suggestive of extra-
pulmonary tuberculosis
Age, months: median (IQR) 70 (29 to 170)
Sex, female: 48%
HIV infection: 51%
Sample size included for analysis: 129
Clinical setting: inpatient and outpatient
Laboratory level where index test was performed: research lab-
oratory
Country: Tanzania
World Bank income classification: low income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: no
Rachow 2012 
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Prevalence of tuberculosis cases in the study: 22%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
Solid and liquid culture (LJ and MGIT); composite reference
standard; clinical reference standard
Flow and timing Index and reference tests were collected within pre-specified
time period
Comparative  
Notes  
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the
results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have in-
troduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpre-
tation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation
have introduced bias?
  Low risk  
Rachow 2012  (Continued)
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Are there concerns that the target condition as defined by the
reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Rachow 2012  (Continued)
 
 
Study characteristics
Patient Sampling Cohort, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: ≥ 1 of the following inclusion
criteria had to be met: persistent non-remitting cough longer
than 14 days not responding to a course of antibiotics; repeat-
ed episodes of fever within the last 14 days not responding
to a course of antibiotics, after malaria has been excluded;
weight loss or failure to thrive within previous 3 months
Age, months: median (IQR) 67 (67 to 118)
Sex, female: 51%
HIV infection: 44%
Sample size included for analysis: 356
Clinical setting: inpatient and outpatient
Laboratory level where index test was performed: research
laboratory
Country: Uganda and Tanzania
World Bank income classification: low income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: no
Prevalence of tuberculosis cases in the study: 10%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
Solid and liquid culture (MGIT and LJ); composite reference
standard; clinical reference standard
Flow and timing Index and reference tests were collected within pre-specified
time period
Comparative  
Notes  
Methodological quality
Reither 2015 
Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children (Review)
Copyright © 2020 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
111
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Item Authors' judge-
ment
Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the re-
sults of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpre-
tation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target con-
dition?
Yes    
Were the reference standard results interpreted without knowledge
of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation
have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by the
reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Reither 2015  (Continued)
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Study characteristics
Patient Sampling Cohort, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: children must have had
1 of the following symptoms: persistent non-remitting
cough longer than 14 days not responding to antibiotics;
repeated episodes of fever within the last 14 days not re-
sponding to antibiotics, after malaria has been excluded;
weight loss or failure to thrive during previous 3 months;
signs and symptoms suggestive of extrapulmonary TB
Age, months: median (IQR) 65 (18 to 120)
Sex, female: 43%
HIV infection: 52%
Sample size included for analysis: 215
Clinical setting: inpatient and outpatient
Laboratory level where index test was performed: re-
search laboratory
Country: Tanzania
World Bank income classification: low income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: no
Prevalence of tuberculosis cases in the study: 13%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
Solid and liquid culture (MGIT and LJ); composite refer-
ence standard; clinical reference standard
Flow and timing Index and reference tests were collected within pre-speci-
fied time period
Comparative  
Notes Ultra was performed on frozen specimens
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Sabi 2018 
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Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Yes    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Low risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Sabi 2018  (Continued)
 
 
Study characteristics
Patient Sampling Cross-sectional, manner of selection not reported, prospec-
tive
Saini 2018 
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Patient characteristics and setting Presenting signs and symptoms: cough for longer than 2
weeks, fever, lethargy, contact with an adult patient with TB,
positive tuberculin skin test, or chest radiograph consistent
with TB. In addition, the patient needed to have negative test-
ing by AFB smear and Xpert before moving to bronchoscopy
for BAL
Age, months: median (IQR) 120 (66 to 156)
Sex, female: 53%
HIV infection: 0%
Sample size included for analysis: 41
Clinical setting: inpatient
Laboratory level where index test was performed: central
Country: India
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 27%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
MGIT; composite reference standard; clinical reference stan-
dard
Flow and timing Participants were enrolled for BAL sample collection if they
had probable TB and negative testing by AFB smear and Xpert
by standard less invasive methods
Comparative  
Notes  
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Did the study avoid inappropriate exclusions? No    
Could the selection of patients have introduced bias?   High risk  
Are there concerns that the included patients and setting do not
match the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the re-
sults of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Saini 2018  (Continued)
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Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpre-
tation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target con-
dition?
Yes    
Were the reference standard results interpreted without knowledge
of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation
have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by the
reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Saini 2018  (Continued)
 
 
Study characteristics
Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: persistent cough of
2 weeks or longer and 1 of the following: household
TB contact, unexplained weight loss or failure to gain
weight, unexplained fever for 2 weeks or longer
Age, months: median (IQR) 36 (16 to 75)
Sex, female: 46%
HIV infection: 41%
Sample size included for analysis: 235
Clinical setting: outpatient
Laboratory level where index test was performed:
central
Country: Uganda
World Bank income classification: low income
High TB burden country: no
High TB/HIV burden country: yes
High MDR-TB burden country: no
Sekadde 2013 
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Prevalence of tuberculosis cases in the study: 14%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
Solid and liquid culture (MGIT and LJ)
Flow and timing Index and reference tests were collected within pre-
specified time period
Comparative  
Notes  
Methodological quality
Item Authors'
judgement
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Sekadde 2013  (Continued)
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Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Sekadde 2013  (Continued)
 
 
Study characteristics
Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: ≥ 1 of the following: per-
sistent fever and/or cough for ≥ 2 weeks, loss of weight/no
weight gain, and history of contact with an infectious TB
case
Age, months: median (IQR) 64 (2 to 144)
Sex, female: 38%
HIV infection: not reported
Sample size included for analysis: 50
Clinical setting: inpatient
Laboratory level where index test was performed: inter-
mediate
Country: India
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 24%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
MGIT; composite reference standard; clinical reference
standard
Flow and timing Index and reference tests were collected within pre-speci-
fied time period
Comparative  
Notes IS and GLA samples were combined; study was analysed
as a sputum specimen
Methodological quality
Singh M 2016 
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Item Authors' judge-
ment
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Unclear    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Singh M 2016  (Continued)
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Study characteristics
Patient Sampling Cross-sectional, manner of selection not reported,
prospective
Patient characteristics and setting Presenting signs and symptoms: age 3 months to 13
years with clinical suspicion of meningitis, CSF sample
collected for fluorescent auramine-O microscopy, TB
culture, Xpert assays
Age, months: median (IQR) 36 (21 to 54)
Sex, female: 44%
HIV infection: 8%
Sample size included for analysis: 101
Clinical setting: inpatient
Laboratory level where index test was performed: inter-
mediate
Country: South Africa
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 12%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Tuberculous meningitis
MGIT; composite reference standard; clinical reference
standard
Flow and timing Index and reference tests were collected in pre-speci-
fied time period
Comparative  
Notes  
Methodological quality
Item Authors'
judgement
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Unclear risk  
Are there concerns that the included patients and setting do not
match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
Solomons 2015 
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If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Solomons 2015  (Continued)
 
 
Study characteristics
Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: unremitting cough ≥
14 days and ≥ 1 of fever, weight loss or failure to thrive,
malaise or fatigue, haemoptysis, night sweats, or en-
larged cervical lymph nodes
Age, months: median (IQR) 72 (36 to 108)
Sex, female: 47%
HIV infection: 0%
Sample size included for analysis: 487
Clinical setting: outpatient
Laboratory level where index test was performed: cen-
tral
Country: Gambia
World Bank income classification: low income
High TB burden country: no
High TB/HIV burden country: no
High MDR-TB burden country: no
Togun 2015 
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Prevalence of tuberculosis cases in the study: 3%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
Solid and liquid culture (MGIT or LJ); composite refer-
ence standard; clinical reference standard
Flow and timing Index and reference tests were collected within pre-
specified time period
Comparative  
Notes  
Methodological quality
Item Authors'
judgement
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Low risk  
Togun 2015  (Continued)
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Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Togun 2015  (Continued)
 
 
Study characteristics
Patient Sampling Cross-sectional, manner of selection not reported,
retrospective
Patient characteristics and setting Presenting signs and symptoms: Not reported
Age, months: median 84
Sex, female: not reported
HIV infection: not reported
Sample size included for analysis: 174 pulmonary tu-
berculosis; 89 LNTB; 43 TBM
Clinical setting: laboratory
Laboratory level where index test was performed:
central
Country: Italy
World Bank income classification: high income
High TB burden country: no
High TB/HIV burden country: no
High MDR-TB burden country: no
Prevalence of tuberculosis cases in the study: 22%
PTB; 17% LNTB; 9% TBM
Index tests Xpert MTB/RIF
Target condition and reference standard(s) PTB, LNTB, TBM
Solid and liquid culture (LJ and MGIT)
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors'
judgement
Risk of bias Applicability
concerns
Tortoli 2012 
Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children (Review)
Copyright © 2020 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
123
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Did the study avoid inappropriate exclusions? Unclear    
Could the selection of patients have introduced bias?   Unclear risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Unclear    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Unclear risk  
Tortoli 2012  (Continued)
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Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: TBM symptoms includ-
ed irritability, restlessness, neck stiffness, headache per-
sistent for 2 to 3 weeks, vomiting, seizures, and changes in
mental condition or behaviour. LNTB symptoms included
enlargement of lymph nodes and mass formation in the
neck
Age, months: median (IQR) 66 (12 to 168)
Sex, female: not reported
HIV infection: 3%
Sample size included for analysis: 14: 5 LNTB; 9 TBM
Clinical setting: inpatient
Laboratory level where index test was performed: central
Country: India
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 20% LNTB
and TBM
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Lymph node TB and tuberculous meningitis
Solid and liquid culture (LJ and MGIT)
Flow and timing Index and reference tests were collected within pre-speci-
fied time period
Comparative  
Notes  
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Vadwai 2011  (Continued)
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Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Yes    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Unclear    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Vadwai 2011  (Continued)
 
 
Study characteristics
Patient Sampling Cross-sectional, convenience, prospective
Patient characteristics and setting Presenting signs and symptoms: chronic respiratory symp-
toms, contact with a known TB source case or a reactive Man-
toux skin test in combination with any of the following: severe
life-threatening intrathoracic large airway obstruction, radi-
ographic evidence of complicated intrathoracic disease, or
suspicion of drug-resistant TB based on the susceptibility pat-
tern of an adult source case; none of the bacteriological sam-
ples taken from the child to date had been positive
Age, months: median (IQR) 16 (5 to 132)
Sex, female: 43%
HIV infection: 14%
Sample size included for analysis: 14
Clinical setting: inpatient
Laboratory level where index test was performed: intermedi-
ate
Country: South Africa
World Bank income classification: middle income
Walters 2014 
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High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 60%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
MGIT; composite reference standard
Flow and timing Index and reference tests were collected within pre-specified
time period
Comparative  
Notes Study on BAL samples
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? No    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   High risk  
Are there concerns that the included patients and setting do not
match the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the re-
sults of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpre-
tation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target con-
dition?
Yes    
Were the reference standard results interpreted without knowledge
of the results of the index tests?
Yes    
Walters 2014  (Continued)
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Could the reference standard, its conduct, or its interpretation
have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by the
reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Walters 2014  (Continued)
 
 
Study characteristics
Patient Sampling Cohort, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: 1 or more of cough ≥ 2 weeks, unex-
plained fever of ≥ 1 week, or poor growth or weight loss over preced-
ing 3 months. Also included were children with any duration of cough,
if 1 or more of the following were present: exposure to an identified TB
source case in the past 12 months, positive tuberculin skin test if pre-
viously negative or unknown, or chest radiograph suggestive of TB as
assessed by the study clinician. Infants younger than 3 months were
also eligible if they had pneumonia unresponsive to appropriate an-
timicrobials, or unexplained and unresponsive sepsis syndrome
Age, months: median (IQR) 16 (9 to 29)
Sex, female: 48%
HIV infection: 13%
Sample size included for analysis: 379
Clinical setting: inpatient
Laboratory level where index test was performed: intermediate
Country: South Africa
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 18%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
MGIT; composite reference standard; clinical reference standard
Flow and timing Index and reference tests were collected within pre-specified time pe-
riod
Comparative  
Walters 2017a 
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Notes No consensus has been reached for stool processing before Xpert; this
study used centrifugation
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and set-
ting do not match the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test
have introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or in-
terpretation differ from the review question?
    Unclear
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the tar-
get condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its inter-
pretation have introduced bias?
  Low risk  
Are there concerns that the target condition as defined
by the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Walters 2017a  (Continued)
Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children (Review)
Copyright © 2020 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
129
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Could the patient flow have introduced bias?   Low risk  
Walters 2017a  (Continued)
 
 
Study characteristics
Patient Sampling Cohort, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: well-defined TB symp-
toms or shorter history of cough with known TB exposure,
positive tuberculin skin test, or chest radiographic changes
of concern for tuberculosis
Age, months: median (IQR) 16 (11 to 29)
Sex, female: 44%
HIV infection: 13%
Sample size included for analysis: 244
Clinical setting: inpatient and outpatient
Laboratory level where index test was performed: interme-
diate
Country: South Africa
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 8%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
MGIT; composite reference standard; clinical reference
standard
Flow and timing Index and reference tests were collected within pre-speci-
fied time period
Comparative  
Notes No consensus protocol for stool processing before Xpert is
available; this study reported on stool filtration and swab
processing
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Unclear    
Could the selection of patients have introduced bias?   Low risk  
Walters 2018a 
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Are there concerns that the included patients and setting do not
match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the re-
sults of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpreta-
tion differ from the review question?
    Unclear
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Yes    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation
have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by the ref-
erence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Walters 2018a  (Continued)
 
 
Study characteristics
Patient Sampling Cross-sectional, manner of selection not reported, prospec-
tive
Patient characteristics and setting Presenting signs and symptoms: children aged 18 years or
younger were eligible for enrolment if they had been ad-
mitted to hospital, with suspected PTB, having a cough for
longer than 2 weeks, and a chest radiograph suggesting the
need for routine fibreoptic bronchoscopy
Yin 2014 
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Age, months: mean 73
Sex, female: 56%
HIV infection: not reported
Sample size included for analysis: 255
Clinical setting: inpatient
Laboratory level where index test was performed: central
Country: China
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 10%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
Solid and liquid culture (LJ and MGIT); composite reference
standard; clinical reference standard
Flow and timing Index and reference tests were collected within pre-speci-
fied time period
Comparative  
Notes Xpert was performed on BAL samples
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Did the study avoid inappropriate exclusions? No    
Could the selection of patients have introduced bias?   High risk  
Are there concerns that the included patients and setting do not
match the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the re-
sults of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpreta-
tion differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Yin 2014  (Continued)
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DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Unclear    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation
have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the ref-
erence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Yin 2014  (Continued)
 
 
Study characteristics
Patient Sampling Cohort, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: children 0 to 14 years
with cough lasting longer than 2 weeks and at least 1 of
the following: household tuberculosis contact in previ-
ous 3 months, weight loss or failure to gain weight in pre-
vious 3 months, positive tuberculin skin test, or chest radi-
ograph suggestive of PTB
Age, months: median (IQR) 19 (11 to 38)
Sex, female: 45%
HIV infection: 22%
Sample size included for analysis: 474
Clinical setting: inpatient
Laboratory level where index test was performed: inter-
mediate
Country: South Africa
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 17%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
Zar 2012 
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MGIT; composite reference standard; clinical reference
standard
Flow and timing Index and reference tests were collected within pre-speci-
fied time period
Comparative  
Notes  
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Yes    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Low risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Zar 2012  (Continued)
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Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Zar 2012  (Continued)
 
 
Study characteristics
Patient Sampling Cohort, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: children 0 to 14 years of
age with cough lasting longer than 2 weeks and at least 1
of the following: household tuberculosis contact in previ-
ous 3 months, weight loss or failure to gain weight in pre-
vious 3 months, positive tuberculin skin test, or chest radi-
ograph suggestive of PTB
Age, months: median (IQR) 38 (21 to 57)
Sex, female: 53%
HIV infection: 8%
Sample size included for analysis: 384
Clinical setting: outpatient
Laboratory level where index test was performed: inter-
mediate
Country: South Africa
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 8%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
MGIT; composite reference standard; clinical reference
standard
Flow and timing Index and reference tests were collected within pre-speci-
fied time period
Comparative  
Notes  
Methodological quality
Item Authors' judge-
ment
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Zar 2013 
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Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Yes    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Low risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Zar 2013  (Continued)
 
 
Study characteristics
Patient Sampling Cohort, consecutive, prospective
Zar 2019 
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Patient characteristics and setting Presenting signs and symptoms: children 0 to 14 years
of age with cough lasting longer than 2 weeks and at
least 1 of the following: household tuberculosis con-
tact in previous 3 months, weight loss or failure to
gain weight in previous 3 months, positive tuberculin
skin test, or chest radiograph suggestive of PTB
Age, months: median (IQR) 23 (14 to 47)
Sex, female: not reported
HIV infection: 16%
Sample size included for analysis: 195
Clinical setting: inpatient
Laboratory level where index test was performed: in-
termediate
Country: South Africa
World Bank income classification: middle income
High TB burden country: yes
High TB/HIV burden country: yes
High MDR-TB burden country: yes
Prevalence of tuberculosis cases in the study: 21%
Index tests Xpert MTB/RIF
Target condition and reference standard(s) Pulmonary tuberculosis
MGIT; composite reference standard; clinical refer-
ence standard
Flow and timing Index and reference tests were collected within pre-
specified time period
Comparative  
Notes Xpert Ultra test was performed on frozen specimens
Methodological quality
Item Authors'
judgement
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Zar 2019  (Continued)
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Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Zar 2019  (Continued)
AFB: acid-fast bacillus.
BAL: bronchoalveolar lavage.
GLA: gastric lavage aspirate.
IQR: interquartile ratio.
IS: induced sputum.
LJ: Löwenstein-Jensen.
LNTB: lymph node tuberculosis.
M tuberculosis: Mycobacterium tuberculosis.
MDR-TB: multi-drug-resistant tuberculosis.
MGIT: mycobacteria growth indicator tube.
MTB/RIF: Mycobacterium tuberculosis complex and resistance to rifampin.
 
Characteristics of excluded studies [ordered by study ID]
 
Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children (Review)
Copyright © 2020 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
138
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study Reason for exclusion
Ali 2017 Unable to separate paediatric data from adult data
Atashi 2017 Adult population
Atehortúa Muñoz 2017 Not a diagnostic accuracy study
Azevedo 2018 Adult population
Ballif 2015 Not a diagnostic accuracy study
Banada 2016 Case-control study
Biadglegne 2014 Unable to separate paediatric data from adult data
Bojang 2016 Unable to separate paediatric data from adult data
Che 2017 Adult population
Cox 2014 Adult population
Cross 2014 Unable to separate paediatric data from adult data
Diallo 2016 Unable to separate paediatric data from adult data
DiNardo 2016 Not a diagnostic accuracy study
DiNardo 2018 Index test not studied
Ejeh 2018 Unable to separate paediatric data from adult data
Gautam 2018 Unable to separate paediatric data from adult data
Gelalcha 2017 Unable to separate paediatric data from adult data
Geleta 2015 Adult population
Ghariani 2015 Unable to separate paediatric data from adult data
Giang 2015 Unable to extract data by sample type
Guajardo-Lara 2018 Insufficient data
Gulla 2019 Not a diagnostic accuracy study
Hakim 2017 Not a diagnostic accuracy study
Helb 2010 Adult population
Horo 2017 Unable to separate paediatric data from adult data
Huh 2014 Adult population
Kuyinu 2018 Inappropriate reference standard
Lopez 2019 Index text not studied
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Study Reason for exclusion
Lu J 2017 Screening for clinical tuberculosis before enrolment
Lu Y 2018 Adult population
Malik 2018 Not a diagnostic accuracy study
Marcy 2018 Duplicate data for Marcy 2016
Masenga 2017 Unable to separate paediatric data from adult data
Mekonnen 2015 Adult population
Memon 2018 Clinical diagnosis of tuberculosis established at enrolment
Metaferia 2018 Inappropriate reference standard
Mijovic 2018 Not a diagnostic accuracy study
Modi 2016 Index test not studied
Mulenga 2015 Index test not studied
Naidoo 2016 Not a diagnostic accuracy study
Nair 2016 Not a diagnostic accuracy study
Nansumba 2016 Index test not studied
Nataprawira 2016 Not a diagnostic accuracy study
Ncube 2017 Not a diagnostic accuracy study
Nduba 2015 Index text not studied
Ngabonziza 2016 Adult population
Ntinginya 2012 Not a diagnostic accuracy study
Opota 2019 Adult population
Pandey 2017 Unable to separate paediatric data from adult data
Pink 2016 Unable to separate paediatric data from adult data
Planting 2014 Not a diagnostic accuracy study
Raizada 2014 Inappropriate reference standard
Raizada 2015a Inappropriate reference standard
Raizada 2015b Inappropriate reference standard
Raizada 2018b Inappropriate reference standard
Raizada 2018c Inappropriate reference standard
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Study Reason for exclusion
Rathour 2019 Screening for clinical tuberculosis before enrolment
Rebecca 2018 Case-control study
Rivera 2017 Not a diagnostic accuracy study
Sabi 2016 Not a diagnotic accuracy study
Sachdeva 2015 Not a diagnostic accuracy study
Sanchini 2014 Not a diagnostic accuracy study
Sander 2019 Adult population
Sanjuan-Jimenez 2015 Adult population
Schumacher 2016 Not a diagnostic accuracy study
Scott 2014 Unable to separate paediatric data from adult data
Shah 2016a Insufficient data
Shah 2018 Not a diagnostic accuracy study
Shah 2019 Case-control study
Sharma 2015 Unable to separate paediatric data from adult data
Sieiro 2018 Unable to separate paediatric data from adult data
Singh 2015 Clinical diagnosis of tuberculosis established at enrolment
Singh UB 2016 Adult population
Solomons 2016 Not a diagnostic accuracy study
Sureshbabu 2016 Unable to separate paediatric data from adult data
Tadesse 2015 Unable to separate paediatric data from adult data
Tafur 2018 Not a diagnostic accuracy study
Tang 2017 Adult population
Theron 2011 Adult population
Triasih 2015 Not a diagnostic accuracy study
Ullah 2017 Unable to separate paediatric data from adult data
Walters 2012 Insufficient data
Walters 2017b Index text not studied
Walters 2018b Not a diagnostic accuracy study
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Study Reason for exclusion
Zhang 2016 Insufficient data
 
Characteristics of ongoing studies [ordered by study ID]
 
Study name Diagnostic accuracy of Xpert MTB/RIF Ultra assay on diagnosing paediatric
pulmonary tuberculosis
Target condition and reference standard(s) Pulmonary tuberculosis
Index and comparator tests Xpert Ultra
Starting date 1 January 2018
Contact information Xuhui Liu; liuxuhui@shaphc.org
Notes  
ChiCTR1800015075 
 
 
Study name TB-speed pneumonia
Target condition and reference standard(s) Tuberculosis, pneumonia
Index and comparator tests Xpert Ultra
Starting date 20 March 2019
Contact information Aurelia Vessiere, PhD; aurelia.vessiere@u-bordeaux.fr
Notes  
NCT03831906 
MTB/RIF: Mycobacterium tuberculosis complex and resistance to rifampin.
TB: tuberculosis.
 
 
D A T A
Presented below are all the data for all of the tests entered into the review.
 
Table Tests.   Data tables by test
Test No. of studies No. of participants
1 Xpert MTB/RIF, sputum, culture 25 6812
2 Xpert MTB/RIF, sputum, composite reference standard 17 4382
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Test No. of studies No. of participants
3 Xpert Ultra, sputum, culture 3 697
4 Xpert Ultra, sputum, composite reference standard 3 753
5 Xpert MTB/RIF, gastric aspirate specimen, culture 15 3487
6 Xpert MTB/RIF, gastric aspirate specimen, composite reference standard 7 948
7 Xpert MTB/RIF, stool, culture 11 1592
8 Xpert MTB/RIF, stool, composite reference standard 10 1739
9 Xpert MTB/RIF, nasopharyngeal aspirate, culture 4 1125
10 Xpert Ultra, nasopharyngeal aspirate, culture 1 195
11 Xpert MTB/RIF, sputum, culture, direct comparison 3 609
12 Xpert Ultra, sputum, culture, direct comparison 3 697
13 Xpert MTB/RIF, sputum, smear-positive, culture 11 103
14 Xpert MTB/RIF, sputum, smear-negative, culture 13 3121
15 Xpert MTB/RIF, sputum, HIV-positive, culture 11 694
16 Xpert MTB/RIF, sputum, HIV-negative, culture 12 2784
17 Xpert Ultra, sputum, HIV-positive, culture 1 32
18 Xpert Ultra, sputum, HIV-negative, culture 1 157
19 Xpert MTB/RIF, gastric aspirate specimen, HIV-positive, culture 3 634
20 Xpert MTB/RIF, gastric aspirate specimen, HIV-negative, culture 4 1531
21 Xpert MTB/RIF, stool, HIV-positive, culture 4 526
22 Xpert MTB/RIF, stool, HIV-negative, culture 4 369
23 Xpert MTB/RIF, sputum, 5 to 14 years, culture 8 806
24 Xpert MTB/RIF, sputum, 0 to 4 years, culture 10 2184
25 Xpert MTB/RIF, induced sputum, 5 to 14, culture 5 627
26 Xpert MTB/RIF, induced sputum, 0 to 4 years, culture 7 2062
27 Xpert MTB/RIF, gastric aspirate specimen, 0 to 4 years, culture 4 1795
28 Xpert MTB/RIF, sputum, culture, high tuberculosis burden, yes 19 5268
29 Xpert MTB/RIF, sputum, culture, high tuberculosis burden, no 6 1469
30 Xpert MTB/RIF, sputum, inpatients, culture 4 869
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Test No. of studies No. of participants
31 Xpert MTB/RIF, sputum, outpatients, culture 4 1140
32 Xpert MTB/RIF, CSF, culture 8 268
33 Xpert MTB/RIF, CSF, composite reference standard 2 155
34 Xpert MTB/RIF, lymph node specimen, culture 7 211
35 Xpert MTB/RIF, lymph node specimen, composite reference standard 3 107
36 Xpert MTB/RIF, rifampicin resistance, any specimen 14 326
37 Xpert MTB/RIF, sputum, multiple tests, culture 5 1925
38 Xpert MTB/RIF, sputum, initial test, culture 5 1939
39 Xpert MTB/RIF, gastric aspirate specimen, multiple tests, culture 1 921
40 Xpert MTB/RIF, gastric aspirate specimen, initial test, culture 1 935
41 Xpert MTB/RIF, stool, multiple tests, culture 1 247
42 Xpert MTB/RIF, stool, initial test, culture 1 236
43 Xpert MTB/RIF, nasopharyngeal aspirate, multiple tests, culture 2 705
44 Xpert MTB/RIF, nasopharyngeal aspirate, initial test, culture 2 705
45 Xpert Ultra, sputum, multiple tests, culture 1 135
46 Xpert Ultra, sputum, initial test, culture 1 135
47 Xpert Ultra, nasopharyngeal aspirate, multiple tests, culture 1 130
48 Xpert Ultra, nasopharyngeal aspirate, initial test, culture 1 130
49 Xpert MTB/RIF, sputum, multiple cultures 12 3280
50 Xpert MTB/RIF, sputum, single culture 13 3442
51 Xpert MTB/RIF, induced sputum, culture 15 3844
52 Xpert MTB/RIF, gastric aspirate specimen, 5 to 14, culture 2 154
53 Xpert MTB/RIF, nasopharyngeal aspirate, 5 to 14, culture 1 70
54 Xpert MTB/RIF, nasopharyngeal aspirate, 0 to 4, culture 1 404
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Test 1.   Xpert MTB/RIF, sputum, culture
 
 
Test 2.   Xpert MTB/RIF, sputum, composite reference standard
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Test 3.   Xpert Ultra, sputum, culture
 
 
Test 4.   Xpert Ultra, sputum, composite reference standard
 
 
Test 5.   Xpert MTB/RIF, gastric aspirate specimen, culture
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Test 6.   Xpert MTB/RIF, gastric aspirate specimen, composite reference standard
 
 
Test 7.   Xpert MTB/RIF, stool, culture
 
 
Test 8.   Xpert MTB/RIF, stool, composite reference standard
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Test 9.   Xpert MTB/RIF, nasopharyngeal aspirate, culture
 
 
Test 10.   Xpert Ultra, nasopharyngeal aspirate, culture
 
 
Test 11.   Xpert MTB/RIF, sputum, culture, direct comparison
 
 
Test 12.   Xpert Ultra, sputum, culture, direct comparison
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Test 13.   Xpert MTB/RIF, sputum, smear-positive, culture
 
 
Test 14.   Xpert MTB/RIF, sputum, smear-negative, culture
 
 
Test 15.   Xpert MTB/RIF, sputum, HIV-positive, culture
 
Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children (Review)
Copyright © 2020 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
149
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
 
Test 16.   Xpert MTB/RIF, sputum, HIV-negative, culture
 
 
Test 17.   Xpert Ultra, sputum, HIV-positive, culture
 
 
Test 18.   Xpert Ultra, sputum, HIV-negative, culture
 
 
Test 19.   Xpert MTB/RIF, gastric aspirate specimen, HIV-positive, culture
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Test 20.   Xpert MTB/RIF, gastric aspirate specimen, HIV-negative, culture
 
 
Test 21.   Xpert MTB/RIF, stool, HIV-positive, culture
 
 
Test 22.   Xpert MTB/RIF, stool, HIV-negative, culture
 
 
Test 23.   Xpert MTB/RIF, sputum, 5 to 14 years, culture
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Test 24.   Xpert MTB/RIF, sputum, 0 to 4 years, culture
 
 
Test 25.   Xpert MTB/RIF, induced sputum, 5 to 14, culture
 
 
Test 26.   Xpert MTB/RIF, induced sputum, 0 to 4 years, culture
 
 
Test 27.   Xpert MTB/RIF, gastric aspirate specimen, 0 to 4 years, culture
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Test 28.   Xpert MTB/RIF, sputum, culture, high tuberculosis burden, yes
 
 
Test 29.   Xpert MTB/RIF, sputum, culture, high tuberculosis burden, no
 
 
Test 30.   Xpert MTB/RIF, sputum, inpatients, culture
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Test 31.   Xpert MTB/RIF, sputum, outpatients, culture
 
 
Test 32.   Xpert MTB/RIF, CSF, culture
 
 
Test 33.   Xpert MTB/RIF, CSF, composite reference standard
 
 
Test 34.   Xpert MTB/RIF, lymph node specimen, culture
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Test 35.   Xpert MTB/RIF, lymph node specimen, composite reference standard
 
 
Test 36.   Xpert MTB/RIF, rifampicin resistance, any specimen
 
 
Test 37.   Xpert MTB/RIF, sputum, multiple tests, culture
 
 
Test 38.   Xpert MTB/RIF, sputum, initial test, culture
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Test 40.   Xpert MTB/RIF, gastric aspirate specimen, initial test, culture
 
 
Test 41.   Xpert MTB/RIF, stool, multiple tests, culture
 
 
Test 42.   Xpert MTB/RIF, stool, initial test, culture
 
 
Test 43.   Xpert MTB/RIF, nasopharyngeal aspirate, multiple tests, culture
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Test 44.   Xpert MTB/RIF, nasopharyngeal aspirate, initial test, culture
 
 
Test 45.   Xpert Ultra, sputum, multiple tests, culture
 
 
Test 46.   Xpert Ultra, sputum, initial test, culture
 
 
Test 47.   Xpert Ultra, nasopharyngeal aspirate, multiple tests, culture
 
 
Test 48.   Xpert Ultra, nasopharyngeal aspirate, initial test, culture
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Test 49.   Xpert MTB/RIF, sputum, multiple cultures
 
 
Test 50.   Xpert MTB/RIF, sputum, single culture
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Test 51.   Xpert MTB/RIF, induced sputum, culture
 
 
Test 52.   Xpert MTB/RIF, gastric aspirate specimen, 5 to 14, culture
 
 
Test 53.   Xpert MTB/RIF, nasopharyngeal aspirate, 5 to 14, culture
 
 
Test 54.   Xpert MTB/RIF, nasopharyngeal aspirate, 0 to 4, culture
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Study Index test Reference stan-
dard
Study de-
sign
HIV status Clinical set-
ting
High TB
burden
Specimens Uninter-
pretable re-
sults for tu-
berculosis
detection
Anderson
2014
Xpert MTB/RIF Culture, Compos-
ite
Cohort Both Both Yes Sputum NR
Andriyoko
2019
Xpert MTB/RIF Culture Cross-sec-
tional
NR NR Yes Gastric aspirate specimen, stool,
sputum
6/40 (15%)
stool, in-
duced spu-
tum or gas-
tric aspirate
specimen
1/30 (3%)
Atwebem-
beire 2016
Xpert MTB/RIF Culture Cross-sec-
tional
Both NR No Sputum NR
Bacha 2017 Xpert MTB/RIF Culture, Compos-
ite
Cohort Both Both Yes Sputum 3/455 (0.6%)
Bates 2013 Xpert MTB/RIF Culture Cross-sec-
tional
Both Inpatient Yes Sputum, gastric aspirate specimen 17/930
(1.8%)
Bhatia 2016 Xpert MTB/RIF Culture, Compos-
ite
Cross-sec-
tional
NR Inpatient Yes Cerebrospinal fluid NR
Bholla 2016 Xpert MTB/RIF Culture Cohort Both NR Yes Lymph node specimen 0/70 (0%)
Brent 2017 Xpert MTB/RIF Culture, Compos-
ite
Cohort Both NR Yes Sputum NR
Bunyasi
2015
Xpert MTB/RIF Culture Randomized
trial
HIV- Inpatient Yes Sputum, gastric aspirate specimen 47/4856
(0.9%)
Causse 2011 Xpert MTB/RIF Culture Cross-sec-
tional
HIV- Laboratory No Gastric aspirate specimen, cere-
brospinal fluid
NR
Chipinduro
2017
Xpert MTB/RIF Culture, Compos-
ite
Cross-sec-
tional
Both Outpatient Yes Sputum, stool 1/218 (0.4%)
induced
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sputum,
0/218 stool
Chisti 2014 Xpert MTB/RIF Culture, Compos-
ite
Cross-sec-
tional
NR Inpatient Yes Gastric aspirate specimen, sputum NR
Coetzee
2014
Xpert MTB/RIF Culture Cross-sec-
tional
Both Both Yes Lymph node 1/110 (0.9%)
Das 2019 Xpert MTB/RIF Culture Cross-sec-
tional
Both Both Yes Gastric aspirate specimen, cere-
brospinal fluid, lymph node, spu-
tum
2/181 (1%)
Gous 2015 Xpert MTB/RIF Culture Cross-sec-
tional
NR NR Yes Sputum 27/467
(5.6%)
Hanrahan
2018
Xpert MTB/RIF Culture Cohort Both Outpatient Yes Gastric aspirate specimen, na-
sopharyngeal specimen, sputum,
stool
15/114
(13%) stool,
1/57 (1.7%)
gastric,
1/103 (.9%)
IS
Hasan 2017 Xpert MTB/RIF Culture, Compos-
ite
Cross-sec-
tional
HIV- Both Yes Gastric aspirate specimen, stool,
sputum
NR
Kasa Tom
2018
Xpert MTB/RIF Composite Cohort Both Inpatient Yes Gastric aspirate specimen, sputum NR
Kim 2015 Xpert MTB/RIF Culture Cross-sec-
tional
NR Inpatient No Lymph node specimen NR
LaCourse
2014
Xpert MTB/RIF Culture, Compos-
ite
Cross-sec-
tional
Both Inpatient No Sputum 0/300 (0%)
LaCourse
2018
Xpert MTB/RIF Culture, Compos-
ite
Cohort HIV+ Inpatient Yes Gastric aspirate specimen, sputum,
stool
2/150 (1.3%)
Ligthelm
2011
Xpert MTB/RIF Culture Cross-sec-
tional
NR Both Yes Lymph node specimen 0/2 (0%)
Malbruny
2011
Xpert MTB/RIF Culture Cross-sec-
tional
NR Laboratory No Gastric aspirate specimen, cere-
brospinal fluid, lymph node, spu-
tum
NR
Table 1.   Key characteristics of included studies  (Continued)
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Marcy 2016 Xpert MTB/RIF Culture Cohort HIV+ NR Yes Gastric aspirate specimen, na-
sopharyngeal specimen, sputum,
stool
NR
Moussa
2016
Xpert MTB/RIF Culture, Compos-
ite
Cohort HIV- NR No Sputum, stool 1/230 (.4%)
Myo 2018 Xpert MTB/RIF Culture, Compos-
ite
Cross-sec-
tional
Both Inpatient Yes Gastric aspirate specimen 4/231 (1.7%)
Nhu 2013 Xpert MTB/RIF Culture, Compos-
ite
Cross-sec-
tional
Both Inpatient Yes Gastric aspirate specimen, sputum,
cerebrospinal fluid
NR
Nicol 2011 Xpert MTB/RIF Culture, Compos-
ite
Cross-sec-
tional
Both Inpatient Yes Sputum NR
Nicol 2013 Xpert MTB/RIF Culture, Compos-
ite
Cohort Both Both Yes Sputum, stool NR
Nicol 2018 Xpert MTB/RIF
and Xpert Ultra
Culture, Compos-
ite
Cohort Both Inpatient Yes Sputum NR
Orikiriza
2018
Xpert MTB/RIF Culture, Compos-
ite
Cohort Both Both No Sputum, stool 2/357 (0.5%)
sputum,
1/64 (1.5%)
stool
Pang 2014 Xpert MTB/RIF Culture, Compos-
ite
Cross-sec-
tional
Unk/NR Inpatient Yes Gastric aspirate specimen NR
Rachow
2012
Xpert MTB/RIF Culture, Compos-
ite
Cohort Both Both Yes Sputum NR
Reither 2015 Xpert MTB/RIF Culture, Compos-
ite
Cohort Both NR Yes Sputum NR
Sabi 2018 Xpert MTB/RIF
and Xpert Ultra
Culture, Compos-
ite
Cohort Both Both Yes Sputum 3/520 (0.5%)
Saini 2018 Xpert MTB/RIF Culture, Compos-
ite
Cross-sec-
tional
HIV- Inpatient Yes Bronchoalveolar lavage NR
Table 1.   Key characteristics of included studies  (Continued)
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Sekadde
2013
Xpert MTB/RIF Culture Cross-sec-
tional
Both Both No Sputum 2/250 (0.8%)
Singh M
2016
Xpert MTB/RIF Culture, Compos-
ite
Cross-sec-
tional
NR Inpatient Yes Gastric aspirate specimen, sputum NR
Solomons
2015
Xpert MTB/RIF Culture, Compos-
ite
Cross-sec-
tional
Both Inpatient Yes Cerebrospinal fluid NR
Togun 2015 Xpert MTB/RIF Culture, Compos-
ite
Cross-sec-
tional
HIV- Outpatient No Sputum NR
Tortoli 2012 Xpert MTB/RIF Culture Cross-sec-
tional
NR Laboratory No Gastric aspirate specimen, cere-
brospinal fluid, lymph node speci-
men
0/306
Vadwai 2011 Xpert MTB/RIF Culture Cross-sec-
tional
Both Both Yes Cerebrospinal fluid NR
Walters
2014
Xpert MTB/RIF Culture Cross-sec-
tional
Both Inpatient Yes Bronchoalveolar lavage NR
Walters
2017a
Xpert MTB/RIF Culture, Compos-
ite
Cohort Both Both Yes Gastric aspirate specimen, sputum,
stool
28/379 (7%)
Walters
2018a
Xpert MTB/RIF Culture, Compos-
ite
Cohort Both Both Yes Gastric aspirate specimen, sputum,
stool
12/259 (5%)
stool, 8/259
(3%) respi-
ratory
Yin 2014 Xpert MTB/RIF Culture Cross-sec-
tional
NR Inpatient Yes Bronchoalveolar lavage 4/255 (1.6%)
Zar 2012 Xpert MTB/RIF Culture, Compos-
ite
Cohort Both Inpatient Yes Nasopharyngeal specimen, spu-
tum
NR
Zar 2013 Xpert MTB/RIF Culture, Compos-
ite
Cohort Both Outpatient Yes Nasopharyngeal specimen, spu-
tum
12/1754
(0.6%)
Zar 2019 Xpert MTB/RIF
and Xpert Ultra
Culture, Compos-
ite
Cohort Both Inpatient Yes Nasopharyngeal specimen, spu-
tum
NR
Table 1.   Key characteristics of included studies  (Continued)
IS: induced sputum; NR: not reported; TB: tuberculosis.
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Test, analysis group Reference
standard
Studies Number of
children (TB
cases)
Sensitivity %
(95% CI)
Specificity %
(95% CI)
Positive predic-
tive value % (95%
CI)a
Negative predic-
tive value % (95%
CI)a
Xpert MTB/RIF, sputum Culture 23 6703 (493) 64.6 (55.3 to 72.9) 99.0 (98.1 to 99.5) 88.2 (79.6 to 93.5) 96.2 (95.1 to 97.0)
Xpert MTB/RIF, sputum Composite 16 4379 (1541) 19.7 (12.1 to 30.4) 100 (99.8 to 100) 98.4 (89.2 to 99.8) 91.8 (90.9 to 92.6)
Xpert Ultra, sputum Culture 3 697 (136) 72.8 (64.7 to 79.6) 97.5 (95.8 to 98.5) 76.4 (65.6 to 84.6) 97.7 (95.9 to 97.7)
Xpert Ultra, sputum Composite 3 753 (498) 23.5 (20.0 to 27.4) 99.2 (96.9 to 99.8) 76.9 (45.3 to 93.0) 92.1 (91.7 to 92.5)
Xpert MTB/RIF, gastric aspi-
rate specimen
Culture 14 3482 (273) 73.0 (52.9 to 86.7) 98.1 (95.5 to 99.2) 81.0 (65.5 to 90.6) 97.0 (94.5 to 98.4)
Xpert MTB/RIF, gastric aspi-
rate specimen
Composite 6 933 (461) 31.7 (20.2 to 46.0) 99.7 (97.1 to 100) 91.7 (58.3 to 98.9) 92.9 (91.6 to 94.0)
Xpert MTB/RIF, stool speci-
men
Culture 11 1592 (174) 61.5 (44.1 to 76.4) 98.5 (97.0 to 99.2) 81.7 (72.2 to 88.5) 95.8 (93.8 to 97.3)
Xpert MTB/RIF, stool speci-
men
Composite 10 1739 (879) 16.3 (8.4 to 29.2) 99.7 (97.8 to 100) 87.4 (42.8 to 98.5) 91.5 (90.5 to 92.4)
Xpert MTB/RIF, nasopharyn-
geal specimen
Culture 4 1125 (144) 45.7 (27.6 to 65.1) 99.6 (98.9 to 99.8) 92.6 (81.1 to 97.3) 94.3 (92.0 to 95.9)
Xpert Ultra, nasopharyngeal
specimen
Culture 1 195 (35) 45.7 (28.9 to 63.3) 97.5 (93.7 to 99.3) 67.0 (42.0 to 85.1) 94.1 (92.2 to 95.6)
Xpert MTB/RIF, sputum,
smear-positiveb
Culture 11 91 (88) 97.8 (91.6 to 99.4) − − −
Xpert MTB/RIF, sputum,
smear-negative
Culture 12 3118 (184) 58.9 (45.6 to 71.0) 99.1 (97.1 to 99.7) 88.4 (68.8 to 96.3) 95.6 (94.0 to 96.8)
Xpert MTB/RIF, sputum, HIV-
positive
Culture 10 642 (88) 72.2 (59.9 to 81.8) 99.4 (97.2 to 99.9) 93.2 (74.0 to 98.5) 97.0 (95.5 to 97.9)
Table 2.   Diagnostic accuracy of Xpert MTB/RIF and Xpert Ultra for pulmonary tuberculosis and rifampicin resistance in children  Cochrane
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Xpert MTB/RIF, sputum, HIV-
negative
Culture 12 2784 (224) 54.3 (43.5 to 64.7) 99.3 (98.1 to 99.7) 89.7 (80.5 to 94.9) 95.1 (93.9 to 96.2)
Xpert MTB/RIF, gastric aspi-
rate specimen, HIV-positive
Culture 3 634 (50) 73.3 (54.9 to 86.1) 98.5 (97.1 to 99.2) 84.1 (72.7 to 91.3) 97.1 (93.8 to 98.4)
Xpert MTB/RIF, stool speci-
men, HIV-positive
Culture 4 526 (53) 69.8 (56.3 to 80.6) 98.6 (96.1 to 99.5) 84.7 (66.2 to 94.0) 96.7 (95.1 to 97.8)
Xpert MTB/RIF, rifampicin re-
sistance
Culture-DST,
MTBDRplus
6 223 (20) 90.0 (67.6 to 97.5) 98.3 (87.7 to 99.8) 85.7 (42.7 to 98.0) 98.9 (95.9 to 99.7)
Table 2.   Diagnostic accuracy of Xpert MTB/RIF and Xpert Ultra for pulmonary tuberculosis and rifampicin resistance in children  (Continued)
CI: confidence interval; DST: drug susceptibility testing; MTBDRplus: molecular assay for detection of Mycobacterium tuberculosis and drug resistance; TB: tuberculosis.
aPredictive values were determined at a pre-test probability of 10%.
bWe performed a univariate meta-analysis for this analysis group because in many studies, few or zero false-positive and true-negative values were reported.
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Test, analysis group Studies Number of
children (cas-
es)
Sensitivity % (95% CI) Specificity % (95% CI)
Xpert Ultra 3 697 (146) 70.5 (62.7 to 77.4) 97.3 (95.5 to 98.4)
Xpert MTB/RIF 3 609 (136) 63.2 (54.8 to 70.9) 99.2 (97.8 to 99.7)
Absolute difference     7.31 (-3.66 to 18.3), P = 0.19 -1.88 (-3.47 to -0.29), P = 0.02
Table 3.   Direct comparison of Xpert MTB/RIF and Xpert Ultra, sputum specimen (culture reference standard) 
CI: confidence interval.
Sensitivity and specificity estimates were determined with respect to culture.
 
 
Test, analysis group Studies Number
of chil-
dren (cas-
es)
Sensitivity % (95% CI) Specificity % (95% CI)
Age group
Induced sputum, 5 to 14
years
5 627 (65) 80.5 (66.9 to 89.4) 98.2 (94.4 to 99.4)
Induced sputum, 0 to 4
years
7 2062 (143) 48.6 (32.5 to 65.0) 99.4 (96.7 to 99.9)
Absolute difference     31.9 (11.7 to 52.2), P = 0.002 -1.15 (-3.49 to 1.20), P = 0.34
Gastric aspirate speci-
men, 0 to 4 years
4 1795 (77) 43.0 (16.2 to 74.6) 99.5 (97.0 to 99.9)
High tuberculosis burden
Yes 18 5162 (422) 63.8 (53.5 to 73.0) 99.1 (97.9 to 99.6)
No 5 1466 (72) 70.2 (46.9 to 86.3) 98.8 (97.6 to 99.4)
Absolute difference     -6.42 (-29.2 to 16.3), P = 0.58 0.35 (-0.79 to 1.49), P = 0.55
High TB/HIV burden
Yes 19 5824 (415) 65.7 (55.0 to 75.1) 99.2 (98.3 to 99.7)
No 4 879 (79) 59.5 (39.6 to 76.7) 97.4 (93.8 to 98.9)
Absolute difference     6.26 (-15.7 to 28.2), P = 0.58 1.88 (-0.51 to 4.26), P = 0.12
Cultures used to verify tuberculosis
Multiple 11 3174 (312) 61.0 (48.9 to 71.9) 99.3 (98.4 to 99.7)
Table 4.   E?ects of potential sources of heterogeneity on the accuracy of Xpert MTB/RIF accuracy for pulmonary
tuberculosis 
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Single 12 3439 (181) 69.1 (56.6 to 79.3) 98.6 (96.5 to 99.5)
Absolute difference     -8.05 (-24.4 to 8.35), P = 0.34 0.67 (-0.74 to 2.09), P = 0.35
Table 4.   E?ects of potential sources of heterogeneity on the accuracy of Xpert MTB/RIF accuracy for pulmonary
tuberculosis  (Continued)
CI: confidence interval; TB: tuberculosis.
Sensitivity and specificity estimates were determined with respect to culture.
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Test, analysis group Reference
standard
Studies Number of
children (TB
cases)
Sensitivity %
(95% CI)
Specificity %
(95% CI)
Positive predictive
value % (95% CI)a
Negative predictive
value % (95% CI)a
Xpert MTB/RIF, CSF Culture 6 262 (28) 54.0 (27.8 to
78.2)
93.8 (84.5 to
97.6)
49.1 (26.8 to 71.7) 94.8 (91.1 to 97.1)
Xpert MTB/RIF, CSFb Composite 3 160 (94) − − − −
Xpert MTB/RIF, Lymph node Culture 6 210 (54) 90.4 (55.7 to
98.6)
89.8 (71.5 to
96.8)
49.6 (23.7 to 75.7) 98.8 (93.1 to 99.8)
Xpert MTB/RIF, Lymph nodeb Composite 3 107 (63) − − − −
Table 5.   Diagnostic accuracy of Xpert MTB/RIF and Xpert Ultra for tuberculous meningitis and lymph node tuberculosis 
CI: confidence interval; CSF: cerebrospinal fluid; TB: tuberculosis.
aPredictive values were determined at a pre-test probability of 10%.
bWe did not perform a meta-analysis owing to limited data.
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Test, analysis group Studies Number
of chil-
dren (TB
cases)
Sensitivity %(95% CI) Specificity %(95% CI)
More than 1 Xpert MTB/RIF, spu-
tum
5 1925 (177) 59.1 (43.0 to 73.4) 99.5 (97.7 to 99.9)
One Xpert MTB/RIF, sputum 5 1939 (180) 46.3 (35.0 to 57.9) 99.9 (99.5 to 100)
Absolute difference     12.8 (-6.78 to 32.3), P = 0.20 -0.34 (-1.09 to 0.41), P = 0.37
More than 1 Xpert Ultra, sputum 1 135 (28) 75.0 (55.1 to 89.3) 98.1 (93.4 to 99.8)
One Xpert Ultra, sputum 1 135 (28) 64.3 (44.1 to 81.4) 100 (96.6 to 100)
Absolute difference     10.7 (-13.2 to 34.6), P = 0.38 -1.87 (-4.44 to 0.70), P = 0.16
More than 1 Xpert MTB/RIF, gastric
aspirate specimen
1 921 (31) 22.6 (9.59 to 41.1) 99.4 (98.7 to 99.8)
One Xpert MTB/RIF, gastric aspi-
rate specimen
1 935 (32) 9.38 (1.98 to 25.0) 99.9 (99.4 to 100)
Absolute difference     13.2 (-4.64 to 31.1), P = 0.15 -0.45 (-0.99 to 0.09), P = 0.10
More than 1 Xpert MTB/RIF, stool
specimen
1 247 (17) 35.3 (14.2 to 61.7) 99.6 (97.6 to 100)
One Xpert MTB/RIF, stool specimen 1 236 (16) 25.0 (7.27 to 52.4) 99.5 (97.5 to 100)
Absolute difference     10.3 (-20.8 to 41.4), P = 0.52 0.02 (-1.21 to 1.25), P = 0.97
More than 1 Xpert MTB/RIF, na-
sopharyngeal specimen
2 705 (91) 54.2 (36.1 to 71.3) 98.7 (97.4 to 99.3)
One Xpert MTB/RIF, nasopharyn-
geal specimen
2 705 (91) 40.7 (27.9 to 54.9) 99.2 (98.1 to 99.7)
Absolute difference     13.5 (-9.50 to 36.5), P = 0.25 -0.49 (-1.63 to 0.66), P = 0.40
More than 1 Xpert Ultra, nasopha-
ryngeal specimen
1 130 (24) 54.2 (32.8 to 74.4) 96.2 (90.6 to 99.0)
One Xpert Ultra, nasopharyngeal
specimen
1 130 (24) 37.5 (18.8 to 59.4) 98.1 (93.4 to 99.8)
Absolute difference     16.7 (-11.1 to 44.5), P = 0.25 -1.89 (-6.34 to 2.57), P = 0.41
Table 6.   Diagnostic accuracy of Xpert MTB/RIF and Xpert Ultra for pulmonary tuberculosis in children, comparison
of repeated testing versus first test (culture reference standard) 
CI: confidence interval; TB: tuberculosis.
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Analysis Studies Number of
children (TB
cases)
Sensitivity % (95%
CI)
Specificity % (95%
CI)
Random or consecutive recruitment of partici-
pants
22 6485 (485) 64.0 (54.4 to 72.6) 99.1 (98.2 to 99.6)
Blinding of reference standard to index test re-
sults
18 5796 (454) 65.5 (55.3 to 74.4) 99.0 (98.0 to 99.5)
No pretreatment of participants 21 5877 (469) 64.2 (54.8 to 72.7) 99.1 (98.0 to 99.6)
Enrolled only children 0 to 14 years old 20 5950 (437) 65.5 (54.9 to 74.7) 99.1 (98.1 to 99.6)
Sputum only (excluding studies that also collect-
ed gastric aspirate specimen)
22 6653 (482) 63.0 (53.8 to 71.3) 99.2 (98.4 to 99.6)
Table 7.   Sensitivity analyses for accuracy of Xpert MTB/RIF for detection of pulmonary tuberculosis, sputum
specimen (culture reference standard) 
CI: confidence interval; TB: tuberculosis.
 
 
A P P E N D I C E S
Appendix 1. Detailed search strategies
Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to April 25,
2019>
Search Strategy:
Search Name: Cochrane Central Register of Controlled Trials
1 Mycobacterium tuberculosis/
2 Tuberculosis/ or "Tuberculosis, Multidrug-Resistant"/ or Extensively Drug-Resistant Tuberculosis/ or Tuberculosis, Pulmonary/ or
Tuberculosis, Lymph Node/ or Tuberculosis, Meningeal/
3 (Tuberculosis or MDR-TB or XDR-TB or tuberculous).ti. or (Tuberculosis or MDR-TB or XDR-TB or tuberculous).ab.
4 ((extrapulmonary or lymph node* or mening* or pulmonary) and TB).ti. or ((extrapulmonary or lymph node* or mening* or pulmonary)
and TB).ab.
5 1 or 2 or 3 or 4
6 Xpert*.ti. or Xpert*.ab.
7 (GeneXpert or cepheid).ti. or (GeneXpert or cepheid).ab.
8 (Xpert* and Ultra).mp.
9 (near* patient or near-patient).ti. or (near* patient or near-patient).ab.
10 6 or 7 or 8 or 9
11 5 and 10
12 (pediatric* or paediatric*).mp.
13 (child or children* or childhood or infan* or newborn or neonat* or toddler* or adolescen*).mp.
14 exp Child/ or exp Infant/ or Adolescent/ or exp Pediatrics/
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15 12 or 13 or 14
16 11 and 15
20 19 and 16
Database: Embase 1947-Present, updated daily
Search Strategy:
1 Mycobacterium tuberculosis.mp. or Mycobacterium tuberculosis/
2 lung tuberculosis/ or extrapulmonary tuberculosis/ or extensively drug resistant tuberculosis/ or multidrug resistant tuberculosis/ or
drug resistant tuberculosis/ or tuberculosis/
3 (Tuberculosis or MDR-TB or XDR-TB or tuberculous).ti. or (Tuberculosis or MDR-TB or XDR-TB or tuberculous).ab.
4 ((extrapulmonary or lymph node* or mening* or pulmonary) and TB).ti. or ((extrapulmonary or lymph node* or mening* or pulmonary)
and TB).ab.
5 1 or 2 or 3 or 4
6 Xpert*.ti. or Xpert*.ab.
7 (GeneXpert or cepheid).ti. or (GeneXpert or cepheid).ab.
8 (Xpert* and Ultra).mp.
9 (near* patient or near-patient).ti. or (near* patient or near-patient).ab.
10 6 or 7 or 8 or 9
11 5 and 10
12 (pediatric* or paediatric*).mp.
13 (child or children* or childhood or infan* or newborn or neonat* or toddler* or adolescen*).mp.
14 child/
15 infant/
16 adolescent/
17 pediatrics/
18 12 or 13 or 14 or 15 or 16 or 17
19 11 and 18
Search Name: Cochrane Central Register of Controlled Trials
Issue 4 of 12, April 2019
ID Search
#1 mycobacterium tuberculosis
#2 MeSH descriptor: [Mycobacterium tuberculosis] explode all trees
#3 Tuberculosis or MDR-TB or XDR-TB or tuberculous
#4 MeSH descriptor: [Tuberculosis, Pulmonary] explode all trees
#5 MeSH descriptor: [Tuberculosis] explode all trees
#6 MeSH descriptor: [Extensively Drug-Resistant Tuberculosis] explode all trees
#7 MeSH descriptor: [Tuberculosis, Multidrug-Resistant] explode all trees
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#8 MeSH descriptor: [Tuberculosis, Lymph Node] explode all trees
#9 MeSH descriptor: [Tuberculosis, Meningeal] explode all trees
#10 ((extrapulmonary or lymph node* or mening* or pulmonary) and TB)
#11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
#12 Xpert* or GeneXpert or cepheid
#13 (Xpert* and Ultra)
#14 (near* patient or near-patient)
#15 #12 or #13 or #14
#16 #11 and #15
#17 child or children* or childhood or infan* or newborn or neonat* or toddler* or adolescen*
#18 pediatric* or paediatric*
#19 #17 or #18
CINAHL (EBSCOHost)
# Query
S9 S7 AND S8
S8 "( child or children* or childhood or infan* or newborn or neonat* or toddler* or adolescen* ) OR ( pediatric* or paediatric* )"
S7 S3 AND S6
S6 S4 OR S5
S5 "Xpert MTB/RIF"
S4 "( Xpert* or GeneXpert or cepheid ) OR ( Xpert* and Ultra ) OR ( near* patient or near-patient )"
S3 S1 OR S2
S2 "( XDR-TB or MDR-TB ) OR extrapulmonary tuberculosis"
S1 (MH "Mycobacterium Tuberculosis") OR (MH "Tuberculosis, Multidrug-Resistant") OR (MH "Tuberculosis, Meningeal") OR (MH
"Tuberculosis") OR "tuberculosis OR drug resistant tuberculosis OR Mycobacterium tuberculosis"
SCI-EXPANDED, CPCI-S (Web of Science)
# 7 #6 AND #5
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 6 TOPIC: (child or children* or childhood or infan* or newborn or neonat* or toddler* or adolescen*) OR TOPIC: (pediatric* or paediatric*)
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 5 #4 AND #1
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 4 #3 OR #2
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 3 TOPIC: (Xpert* Ultra or Cepheid or near* patient)
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
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# 2 TOPIC: (Xpert* or Xpert MTB RIF)
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 1 TOPIC: (Tuberculosis or MDR-TB or XDR-TB or tuberculous) OR TOPIC: (mycobacterium tuberculosis) OR TOPIC: (((extrapulmonary or
lymph node* or mening* or pulmonary) and TB))
Indexes=SCI-EXPANDED, CPCI-S Time span=All years
SCOPUS (Elsevier)
( TITLE-ABS-KEY ( ( tuberculosis OR mdr-tb OR xdr-tb OR tuberculous ) OR ( mycobacterium AND tuberculosis ) OR ( ( ( extrapulmonary OR
lymph AND node* OR mening* OR pulmonary ) AND tb ) ) ) ) AND ( TITLE-ABS-KEY ( ( xpert* OR xpert AND mtb AND rif ) OR ( xpert* AND
ultra OR cepheid OR near* AND patient ) ) ) AND ( TITLE-ABS-KEY ( ( child OR children* OR childhood OR infan* OR newborn OR neonat*
OR toddler* OR adolescen* ) OR ( pediatric* OR paediatric* ) ) )
ClinicalTrials.gov, WHO ICTRP, and ISRCTN Registry: tuberculosis and Xpert* and children
Appendix 2. Data extraction form
 
Diagnostic accuracy of Xpert in the diagnosis of child tuberculosis: data extraction form
I. ID  
Study ID First Name/Publication Year
First author Name
Corresponding author Name
Corresponding author email Email
Was author contacted? 1 – Yes
2 – No
If yes, dates(s)
If yes, author response?  
Study data 1 - Published
2 - In press
3 - Ongoing
Title  
Year (of publication) YYYY or 9 – Not reported
Year study start date YYYY or 9 – Not reported
Language 1 – English
2 – Other
If other, specify:
II. Study details
Country where study was conducted  
Country World Bank classification 1 - Low income
2 - Middle income
3 - High income
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4 - Low and high income
5 - Other combination, describe
Country tuberculosis burden (WHO 2015) 1 - WHO tuberculosis high burden
2 - WHO tuberculosis/HIV high burden
3 - WHO MDR tuberculosis high burden
4 - WHO tuberculosis + MDR tuberculosis high burden
5 - WHO tuberculosis + HIV/tuberculosis high burden
6 - WHO tuberculosis + HIV/tuberculosis + MDR tuberculosis high burden
7 - Not a WHO high-burden country
8 - Both non-high-burden and high-burden countries included
9 - Other
Study design 1 – Randomized controlled trial
2 – Cross-sectional
3 – Cohort
4 – Other, specify
9 – Could not tell
If other, describe:
Participant selection 1 – Consecutive
2 – Random
3 – Convenience
7 – Other
9 – Unknown/Not reported
Direction of study data collection 1 – Prospective
2 – Retrospective
9 – Unknown/Not reported
Inclusion criteria 1 – Broad
2 – Rigorous
9 – Unknown/Not reported
Inclusion criteria for presumptive tuberculosis 1 – Tuberculosis contact
2 – Cough
3 – Loss of weight
4 – Suggestive chest X-ray
5 – Immunological evidence of tuberculosis infection (TST/IGRA)
6 - Malnutrition
7 – HIV
8 - Other, describe
9 – Unknown/Not reported
Describe inclusion criteria as in study  
Number included after recruitment by inclusion
and exclusion criteria
Enter number or 9 – Unknown/Not reported
Total number of children included in systematic re-
view analysis
Enter number or 9 – Unknown/Not reported
  (Continued)
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Total number of specimens included in analysis
with collection method
Enter number or 9 – Unknown/Not reported
Unit of analysis (Xpert) 1 – One specimen per patient
2 – Multiple specimens per patient
3 - Unknown number of specimens per patient
9 – Unknown/Not reported
Describe as written in study, if unclear:
Did the study include patients with previous tuber-
culosis history?
1 – Yes
0 – No
9 – Unknown/Not reported
If so, what is the percentage? Enter % and specify numerator/denominator
Target condition? Pulmonary tuberculosis? 1 - Yes
0 - No
Target condition? Rifampicin resistance? 1 - Yes
0 - No
Target condition? Lymph node tuberculosis? 1 - Yes
0 - No
Target condition? Tuberculous meningitis? 1 - Yes
0 - No
Comments about study design  
III. Patient characteristics and setting
Description of study population (age, HIV info, etc.) 1 – All enrolled
2 – All analysed
9 – Unknown/Not reported
Age: median, mean, range by months Enter number or 9 – Unknown/Not reported
Gender ##/total and % female
HIV status of participants 0 – HIV-
1 – HIV+
2 – Both HIV+/-
9 – Unknown/Not reported
If HIV-positive participants included, what is the
percentage?
% and specify numerator/denominator
Type of respiratory specimen included 1 – All expectorated
2 – All induced
3 – All bronchoalveolar lavage
4 – All gastric lavage
5 – Nasopharyngeal aspirate
6 - Stool
7 – Multiple types
8 – Other
9 – Unknown/Not reported
If 7 or 8, describe types and record numbers:
  (Continued)
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Type of non-respiratory specimen 1 – Fine needle aspirate
2 – Lymph node biopsy
3 – Cerebrospinal fluid
4 – Multiple types
5 - Other
9 - Unknown/Not reported
If 4 or 5, describe types and record numbers:
Were Xpert sample and culture obtained from
same specimen?
1 – Yes
0 – No
9 – Unknown/Not reported
Number of cultures used to exclude tuberculosis Describe
Information on smear microscopy: was it used? 1 – Yes
0 – No
9 – Unknown/Not reported
Type of microscopy used 1 – Ziehl-Neelsen
2 – Fluoresence microscopy
3 - Light emitting diode-based fluorescence microscopy
4 - Multiple, describe:
9 – Unknown/Not reported
Smear type 1 – Direct
2 – Concentrated (processed)
3 - Both direct and concentrated
9 – Unknown/Not reported
Data on culture performance provided? # of contaminated culture/Total # cultures performed
or 9 - Unknown/Not reported
Were patient-important outcomes evaluated?
(time to diagnosis, time to treatment, others)
1 – Yes
2 – No
9 – Unknown/Not reported
Time to diagnosis? Xpert:
Culture:
9 – Unknown/Not reported
Specify whether time from sample collection to diagnosis in lab or just turn-
around time in lab
Time to treatment initiation Xpert:
Culture:
9 – Unknown/Not reported
Clinical setting, describe as written in the paper 1 – Outpatient
2 – Inpatient
3 – Both outpatient and inpatient
4 – Other, specify
5 – Laboratory based
9 – Unknown/Not reported
Describe as in paper:
Laboratory services level 1 - Central (reference)
2 - Intermediate (regional)
3 - Peripheral (microscopy centre, provincial hospital)
4 – Research laboratory
  (Continued)
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5 - Other, specify
Where were Xpert tests performed?
(tests generally available at different laboratory
levels, although tests may overlap)
Peripheral: acid-fast bacilli (Ziehl-Neelsen, Au-
ramine-rhodamine, Auramine-O staining) and
Xpert MTB/RIF
Intermediate: peripheral laboratory tests and cul-
ture on solid media and line probe assay (LPA) from
smear-positive sputum
Central: intermediate laboratory tests and culture
on liquid media and DST (1st-line and 2nd-line an-
ti-tuberculosis drugs) on solid or in liquid media
and LPA on positive cultures and rapid speciation
tests
1 - Central (reference)
2 - Intermediate (regional)
3 - Peripheral (microscopy centre, provincial hospital)
4 - Other, specify
Was Xpert run outside of a laboratory? 1 - Yes
0 - No
Current treatment: were patients on treatment (de-
fined as tuberculosis drugs for longer than 7 days)
for the current tuberculosis episode? (note: may
impact culture results)
1 – Yes
2 – No
9 – Unknown/Not reported
If so, what is the percentage? % Specify numerator/denominator
IV. Index test
Xpert cartridge(s) evaluated 1 - Xpert only
2 - Ultra only
3 - Any combination Xpert and Ultra
Xpert platform: was Omni used? Unless Omni was
explicitly described, assume standard platform
1 – Yes, only Omni used for Xpert tests
2 – Yes, both Omni and standard platform used for Xpert tests
3 - No
Pretreatment processing procedure for GeneXpert 1 – None
2 – NALC-NaOH
3 – NaOH (PetroQ)
4 – Other
9 – Unknown/Not reported
For Xpert specimen, what was the condition of the
specimen when tested?
1 – Fresh
2 – Frozen
9 – Unknown/Not reported
Were uninterpretable (invalid error or no result) re-
sults reported for Xpert for tuberculosis detection?
1 – Yes
9 – Unknown/Not reported
If yes, describe numbers:
Were indeterminate results reported for Xpert for
rifampicin resistance?
1 – Yes
9 – Unknown/Not reported
If yes, describe numbers:
V. Reference standard
For tuberculosis detection, what reference stan-
dard(s) was used?
1 – Solid culture (specify 1a)
2 – Liquid culture (specify 2a)
  (Continued)
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Respiratory samples? 3 – Both solid and liquid culture (specify 1a and 2a)
9 – Unknown/Not reported
1a - Solid culture
LJ
7H10
7H11
Other
2a – Liquid culture
MGIT 960
Other (specify):
For tuberculosis detection, what reference stan-
dard(s) was used?
Lymph node?
1 – Solid culture (specify 1a)
2 – Liquid culture (specify 2a)
3 – Both solid and liquid culture (specify 1a and 2a)
9 – Unknown/Not reported
1a - Solid culture
LJ
7H10
7H11
Other
2a – Liquid culture
MGIT 960
Other (specify):
For tuberculosis detection, what reference stan-
dard(s) was used?
Cerebrospinal fluid?
1 – Solid culture (specify 1a)
2 – Liquid culture (specify 2a)
3 – Both solid and liquid culture (specify 1a and 2a)
9 – Unknown/Not reported
1a - Solid culture
LJ
7H10
7H11
Other (specify):
2a – Liquid culture
MGIT 960
Other (specify):
Reference standard pulmonary tuberculosis: clini-
cal
1 - Yes
0 – No
Multiple answers, list:
If clinical, describe as in paper  
For rifampicin resistance detection, what reference
standard(s) was used?
Respiratory samples?
1 – Solid culture (specify 1a)
2 – Liquid culture (specify 2a)
3 – Both solid and liquid culture (specify 1a and 2a)
4 – M tuberculosis DRplus
9 – Unknown/NR
1a - Solid culture
LJ
7H10
7H11
Other:
Specify method (e.g. proportion):
2a – Liquid culture
MGIT 960
Other (specify):
For rifampicin resistance detection, what reference
standard(s) was used?
1 – Solid culture (specify 1a)
2 – Liquid culture (specify 2a)
  (Continued)
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Lymph node? 3 – Both solid and liquid culture (specify 1a and 2a)
4 – M tuberculosis DRplus
9 – Unknown/Not reported
1a - Solid culture
LJ
7H10
7H11
Other:
Specify method (e.g. proportion):
2a – Liquid culture
MGIT 960
Other (specify):
For rifampicin resistance detection, what reference
standard(s) was used?
Cerebrospinal fluid?
1 – Solid culture (specify 1a)
2 – Liquid culture (specify 2a)
3 – Both solid and liquid culture (specify 1a and 2a)
4 – M tuberculosis DRplus
9 – Unknown/Not reported
1a - Solid culture
LJ
7H10
7H11
Other:
Specify method (e.g. proportion):
2a – Liquid culture
MGIT 960
Other (specify):
If information is available  
Is information on quality assurance of DST avail-
able in the study?
1 – Yes
2 - No
9 – Unknown/Not reported
If yes, describe potential sources of bias
  (Continued)
 
DST: drug susceptibility testing; IGRA: Interferon-gamma release assay; LJ: Löwenstein-Jensen; MDR-TB: multidrug-resistant tuberculosis;
MGIT: mycobacterial growth indicator tube; NALC: N-acetyl-L-cysteine; NAOH: sodium hydroxide; TST: tuberculin skin test; WHO: World
Health Organization.
Appendix 3. Example of 2 × 2 result table
 
Pulmonary tuberculosis,
Xpert MTB/RIF
Tuberculosis, culture 
Yes No Total
Positive      
Negative      
Xpert MTB/RIF in sputum
Total      
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Pulmonary tuberculosis,
Xpert Ultra
Tuberculosis, culture 
Yes No Total
Positive      
Negative      
Xpert Ultra in sputum
Total      
 
Tuberculous meningitis Tuberculosis, culture 
Yes No Total
Positive      
Negative      
Xpert MTB/RIF in CSF
Total      
 
Pulmonary tuberculosis Tuberculosis, CRS 
Yes No Total
Positive      
Negative      
Xpert MTB/RIF in sputum
Total      
  (Continued)
 
CRS: composite reference standard; CSF: cerebrospinal fluid.
Appendix 4. QUADAS-2 review-specific guidance
Domain 1 - Patient selection
Risk of bias: could the selection of patients have introduced bias?
Signalling question 1: was a consecutive or random sample of patients enrolled? We answered ‘yes' if the study enrolled a consecutive or
random sample of eligible patients; ‘no' if the study selected patients by convenience; and ‘unclear' if the study did not report the manner
of patient selection or if we could not tell.
Signalling question 2: did the study avoid inappropriate exclusions?
a. For pulmonary tuberculosis, we answered 'yes' for all studies because we did not think there were any inappropriate exclusions for
children presumed to have pulmonary tuberculosis. For tuberculous meningitis and lymph node tuberculosis, we answered ‘no' if the
study excluded specimens based on physical appearance (such as purulence) or a biochemical analysis (e.g. adenosine deaminase (ADA)
or cell analysis). We answered ‘unclear' if we could not tell.
Applicability: are there concerns that the included patients and setting do not match the review question?
We are interested in how Xpert performs in patients who were evaluated as they would be in routine practice. Paediatric studies conducted
in tertiary centres tend to include a larger number of children with advanced disease; therefore we answered ‘low concern' if patients
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were evaluated in local hospitals or primary care centres; ‘high concern' if patients were evaluated exclusively as inpatients in tertiary
care centres; and ‘unclear concern' if the clinical setting was not reported or if information was insuQicient to justify a decision. We also
answered ‘unclear concern' if Xpert testing was done at a reference laboratory and the clinical setting was not reported because it is diQicult
to tell if a given reference laboratory provides services mainly to very sick patients (inpatients in tertiary care) or to patients with a broad
spectrum of disease, including very sick patients and those with less severe disease (primary, secondary, and tertiary care).
Domain 2 - Index test
Risk of bias: could the conduct or interpretation of the index test have introduced bias?
Signalling question 1: were the index test results interpreted without knowledge of results of the reference standard? We answered this
question ‘yes' for all studies because Xpert MTB/RIF and Xpert Ultra test results are automatically generated, and the user is provided with
printable test results; thus there is no room for subjective interpretation of test results.
Signalling question 2: if a threshold was used, was it pre-specified? The threshold is pre-specified in all versions of Xpert MTB/RIF and Xpert
Ultra. We answered this question ‘yes' for all studies.
Applicability: are there concerns that the index test, its conduct, or its interpretation diQers from the review question? Variations in test
technology, execution, or interpretation may aQect estimates of the diagnostic accuracy of a test. GeneXpert, the test device platform,
simplifies molecular testing by fully integrating and automating the three processes (sample preparation, amplification, and detection)
required for real-time polymerase chain reaction (PCR)-based molecular testing. All steps in the Xpert MTB/RIF and Xpert Ultra assays
are completely automated and self-contained following sample loading. Minimal training is required for operators such as laboratory
technicians and nurses to run the index test.
For pulmonary tuberculosis, we answered ‘low concern' if the index test was performed as recommended by the manufacturer. For sputum
specimens, we answered ‘unclear concern' if the ratio of the Xpert sample reagent: specimen volume was not 2:1 for a raw specimen or
3:1 for a centrifuged sediment, as recommended by the manufacturer, or if we could not tell (WHO 2014a). Central-level laboratories use
more highly trained staQ than peripheral- and intermediate-level laboratories or health facilities. However, we do not consider this to be
a concern about applicability due to the minimal training required to run the index tests.
With respect to extrapulmonary specimens, the WHO has provided detailed information about processing steps in the ‘Xpert MTB/RIF
implementation manual'. Technical and operational "how-to" practical considerations. Annex 2 - Standard operating procedure (SOP) for
processing extrapulmonary specimens (CSF, lymph nodes, and other tissues) for "Xpert MTB/RIF assay”' (WHO 2014b). For extrapulmonary
specimens, we answered ‘low concern' if the test was performed according to WHO standard operating procedures. We answered ‘high
concern' if the test was performed in a way that deviated from these recommendations. We answered ‘unclear concern' if we could not tell.
Domain 3 - Reference standard
Risk of bias: could the reference standard, its conduct, or its interpretation have introduced bias?
Signalling question 1.a: is a culture reference standard likely to correctly classify the target condition?
For pulmonary tuberculosis, tuberculous meningitis, and lymph node tuberculosis, we anticipated that the vast majority of studies would
perform culture. Culture is generally considered the best reference standard for tuberculosis diagnosis. However, particularly in children
with paucibacillary disease, tuberculosis is verified by culture in only 15% to 50% of cases, depending on disease severity, challenges of
obtaining specimens, and resources (Graham 2015). Evaluation of multiple specimens may increase the yield of culture for confirming
tuberculosis (Cruz 2012; Zar 2012). We answered ‘yes' for studies using multiple specimens and ‘unclear' for studies using only one
specimen.
Signalling question 1.b: is the composite reference standard likely to correctly classify the target condition? A composite reference
standard aims to classify children who were not detected by culture. The definition of the composite reference standard is heterogeneous
across studies. Irrespective of how tuberculosis was defined in the publications, we classified children as having tuberculosis if they
were presumed to have tuberculosis and were started on anti-tuberculosis treatment. For a composite reference standard, we answered
‘unclear’ for all studies.
For rifampicin resistance, we answered ‘yes' if a study used phenotypic culture-based drug susceptibility testing or MTBDRplus as the
reference standard. As this is an inclusion criterion for the review, we answered 'yes' for all studies.
Signalling question 2: were the reference standard results interpreted without knowledge of results of the index test? For pulmonary
tuberculosis, tuberculous meningitis, and lymph node tuberculosis, we answered ‘yes' if the reference test provided an automated result
(e.g. MGIT 960); blinding was explicitly stated; or it was clear that the reference standard was performed at a separate laboratory or
performed by diQerent people. We answered ‘no' if the study stated that the reference standard result was interpreted with knowledge of
the Xpert test result. We answered ‘unclear' if we could not tell.
For rifampicin resistance, we answered ‘yes' if the reference test provided an automated result (e.g. MGIT 960 SIRE); blinding was explicitly
stated; or it was clear that the reference standard was performed at a separate laboratory or performed by diQerent people. We answered
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‘no' if the study stated that the reference standard result was interpreted with knowledge of the Xpert test result. We answered‘unclear'
if we could not tell.
Applicability: are there concerns that the target condition as defined by the reference standard does not match the question?
For pulmonary tuberculosis, tuberculous meningitis, and lymph node tuberculosis, we answered ‘high concern' if the included studies did
not diQerentiate Mycobacterium tuberculosis complex isolated in culture from other mycobacteria using any speciation technique; ‘low
concern' if speciation was performed using any technique; and ‘unclear concern' if we could not tell.
For rifampicin resistance, we considered applicability to be of ‘low concern' for all studies because the method used (phenotypic culture-
based drug susceptibility testing or MTBDRplus) is appropriate.
Domain 4 - Flow and timing
Risk of bias: could the patient flow have introduced bias?
Signalling question 1: was there an appropriate interval between the index test and the reference standard? We expected to find for
most included studies that specimens for Xpert and culture were obtained at the same time when patients were evaluated for presumed
tuberculosis. Even if there were a delay of several days between index test and reference standards, tuberculosis is a chronic disease, and
we consider misclassification of disease status to be unlikely, as long as treatment was not initiated in the interim. We answered ‘yes' if the
index test and the reference standard were performed at the same time, or if the time interval was less than or equal to seven days; ‘no' if
the time interval was greater than seven days; and ‘unclear' if we could not tell.
Signalling question 2: did all patients receive the same reference standard? We answered ‘yes' if all patients received the same reference
standard; ‘no' if all patients did not receive the same reference standard; and ‘unclear' if we could not tell.
Signalling question 3: were all patients included in the analysis? We determined the answer to this question by comparing the number of
patients enrolled with the number of patients included in the 2 × 2 tables. We answered ‘yes' if the numbers matched, and ‘no' if there were
patients enrolled in the study who were not included in the analysis. We answered ‘unclear' if we could not tell.
Judgements for risk of bias assessments for a given domain.
• If we answered all signalling questions for a domain ‘yes', then judged risk of bias as ‘low'.• If we answered all or most signalling questions for a domain ‘no', then we judged risk of bias as ‘high'.• If we answered only one signalling question for a domain ‘no', we discussed further the risk of bias judgement.• If we answered all or most signalling questions for a domain ‘unclear', then we judged risk of bias as ‘unclear'.• If we answered only one signalling question for a domain ‘unclear', we discussed further the risk of bias judgement.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We defined the microbiological reference standard as culture only and did not include smear microscopy, which is less accurate. For stool,
we accepted as a reference standard a positive result by Xpert MTB/RIF or Xpert Ultra in a sputum specimen. For the composite reference
standard, when information about tuberculosis treatment was not available, we accepted the uniform research definition (Graham 2012;
Graham 2015). In these situations, using the older definition (Graham 2012), we defined tuberculosis as (1) confirmed, probable, and
possible cases, and (2) non-tuberculosis. For the newer definition (Graham 2015), we used the categories tuberculosis confirmed and not
confirmed. In cases where a study-specific definition for the composite references standard was applied, this was accepted as well. For
studies in which gastric aspirate specimens and sputum specimens were collected, data were included with the sputum analyses, and
we performed a sensitivity analysis excluding these studies. We added MTBDRplus, a WHO-recommended test, as a reference standard
for rifampicin resistance. We had planned to estimate the pooled proportion of uninterpretable Xpert MTB/RIF and Xpert Ultra results for
tuberculosis detection and indeterminate Xpert MTB/RIF and Xpert Ultra results for rifampicin resistance detection. However, we found
few uninterpretable results reported. We have summarized these results in a table with the key characteristics of the included studies.
We did not perform an indirect test comparison of Xpert MTB/RIF and Xpert Ultra because there were only three Ultra studies. These
three studies also assessed Xpert MTB/RIF, and so we limited our analysis to a direct comparison. Owing to limited data, we were able to
perform investigations of heterogeneity and sensitivity analyses only for Xpert MTB/RIF. Finally, as part of the analysis for the World Health
Organization Molecular Diagnostics Guideline Development Group, we were asked to provide data on the diagnostic accuracy of multiple
Xpert tests compared with a single Xpert test in children; this analysis has been added to the review.
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